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ABSTRACT 
 
Morgan McFarland Goheen: Iron Deficiency Anemia and the Pathogenesis of Falciparum Malaria 
(Under the direction of: Carla Cerami and Steven R. Meshnick) 
 
 
Anemia, primarily iron deficiency anemia (IDA), affects up to 50% of pregnant women and 40% of 
preschool children in the developing world, significantly impacting perinatal and developmental health. 
However, clinical studies have found (1) iron deficiency protects from malaria, and (2) administration of 
iron to iron deficient individuals may increase the risk of malaria, thus complicating universal iron 
supplementation recommendations in malaria-endemic areas. 
Our lab developed an in vitro model, obtaining red blood cells (RBCs) from IDA or healthy donors 
at UNC, to study mechanisms of malaria-associated IDA protection and iron treatment risk. We 
demonstrated decreased P.falciparum invasion and growth in IDA RBCs and increased infection 
susceptibility in young RBCs and reticulocytes. Given iron is essential for the parasite, it was previously 
thought iron deficiency inhibited malaria through starvation. However, IDA also limits erythropoiesis and 
induces physiologic RBC changes. Our UNC-based studies thus generated a novel and paradigm-shifting 
hypothesis – namely that changes in RBC properties and the RBC population structure drive IDA 
resistance to and iron supplementation risk for malaria.  
Our next objective was to evaluate this hypothesis in pregnant women and children from a 
malaria-endemic area, via comprehensive longitudinal examination of P.falciparum pathogenesis in RBCs 
drawn from iron deficient Gambian children and pregnant women before, during, and after iron 
supplementation. RBCs were collected from 135 children and 165 pregnant women throughout 12 weeks 
of iron supplementation and used in flow cytometry-based in vitro assays. Our results demonstrate 
P.falciparum erythrocytic stage growth in vitro is low at baseline, correlating with hemoglobin levels and 
mean corpuscular volume. We also determined parasite growth increases during supplementation, using 
RBCs from both children and pregnant women. Additionally, we found reduced parasite invasion in RBCs 
from iron deficient Gambian children, which increases during iron supplementation. The elevated growth 
iv 
 
rates following iron supplementation paralleled increases in circulating reticulocytes and other markers of 
young RBCs, kinetics of which correlate with overall increased erythropoiesis. We conclude malaria 
growth in vitro corresponds with elevated erythropoiesis, an inevitable consequence of iron 
supplementation. Our findings imply iron supplementation in malarious regions should be accompanied 
by effective preventative measures against falciparum malaria.   
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CHAPTER ONE: INTRODUCTION TO ERYTHROCYTE ALTERATIONS WHICH IMPACT 
FALCIPARUM MALARIA INFECTION 
 
1.1 INTRODUCTION 
Malaria has been a threat to humankind for centuries, impacting vast swaths of societal function 
from geographical settlement to war and colonial infiltration, to economic productivity. Still, today an 
estimated 438,000 people die annually (primarily children under 5 succumbing to Plasmodium falciparum 
in Sub-Saharan Africa) (1). The lost economic cost is substantial, and correlates directly with per capita 
GDP in the developing world (2). This highlights how much more work needs to be done if we are to win 
the battle against this formidable infectious disease. 
The life cycle of malaria parasites is complex, involving the mammalian host and the mosquito 
vector. The mosquito injects the sporozoite form of the parasite into the human host. Sporozoites quickly 
home to the liver and after a brief asymptomatic hepatic stage, merozoites burst out of hepatocytes to 
enter the bloodstream and begin the intra-erythrocytic infection cycle. During this cycle (which lasts 48hrs 
for P.falciparum), the parasite develops from the ring stage to the metabolically active trophozoites, which 
then mature into schizonts. When they are completely mature, the schizonts (up to 36 per RBC) burst out 
of the RBC and again become merozoites. Merozoites remain extracellular for a very brief time before 
invading new red blood cells (RBCs) and starting the 48 hour cycle again. The most severe clinical 
symptoms of malaria are associated with this burst of RBCs when the parasites leave one host RBC and 
move to the next. 
There are five species of Plasmodium that infect humans, P.falciparum, P.vivax, P.malariae, 
P.ovale, and P.knowlesi. All of these species pass from mosquitos to humans, where they infect first 
hepatocytes and then RBCs; however they differ in their abilities to invade RBCs. For example, P.vivax 
and P.knowlesi infect only young RBCs (reticulocytes) and P.falciparum is able to infect RBCs of all ages. 
In fact, it is this ability to invade RBCs of all ages that makes P.falciparum more pathogenic. P.falciparum 
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is endemic throughout parts of Asia, Africa, and Central and South America, however, its highest infection 
burden falls on Sub-Saharan African children under 5.  
There is much to be learned about malaria pathogenesis from uncovering the relationship 
between the human RBC and the malaria parasite. With drug resistance now arising to even the most 
important first line artemisinin-based antimalarials (3), and disappointing recent large-scale vaccine trials 
(the most promising vaccine candidate has been found to only offer roughly 30% reduction in severe 
malaria in infants and children with limited cross-strain protection and waning efficacy over time (4–7)), 
we clearly are still in need of new strategies to combat malaria. Turning our attention towards naturally 
derived alternations in the RBC that confer protection against malaria may provide much needed insight 
into possible drug development strategies as well as better understanding of malaria pathogenesis and 
transmission. Of course the immune system, endothelium, and liver also impact malaria infection; 
however in this introductory chapter, I will focus attention on changes in RBC physiology that impact 
malaria pathogenesis. One such example is sickle-cell trait, which is so well-known that the average high 
school student knows it as a biological example of human evolution and selective pressure. I will discuss 
recent findings on the cellular and molecular mechanisms that help explain how sickle-cell trait and other 
hemoglobinopathies impact malaria pathogenesis. In addition, I will discuss other common genetic 
mutations that effect RBC physiology (via RBC enzyme deficiencies and abnormalities in RBC 
membranes) and thereby impact malaria pathogenesis. Finally, in my own work presented in Chapters 2-
5, I will discuss how changes in RBCs secondary to anemia decrease malaria parasite growth and 
development. My work also raises the interesting possibility that the high prevalence of anemia in people 
of African descent may not only be secondary to nutritional iron deficiency, but may also be the result a 
genetic attempt to alter RBC physiology in an effort to adapt to malaria.  
Before delving further into discussion of these topics, however, it is important to review the range of 
clinical presentations of malaria seen in children and non-pregnant adults.  
(1) Asymptomatic malaria. This is also sometimes referred to as asymptomatic parasitemia. In many 
malaria-endemic areas, often significant portions of the population have a relatively low level of 
parasitemia and they remain asymptomatic. The simplest explanation for this is that many of 
these people are immune to malaria and are able to fight it enough to keep the parasite 
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replication in check (8). However, the mechanisms responsible for this non-sterile immunity are 
unclear. There is also controversy about whether or not patients with asymptomatic malaria 
should be treated (9). 
(2) Uncomplicated malaria. Malaria is considered uncomplicated when symptoms are present, but 
there are no clinical or laboratory signs of organ dysfunction. Symptoms of uncomplicated malaria 
are not specific and can include: fever, sweating, general weakness, enlarged spleen, mild 
jaundice, liver enlargement and increased respiratory rate.  
(3) Severe malaria. Malaria is considered severe when it is complicated by serious organ failures or 
abnormalities in the patient's blood or metabolism. The manifestations of severe malaria can 
include cerebral malaria, severe anemia due to hemolysis, hemoglobinuria (hemoglobin in the 
urine) due to hemolysis, acute respiratory distress syndrome (ARDS), abnormalities in blood 
coagulation, acute kidney failure, metabolic acidosis, hypoglycemia, and hyperparasitemia, where 
more than 5% of the red blood cells are infected by malaria parasites.  
Note that the term parasitemia is not a specific term: It is typically used to describe the simple presence of 
parasites or to refer to the level of parasite-infected RBCs, but it does not include any clinical information. 
Hence, people with either asymptomatic or uncomplicated malaria can be referred to as parasitemic.  
Why some people develop severe malaria while others do not and how to predict progression to 
severe malaria remain highly important research topics. One reason children are at greatest risk for 
severe P.falciparum malaria infection certainly is because they have had less exposure and less immunity 
to malaria, although this does not tell the whole story and the role of acquired immunity can vary greatly 
depending on the degree of malaria endemicity in a population. Understanding RBC alterations that 
developed in the human genome in relationship to malaria pressure can shed additional light on the 
variation in human susceptibility to severe malaria. Much of the evidence for malaria protection due to 
RBC alterations will be presented below in the context of the aforementioned levels of malaria infection: 
severe malaria, uncomplicated malaria, and asymptomatic parasitemia. It is important to keep in mind that 
protection from severe malaria (the most important factor from an evolutionarily life-saving point of view) 
may not necessarily translate into protection from uncomplicated malaria or parasitemia. 
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1.2 HEMOGLOBINOPATHIES 
1.2.1 Sickle-cell Trait 
Human hemoglobin is comprised of two α-globin and two β-globin proteins; the sickle-cell 
mutation occurs in the gene encoding β-globin, causing a glutamic acid to valine switch at the 6th codon 
that leads to a sickling hemoglobin phenotype (HbAS in heterozygote form, HbSS for homozygotes) (10). 
This single nucleotide polymorphism is commonly found in populations of sub-Saharan African descent 
but is present globally, reaching a prevalence of 18% in some areas and affecting nearly 6 million 
neonates in 2010 (11). It was first hypothesized by Allison in the 1950s to relate to malaria protection, 
after he observed an increase in HbAS prevalence in the lowland populations where malaria was 
frequently transmitted in comparison to the prevalence in the highland areas of Kenya and Uganda where 
malaria was rare and he observed malaria was less common in people with sickle-cell trait versus those 
without (12, 13).  
Since then, it has been unequivocally shown that the heterozygous HbAS genotype protects 
against risk of severe malaria by analysis and meta-analysis of several studies (discussed and analyzed 
in (14–16)). Specifically, studies in West Africa have found sickle-cell trait to afford significant reduction in 
severe malaria cases (with comparable protection from the sub-types of severe malaria) in the range of 
90% (17–20). Meta-analysis of studies totaling over 10,000 patients revealed the odds ratio of severe 
malaria in HbAS populations to be 0.09, or again a roughly 90% reduction in risk of overall (14). This has 
been further confirmed by extensive genome wide association studies (21). The impact of HbAS 
genotype on uncomplicated malaria is also clear; studies have found lower parasite densities and 
uncomplicated malaria rates in those with sickle-cell trait (22–26). The same meta-analysis showed that 
HbAS genotype protects against uncomplicated malaria by approximately 30% (14). Less clear is the 
impact of HbAS genotype on the risk of parasitemia. Several conflicting cross-sectional studies report a 
range of parasitemia prevalence in HbAS vs HbAA genotype children, from lower prevalence in HbAS 
(12, 27, 28), to comparable (29–32) or higher (33, 34), which together has been taken to mean that there 
is insufficient evidence to show that HbAS genotype protects against parasitemia.  
There are multiple cellular and molecular mechanisms that may impact the pathogenesis of 
falciparum malaria in people with the HbAS genotype and the picture is not yet complete despite decades 
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of research. (1) Effect of HbAS genotype on parasite growth and development: My own work (Chapters 4 
and 5) and that of many others has shown that invasion and growth of P.falciparum in vitro within HbAS 
RBCs is reduced in low oxygen tension growth conditions (1%- 5% gas mixture versus candle jar oxygen 
tension of ~18%) (15, 35–37).  Some have proposed that the increased sickling of infected HbAS RBCs 
may be a mechanism for impaired growth (35, 38, 39), however, more recent research suggests the story 
may not be that simple. LaMonte et al. discovered differential trafficking and effects of host miRNAs from 
HbAS and HbSS RBCs. Their research shows HbAS and HbSS RBCs have higher levels of certain host 
miRNAs (which can specifically inhibit translation of parasite enzymes important for growth and 
development) and treatment with antisense oligonucleotides partially rescued parasite growth (40) in 
HbAS RBCs. (2) Effect of HbAS genotype on adhesion of parasitized RBCs: Fairhurst and colleagues 
have shown that HbAS RBCs exhibit aberrant Plasmodium falciparum erythrocyte membrane protein 1 
(PfEMP1) expression on the RBC surface (41). This parasite protein is primarily responsible for 
cytoadhesion of infected RBCs to the endothelial surface and to other uninfected RBCs (termed 
“rosetting”), both phenomena being significant contributors to severe disease. Cytoadhesion was found to 
be reduced in HbAS RBCs in vitro (41–43). In fact, altered cytoskeletal properties have been described in 
HbS-containing RBCs, hypothesized to impact parasite protein trafficking to the RBC surface (44, 45). (3) 
Effect of HbAS genotype on the immune system: First, it is possible that the reduction in parasite invasion 
and growth in HbAS RBCs (discussed above) and the subsequently reduced levels of parasitemia would 
give the immune system time to better combat the infection which could then prevent severe forms of 
disease (discussed in (15)). Second, it is possible that HbAS genotype favorably alters the host immune 
response to malaria infection, by increasing the rate of clearance of HbAS infected RBCs or by altering 
the induction of inflammatory cytokines following endothelial activation (discussed in (15, 46)). Of note, as 
Mangano et al. find and discuss in relation to others’ findings, HbS protection from parasitemia is often 
not evident by single cross-sectional observations but rather requires longitudinal analysis, and trends 
show enhanced protection with increasing age (46, 47).  They suggest HbAS helps protect the host by 
increasing immunological development against malaria and further hypothesize that altered PfEMP1 
display, which increases the number of infected RBCs in circulation (by reducing cytoadherence), might 
increase display to immune cells (46). In fact, others have found enhanced phagocytosis of HbAS 
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infected RBCs versus HbAA infected RBCs (48). In conclusion, the impact of HbAS genotype is 
multifactorial with several of the aforementioned mechanisms working together to alter the pathogenesis 
of falciparum malaria (discussed in (15)).  
However, this benefit comes with a cost. Individuals with the HbAS genotype are usually 
asymptomatic, but can develop clinical symptoms similar to a sickle cell crisis during extreme 
circumstances such as dehydration. In contrast, individuals with the homozygous HbSS genotype suffer 
from the physiological effects of sickling RBC deformations: microvascular obstruction and hemolysis 
leading to many downstream negative health effects, frequent pain crises, and reduced lifespan 
(reviewed in (10)). The widespread prevalence of HbAS despite the cost of HbSS inheritance 
demonstrates the profound advantage given by HbAS in the face of malaria infection.  
1.2.2 Hemoglobin C 
The Hemoglobin C mutation (HbAC for heterozygotes; HbCC for homozygotes) is very similar to 
sickle-trait, in that it involves a point mutation at the same position in the gene encoding β-globin, 
however it causes a different amino acid substitution (glutamic acid to lysine) at the 6th codon. It is also 
most common in populations in West Africa, with prevalence reported as high as 15% in parts of Burkina 
Faso, though outside of that epicenter the prevalence diminishes accordingly (49). For severe falciparum 
malaria, evidence of protection by the hemoglobin C variant is clear. Homozygous HbCC individuals show 
80% reduction in the risk of severe malaria and heterozyogous HbAC people show 30% reduction (18, 
50–52). Meta-analysis of 4 case-control studies revealed odds ratio of severe malaria to be 0.27 in HbCC 
and 0.83 in HbAC individuals compared to normal genotype children (14) which is on par with these 
results. As further strong evidence for overall protection, a recent genome-wide association study 
(GWAS) concluded that for each copy of the HbC allele, risk for severe malaria was reduced by 29% (21).  
For uncomplicated malaria, the picture is muddled: some studies show protection for HbAC and 
HbCC (24, 50, 53), but others do not (52). A meta-analysis of available studies concluded protection from 
uncomplicated malaria is as yet unknown in terms of HbC mutations (14). Similarly there is no conclusive 
evidence that HbAC or HbCC provides protection against parasitemia (14, 24, 32, 34, 54). The data on 
protection against parasitemia is particularly confusing and further research is needed. A recent study in 
Malian children actually found 15% increased risk of clinical malaria incidence in HbAC individuals (26).  
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However, another recent longitudinal cohort study in Malian children found reduced risk of both 
uncomplicated clinical malaria and lower parasitemia burden in HbAC individuals (55) and a recent cross-
sectional study from Burkina Faso found significant protection from parasitemia in HbCC and HbSC 
individuals (odds ratio 0.04 versus HbAA), even more so than for HbAS (odds ratio 0.27), with no 
differences in parasitemia for HbAC versus HbAA individuals (46).  
The molecular mechanisms of protection from malaria following HbC inheritance are again not 
fully elucidated, but, again, the same three areas of (1) parasite growth and development; (2) adhesion of 
parasitized RBCs to endothelial cells; and (3) immune system changes, have all been implicated. In vitro 
studies indicate reduced growth in HbCC RBCs (56–58), with some further evidence of normal invasion 
but reduced schizont lysis and merozoite egress (58), while growth in HbAC RBCs has been reported to 
be normal (56, 58). Similar to results with the HbAS genotype, both the HbAC and HbCC genotypes can 
result in altered PfEMP1 expression on the infected RBC surface (41, 42). Further microscopic analysis 
has revealed an altered cytoskeleton in RBCs from donors with HbAC genotype which was hypothesized 
to impair trafficking of parasite proteins to the RBC surface (44, 45). The impact of the HbC variants on 
the immune system are even less clear. Thus, exact mechanisms for protection provided by the HbCC 
and HbAC genotypes remain an open question (15, 59).  
Clinically, the tradeoff of inheriting the most protective form, HbCC, is mild hemolysis and anemia, 
while those with the HbAC genotype are asymptomatic. More significant clinical issues tend to arise with 
HbC co-inheritance with HbS or β-thalassemia (60).  
1.2.3 Hemoglobin E 
The Hemoglobin E mutation encompasses a point mutation that results in a glutamic acid to 
lysine switch at position 26 of the β-globin gene. It is most commonly found in parts of Southeast Asia and 
India, even reaching prevalence of up to 60% in some areas (60).  
Hemoglobin E protection against malaria is not well characterized and the available data is 
contradictory. One study examining parasitemia levels and clinical severity in malaria cases in Myanmar 
found no distinctive protective effect from HbAE (61), whereas another study looking at prevalence of 
HbAE in malaria cases from Thailand did find the HbAE genotype associated with a reduced odds of 
severe malaria by almost seven-fold (62). A further study in India examining malaria cases did find 
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reduced prevalence of HbAE and HbEE individuals compared to prevalence of these people in the 
population as a whole (63).  
Little has been done to characterize the mechanisms by which HbE might contribute to reduced 
parasitemia or malaria protection. Again, three broad categories of effects come forward: reduced 
parasite growth and development, altered adhesion of parasitized RBCs to endothelium, and impact on 
the immune system. Indeed, in vitro studies of HbEE and HbAE RBCs have sometimes found reduced 
invasion (in HbEE (64, 65) and HbAE (65)) and growth (in HbEE (66) and HbAE (67)), sometimes not (in 
HbEE (68) and HbAE (64, 66, 68)), reviewed in (15). Clearly more work needs to be done to answer 
these questions.  
The trade-off for harboring the HbE trait seems to be minimal, with mild anemia resulting from 
lower levels of expression of the β-globin gene due to the genetic mutation resulting in a splice site 
insertion that reduces mRNA stability and translation (reviewed in (15))  
1.2.4 Thalassemias 
Human hemoglobin is formed by a complex of two α-globin and two β-globin chains which are 
encoded by two alpha-globin genes (HBA1 and HBA2) and one B globin gene (HBB). The term 
‘thalassemias’ collectively refers to a number of different genetic mutations that result in reduced or 
absent expression of one or more of these globin alleles. Specifically, individuals described as having ‘α-
thalassemia’ can have the loss of one or more α-globin allele(s): αα/α- (heterozygous), α-/α- 
(homozygous), or αα/-- (loss of both paired α-globin gene, also homozygous); there is also HbH disease 
(loss of 3 α-globin alleles, α-/--) and finally hydrops fetalis (loss of all 4 α-globin genes; incompatible with 
life). Individuals with mutations in the beta globin gene(s) can also have a range of genetic defects, 
including β-thalassemia minor (reduced expression of one β-globin allele), and β-thalassemia major 
(reduced expression of both β-globin alleles) (reviewed in (15)). Geographically, the thalassemias can be 
found worldwide, with mild α+-thalassmias reaching prevalence of 10-20% throughout a belt spanning 
Sub-Saharan Africa, the Middle East, India, and Southeast Asia. β-thalassemia is predominantly 
prevalent in the Mediterranean and a few parts of Sub-Saharan Africa (see (15, 59)).  
There is clear protection from malaria associated with each of the thalassemias. In fact, the 
original “malaria hypothesis” or “Haldane’s hypothesis” connecting genetic hemoglobin alterations to 
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geographic malaria prevalence was formulated by Haldane in the 1950s as a result of his observations on  
the presence of β-thalassemia in West Africa (69).  
To begin with α-thalassemia protection, meta-analysis of studies which examined prevalence of 
α-thalassemia in children with severe malaria and healthy children found an odds ratio for severe malaria 
of 0.63 for homozygote α-thalassemia and 0.83 for heterozygotes (14, 18, 70–72). Interestingly, such 
protection from severe malaria is eliminated by co-inheritance of the HbAS allele, perhaps providing an 
explanation for why α-thalassemia mutations are not as prevalent in many parts of Africa (26, 73). When it 
comes to protection from uncomplicated malaria, consensus is less clear – some studies found 
decreased incidence of malaria with any form of α-thalassemia (though consistently lower with 
homozygote versus heterozygote form) (73, 74), while others actually found no difference (75) or 
increased incidence (76) compared to normal genotype. Meta-analysis concluded there was no risk 
reduction of uncomplicated malaria for α-thalassemia carriers (14). Finally, there also seems to be 
inconclusive evidence of asymptomatic parasitemia protection with α-thalassemia, both in terms of 
presence and density of parasites – but most studies do not find an effect on parasitemia (75, 77, 78).  
There are far fewer comprehensive studies relating to β-thalassemia malaria protection; in fact 
the majority of available evidence comes from 2 studies, one finding uncomplicated malaria cases were 
less likely to involve people with β-thalassemia (79) and the other finding upon population screening 
similar parasitemia prevalence amongst those with β-thalassemia as in those with normal genotype, albeit 
lower parasite densities were observed in those with β-thalassemia (80).  
As with most of the aforementioned hemoglobinopathies, the molecular mechanisms by which the 
thalassemias protect against malaria disease are less clear than the clinical protection itself.  
(1) Effects on growth and development. Minimal changes have been observed in invasion and 
growth with heterozygote α-thalassemia (64, 81–83). Similarly for RBCs from individuals with homozygote 
α-thalassemia, studies show conflicting and thus inconclusive evidence regarding growth and invasion 
differences (64, 82–85). RBCs from those with HbH disease more consistently exhibited reduced growth 
and invasion (65, 67, 82). The same phenomenon holds true for β-thalassemia – largely no invasion or 
growth differences have been observed (64, 84) except one study finding reduced growth (67). The 
exception is significantly reduced growth when examining RBCs missing either one copy of α-globin or β-
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globin when cultivated at high oxygen tension (83). Interestingly, invasion is frequently observed to be 
reduced in RBCs harboring both a β-globin thalassemia mutation and HbE (64, 65, 67) and reduced 
growth has been observed here as well (81) (all reviewed in (15)). To explain these findings, it was 
predicted that the thalassemias resulted in loss of ability to counter oxidative stress (15, 83).  
  (2) Effects on endothelial cell adhesion. Others observed reduced rosetting with RBCs from 
individuals with α-thalassemia and β-thalassemia and also reduced binding of α-thalassemia and β-
thalassemia RBCs to endothelial cells (81, 86–88), although the findings of reduced cytoadhesion and 
PfEMP1 expression with α-thalassemia is conflicted and inconsistent (43, 85, 89). Interestingly, as 
mentioned above, there is a reduction in protection against malaria in individuals who carry both HbAS 
and α-thalassemia (18, 23, 73). Investigating this phenomenon further with in vitro studies, Opi et al. 
found that co-inheritance abrogated the reduced PfEMP1 expression, cytoadhesion, and rosetting 
typically observed with HbAS. The mechanism for this remains unknown, though there was some 
speculation it might have to do with α-thalassemia reducing the levels of HbS production, perhaps 
especially if the hypothesis that HbS affects intracellular PfEMP1 and other membrane protein trafficking 
in infected RBCs is true (43). 
  (3) Effects on the immune system. Studies have found that anti-malarial immunoglobulins bind 
thalassemic infected RBCs more than normal infected RBCs (84, 89) and undergo increased 
phagocytosis (48), which may result in enhanced immune clearance of parasitized RBCs from individuals 
with thalassemias (discussed in (15)).  
The drawbacks of maintaining the thalassemic genetic mutations within a population can be 
significant. For example, hydrops fetalis (missing all α-globin genes) is incompatible with life and HbH 
disease (missing 3 copies of α-globin) as well as β-thalassemia major result in severely reduced lifespan 
with chronic and severe anemia and other hematological disruptions. β-thalassemia minor and the α-
thalassemia traits are much less consequential, and are often asymptomatic, only producing mild anemia 
(15). 
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1.3 ENZYMATIC DEFICIENCIES 
1.3.1 Glucose-6-Phosphate Dehydrogenase Deficiency 
Glucose-6-Phosphate Dehydrogenase (G6PD) catalyzes the first step in the pentose phosphate 
shunt, which ultimately produces NADPH, a reducing agent. NADPH is a critical co-factor for glutathione 
reductase which generates the reduced form of glutathione and is critical for lowering oxidative stress in 
RBCs.  
X-linked genetic mutations causing G6PD deficiencies are among the most common genetic 
mutations globally and affect an estimated 400 million people (reviewed in (90)). Given the distribution of 
mutations throughout Africa, the Mediterranean, Middle East, and Asia, and their independent 
development in multiple distinct populations, G6PD deficiency has been hypothesized to have arisen due 
to malaria pressure (discussed in (91, 92)). Yet, despite this long standing hypothesis and a large number 
of studies, there is quite conflicting evidence about whether or not G6PD protects against falciparum 
malaria infection. There is a great deal of controversy surrounding the question of whether or not 
heterozygous and homozygous females are protected, and even the previously commonly held belief that 
hemizygote males are protected is no longer clear cut. Even very recent comprehensive studies report 
nearly the exact opposite results: that heterozygote females are the only ones protected against severe 
malaria (21, 93, 94) or that hemizygote males and homozygote females are the only ones protected 
against severe malaria (95). 
A descriptive review of the dozens of studies that have been done to date to examine the 
question of whether or not G6PD deficiency protects against clinical malaria is beyond the scope of this 
chapter; instead, I will discuss some of the reasons why these studies have often conflicted. There are 
the typical issues: many of the studies have relatively small sample sizes, vary in the immune status of 
the subjects, and some are village surveys while others are hospital studies. This is all further 
complicated by the tremendous diversity in the G6PD gene, which results in a large diversity of enzyme 
levels – even amongst donors with the same genetic variant of G6PD, there is diversity in the levels of 
enzyme activity. In addition, since the gene is carried on the X chromosome, X inactivation of one allele in 
the RBCs results in a heterogeneity within the RBC population of heterozygous females. Finally, there are 
a wide variety of inconsistencies in the methodologies used to characterize G6PD deficiency (genetic 
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sequencing versus analysis of enzymatic activity) in the epidemiological studies linking malaria and G6PD 
deficiency. All of the aforementioned differences and complications are compounded by the fact that 
many of the different studies use different definitions of and categories of clinical malaria, which makes it 
difficult to draw definitive conclusions and compare studies, not to mention practically impossible to 
systematically review this research area. 
The human gene for G6PD contains 13 exons and encodes 515 amino acids. G6PD is a 
monomer, but the active enzyme is a dimer which requires both NADPH and FAD (riboflavin) for its 
activity. Over 140 mutations have been identified (90, 96, 97) that each result in various degrees of 
change in the enzymatic activity and over 400 variants have been characterized that have normal levels 
of G6PD activity (98). To make things more confusing, all of the 400 variants with normal G6PD levels are 
considered wild type and are referred to as G6PD B. One common variant, which is found in 20-30% of 
Black Africans and is therefore often discussed in studies linking malaria and G6PD deficiency, is referred 
to as G6PD A+. G6PD A+ has a single amino acid substitution at position 376 of an asparagine for 
aspartate (98). Another common variant often referred to in the malaria literature is G6PD A- and it is 
found in 10-15% of African-Americans. All G6PD A- variants have a mutation at nucleotide 376 (A→G), 
which also is the nucleotide substitution characteristic of G6PD A+. However, the G6PD A- variants have 
a second mutation, which is usually at nucleotide 202 (G→A) or at nucleotide 680 (G→T) or at nucleotide 
968 (T→C) (98, 99).  
The World Health Organization has classified the different G6PD variants into clinically important 
categories according to the magnitude of the enzyme deficiency and the severity of hemolysis associated 
with each variant (100). Class I variants, which are rare, have severe enzyme deficiency (less than 10% 
of normal) and have chronic hemolytic anemia. Class II variants also have severe enzyme deficiency, but 
there is usually only intermittent hemolysis associated with infection, drugs, or chemicals. Class III 
variants have moderate enzyme deficiency (10-60% of normal) with intermittent hemolysis usually 
associated with infection, drugs, or chemicals. Note that most G6PD A- variants fall into Class III. Class IV 
variants have no enzyme deficiency or hemolysis. Class V variants have increased enzyme activity (98). 
The proposed mechanisms for G6PD deficiency protection against malaria infection are unclear. 
Unfortunately, the literature on this topic, too, is plagued by the same issues discussed above for the 
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clinical studies and there are many conflicting results. As reviewed by Ruwende and Hill, there is 
evidence for two main ways which the increased oxidative stress in G6PD deficient RBCs may protect 
against malaria: (1) it causes increased Heinz body formation and methemoglobin formation which results 
either RBC lysis or enhanced phagocytosis of infected RBCs, (2) it decreases the rate of intra-erythrocytic 
parasite replication (91). Certainly it is logical that reduced parasitemia could be the protective 
mechanism against severe clinical malaria. 
To go into more detail: some original studies do indicate decreased parasite growth in G6PD 
deficient RBCs (101–104) though not decreased invasion (103, 105), but others did not find reduced 
growth (105), or only observed decreased growth with oxidative stress present (83, 102). One study 
looking at growth in individual RBCs from heterozygote women in which X-inactivation occurs found 
decreased growth in the G6PD deficient RBCs specifically (106). Indeed, as G6PD deficiency reduces a 
RBC’s ability to combat oxidative damage, and with evidence that oxidative stress reduces parasite 
growth (107) (especially in G6PD deficient RBCs (108)), this is a plausible link. Others found no 
difference in parasite invasion or maturation in erythrocytes harboring G6PD deficiency, but that infected 
RBCs were more susceptible to phagocytosis due to increased expression of phagocytic markers on the 
G6PD deficient infected RBCs (109).  
But there remains a confusing point about reduced parasitemia in G6PD deficient RBCs being 
protective, as reviewed by others (92): studies finding G6PD deficient RBCs support less parasite growth 
imply both hemizygote males and heterozygote females should be protected, although this has not 
consistently been the case in the clinical literature, where some have found only heterozygote females 
are protected (21, 93, 94). Guindo et al. similarly point out that speculated mechanisms of protection of 
increased phagocytosis or reduced pathogenesis in G6PD deficient RBCs would be expected to have 
increased protection in those “uniformly” deficient (i.e. hemizygote males or homozygote females), not 
heterozygote females (95). As a potential explanation for this conundrum about why some clinical studies 
find heterozygote females are most protected, Ugayo et al. speculate that increased severe malaria 
infection rates in G6PD deficient hemizygote males observed in some studies may have to do with 
increased potential for oxidative damage (induced by infection) resulting in increased RBC lysis and 
anemia. They then speculate protection in heterozygote females might result in part from protection by 
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normal G6PD status cells resisting oxidative stress/lysis, and in part from the presence of X-inactivated 
G6PD deficient RBCs that reduce the portion of habitable RBCs (93). Others have conducted research 
finding replication rates in G6PD deficient RBCs only remain low for a few cycles, surmising that the 
parasite can adapt to G6PD deficient conditions, thus speculating heterozygote females would maintain 
the most protection because there would not be enough pressure to induce parasite adaptation (103, 
110).  
Overall, much like the clinical outcomes, there is substantial conflicting evidence and still a great 
deal left to be learned about the protective molecular mechanisms of G6PD deficiency. It is entirely likely 
that several factors combine to mediate protection. Very likely much of the confusion and conflicting 
evidence of malaria protection in the G6PD literature arises because of the heterogeneity of the G6PD 
mutations themselves, not to mention the mutations’ inconsistent impact on overall enzymatic activity 
within an individual, and furthermore the complications of X-inactivation in females. 
The clinical consequences of G6PD deficiency include increased risks of neonatal jaundice and 
of extensive hemolysis induced by excess oxidative stress. The most common triggers for hemolysis in 
this patient population are medications (including some gametocytic antimalarials), particular foods (most 
famously fava beans), and several types of infections (reviewed in (90)).  
 1.3.2 Pyruvate Kinase Deficiency 
Pyruvate kinase (PK) deficiency, the other enzymatic deficiency that has been found to associate 
with malaria protection, deserves mention, although it is much less well studied. This enzyme is involved 
in the rate limiting step of glycolysis and is thus very important in energy production in RBCs, which lack 
mitochondria. Several mutations are known in humans (111), though the consequences of being 
homozygous are severe (hemolytic anemias requiring transfusions), making homozygotes rare 
(discussed in (111, 112)). Ayi and co-workers studied P.falciparum growth in PK-deficient RBCs and 
found reduced invasion and enhanced phagocytosis, speculating that heterozygote individuals might 
have an advantageous protection against malaria with relatively little negative health effects (112). Mouse 
studies have found protection with PK deficiency against malaria (113, 114), as have in vitro studies using 
RBCs from PK deficient donors, where a mechanism of decreased ATP levels was proposed to impact 
parasite growth (115). Clinical research has also found reduced numbers of PK deficient individuals when 
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examining P.falciparum cases in Thailand (116), again suggesting this is yet another human genetic 
variant that is likely related to malaria pressure, and will result in further studies. 
1.4 RBC MORPHOLOGY AND THE CYTOSKELETON 
Another important type of RBC change involves membrane defects which affect the RBC shape. 
There are several different kinds of these genetic mutations; most frequently mutations are seen in 
cytoskeletal components and associated membrane proteins such as spectrin or band 3 or 4.1 proteins, 
although they can also be seen occasionally in the glycophorins as well (discussed in (117–119)). The 
network of proteins making up the RBC cytoskeleton and junctional membrane tethering sites is 
complicated to visualize. Essentially, there is a lattice-like structure underlying the RBC membrane made 
up of primarily of α- and β-spectrin heterodimers which associate end to end as tetramers. There are also 
clusters of transmembrane proteins and other associated proteins that bridge the gap between binding 
the spectrin-based sub-membrane network and the membrane lipid bilayer. There are two main 
complexes of proteins: the ankyrin complex (consisting of predominantly band 3 tetramers, protein 4.2, 
GPA, CD47, and Rh linked via ankyrin to the spectrin heterodimer junction sites), and the 4.1R complex 
(consisting predominantly of 4.1R, F-actin, tropomysin, and band 3 dimers, as well as GPC, Rh, DARC, 
and Kell linked to the sites of association between the actin cytoskeleton and the subsurface spectrin 
mesh-like lattice). These protein interactions between membrane and cytoskeleton largely determine 
RBC shape and deformability and ability to circulate efficiently in the microvasculature (124, 125). 
Multiple categories of these morphological RBC disorders exist. This includes: 
1) Hereditary elliptocytosis (a heterogeneous disorder in terms of genetics and manifestation, 
ranging from severe hemolytic anemia to absence of symptoms; most mutations arise in spectrin 
and cause issues with spectrin dimer and tetramer associations or junctional associations (119–
121)) 
2) Hereditary pyropoikilocytosis (a severe hemolytic anemia type of hereditary elliptocytosis, often 
from a spectrin deficiency (120, 121)) 
3) Hereditary spherocytosis (another heterogeneous cytoskeletal defect in spectrin, ankyrin, band 3, 
or protein 4.2, and the most common inheritable cause of hemolytic anemia in Caucasians (118, 
119, 122)) 
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4) Southeast Asian ovalocytosis (SAO, a disorder characterized by RBCs with oval shape and 
decreased deformability, possibly linked to a deletion in band 3 protein, and occurring at quite 
high rates in certain geographic areas (118, 119, 123)).  
Most of these disorders are inherited in an autosomal dominant fashion (118–120) and are 
classified not based on genetics, but phenotypes. Generally speaking, mutations causing these RBC 
disorders result in reduced integrity of the RBC cytoskeleton, such that the RBC loses its biconcave 
shape and appears morphologically different by microscopy. Speculation that some of these conditions 
evolutionarily arose due to malaria pressure first arose due to the observed prevalence of hereditary 
elliptocytosis in people of African descent and areas where malaria was traditionally endemic. For 
example, hereditary elliptocytosis was determined by molecular epidemiology to be 30 times more 
prevalent in black people than Caucasians (117, 125, 126). Prevalence of hereditary elliptocytosis 
reached levels as high as 1.6% in Benin (126), and the prevalence of hereditary ovalocytosis can reach 
35% in parts of Southeast Asia (117, 127). Overall there are several different cytoskeletal genetic 
mutations, especially in Africa, making it difficult to pinpoint exact correlations with predicted malaria 
disease protection. However, as discussed, it is hypothesized that these types of mutations are highly 
prevalent (particularly alpha spectrin haplotypes) and were maintained in human populations because 
they protect against malaria (117, 120). 
Not all is understood, but there is clear evidence of malaria protection both in patients and in vitro. 
Clinically speaking, most of the documented association with protection comes from case studies with 
Southeast Asian Ovalocytosis, where reduced severity and prevalence of disease as well as reduced 
parasitemia was found (128–132). Protection against severe malaria was often profound (sometimes with 
odds ratio of 0 reported due to absence of severe malaria cases amongst those with the band 3 deletion) 
(128, 130, 131), and protection against malaria was not just afforded to falciparum but also vivax and 
malariae (129, 131, 132). Ovalocytosis was also found to reduce parasite growth in vitro  (133–135). 
Despite little published evidence of clinical protection with the other types of morphological disorders, in 
vitro studies with P.falciparum have suggested reduced parasite growth in RBCs from people with 
mutations such as hereditary spherocytosis and elliptocytosis (134). Dhermy et al. studied falciparum 
growth in RBCs harboring different elliptocytic spectrin mutations and found overall significantly reduced 
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growth, altered development, and reduced invasion, and that the growth and invasion deficits were more 
apparent with each cumulative replication cycle (117). This is similar to what others observed, finding 
severely decreased growth and invasion in elliptocytes with spectrin mutations (121, 134), as well as in 
elliptocytes with 4.1 mutations (134, 136). As Facer speculated, the relationship between parasite growth 
deficiencies and hereditary elliptocytosis could very plausibly deal with RBC invasion inhibition, either for 
mechanical reasons (reduced deformability, stability, endocytosis), or due to cytoskeletal mutations 
having downstream effects such as altered sialic acid presentation on membrane glycophorins important 
for merozoite attachment and entry (121). Similarly, SAO RBCs are known to be less deformable (137), 
and Gallagher discusses the likelihood of reduced merozoite invasion playing a role in ovalocytosis 
protection, either from poor band 3 binding or inability of band 3 to properly cluster and allow for 
membrane and cytoskeletal dissociations necessary for the parasite to enter the RBC (120). Certainly 
there are many plausible links between cytoskeletal defects and reduced parasite growth or ability to 
cause disease, which will continue to be elucidated with further study. 
For most people harboring cytoskeletal mutations, these morphological RBC changes cause few 
problems and remain asymptomatic throughout their lifetime, however there are some cytoskeletal 
mutations where hemolytic anemias and splenomegaly occur as the less deformable mutant RBCs get 
“caught” in the microvasculature of the spleen (118). Given the commonalities between so many other 
types of RBC mutations arising in malaria endemic areas and the realization that they afford malaria 
protection, the likelihood of these cytoskeletal defects having a similar evolutionary role in terms of 
malaria protection is clear. This is further backed up considering many plausible links between parasite 
pathophysiology and the impact of cytoskeletal defects, such as potential problems with RBC invasion, 
trafficking of parasite proteins to the RBC surface, or altered membrane antigens and deformability. 
Indeed the case of Southeast Asian Ovalocytosis is especially compelling. Autosomal dominance is so 
severe that only heterozygosity is compatible with life – and yet the prevalence of SAO remains high, 
indicating it must exist to confer evolutionary benefit (120).  
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1.5 BLOOD GROUPS 
1.5.1 ABO Blood Groups 
The ABO blood groups are most commonly discussed in the context of blood typing to determine 
compatible blood transfusion donors. Blood type A, B, and AB contain A and/or B antigens on the surface 
of RBCs which blood type O RBCs lack. Specifically, RBCs with A and B antigens express trisaccharides 
and RBCs with O antigens express disaccharides because individuals with Type O lack a specific 
glucotransferase enzyme that adds the third sugar on to the trisaccharide (138). All blood group types 
exist globally (albeit at different frequencies), so perhaps the connection to malaria protection is less 
intuitively obvious than many of the RBC mutations presented above. Early studies were conflicted: some 
researchers found significant associations with severe malaria in blood group A, B, and/or AB, and/or that 
type O was protective (139–141); others did not find an association between blood group type and 
malaria severity (142–144). A 2007 systematic review concluded there were poor controls and small 
sample sizes but likely a real association with ABO blood group type and malaria susceptibility (145). 
Since then, more comprehensive studies have taken place, namely (146, 147), more definitively 
indicating type O individuals are less susceptible to severe malaria and non-type O individuals are at 
increased risk in Sub-Saharan Africa and India (146–153). The correlations appear to be strongest 
between severe clinical disease outcomes and blood type, not simply parasitemia levels or uncomplicated 
infection. The protection is significant, with odds ratio for increased risk of severe malaria in non-O type 
blood groups ranging from 1.26 – 2.95 ((146, 147, 152)and reviewed in (146)). 
In investigating the molecular pathophysiology behind differential susceptibility to severe malaria 
in the case of the ABO blood groups, the consistently arising factor is reduced rosetting. Rosetting refers 
to infected RBCs adhering to and clumping with uninfected RBCs in the bloodstream. This contributes to 
disease pathology through inflammation and obstruction of blood flow in small vessels, with rosetting 
overall shown to correlate with severe disease (reviewed in (154)). In the case of the ABO blood group, 
many in vitro studies examining rosetting potential of different blood types found larger and more stable 
rosettes, as well as increased percent of infected RBCs forming rosettes, in non-O blood types (81, 155–
158). It was found that parasite protein PfEMP1 exported to the infected RBC surface binds to the A and 
B blood group antigens to increase rosetting susceptibility (158, 159). And in fact, this has been backed 
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up clinically by correlative case control studies examining rosetting frequency in parasites harvested 
directly from infected individuals with type O and non-type O blood (146). Others report increased 
hemolysis of infected RBCs with type O blood (153), so perhaps there are additional mechanisms that 
could contribute to malaria protection, but overall the evidence seems quite conclusive that blood group O 
benefits from relative protection against severe malaria due to reduction in rosetting potential of infected 
RBCs. The obvious question thus remains, why is blood group O not nearly universally present in areas 
of high malaria endemicity? As discussed in Rowe et al. (160), this condition, too, is likely under 
balancing selection, as there is evidence of increased association of other infectious agents (i.e. cholera, 
E. coli) with type O blood group (161, 162).  
There is also some indication of altered rosetting susceptibility in certain Knops groups (which 
comprises various antigen presentations on the complement receptor (CR1) molecule), as well as altered 
immune complex formation and removal, though the data is quite preliminary (reviewed in (160)). Blood 
groups affecting the presence of glycophorin B and C have also been preliminarily speculated to relate to 
malaria susceptibility, but little has been as of yet investigated (reviewed in (160)).  
1.5.2 Duffy Antigen Receptor for Chemokines (DARC) 
Although P.vivax malaria is not the focus of this chapter, perhaps one of the most compelling 
pieces of evidence for RBC evolution against malaria is the Duffy antigen receptor for chemokines 
(DARC) found on the RBC surface. DARC is nearly totally absent from individuals in West and Central 
Africa. Molecularly speaking, the Duffy blood group is determined by two co-dominant alleles (Fy*A and 
Fy*B) coding for FyA and FyB proteins. The phenotype found across most of Sub-Saharan Africa is FyA-
FyB-, and this results from a mutation in the promoter of the DARC FY gene which affects GATA-1 
transcription factor binding – specifically, the GATA-1 transcription factor for erythroid lineage cells (thus 
expression of DARC in other tissues such as endothelium is unaffected) ((163) and reviewed in (160, 
164)). There are also mutations found in Papua New Guinea resulting in essentially heterozygotic 
deficiency of DARC (FyA null) in a small population (165).  
The association between vivax malaria protection and African populations originally arose from 
work in the United States where researchers were investigating infection of malaria species with RBCs of 
various blood groups, finding that FyA-B- RBCs from African Americans resisted infection with the non-
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human primate parasite P.knowlesi (166). Subsequent research by this group looking at voluntary vivax 
exposure of inmates (through mosquito feeding) found African Americans with the FyA-B- blood group 
were resistant, while the Caucasians were not (167). This soon became hypothesized to be the reason 
P.vivax was largely absent from the African continent (reviewed in  (168)). As further clinical evidence of 
the association between Duffy antigen presence and vivax susceptibility, it has been determined that 
those populations in Asia with essentially half the amount of Duffy antigen (FyA null) are also 
approximately half as at risk for vivax infection and less likely to have severe disease or high levels of 
parasitemia ((165, 169) and reviewed in (160)). Though P.vivax cell culture remains impossible to this 
day, it was eventually determined that closely related knowelsi parasites require the Duffy antigen for 
merozoite tight junction formation for invasion of RBCs (170). And although extensive in vitro vivax 
studies are restricted, inhibition of invasion has been shown with the presence of antibodies targeting the 
vivax parasite’s Duffy antigen binding protein ((167, 171, 172) and reviewed in (160, 168)). This provides 
a very clear mechanism for the relationship between Duffy antigen absence and vivax absence in much 
of Sub-Saharan Africa.   
Despite the seemingly obvious connection for the existence of Duffy negative blood groups 
(established at near 100% frequency in most of Africa) to have arisen as an evolutionary benefit to resist 
P.vivax infection, this association has still been called into question (reviewed in (168, 173)). For one 
thing, some researchers point out that vivax malaria (at least in its current form) is rarely as severe or 
lethal, questioning how such a strong phenotype regarding the existence and prevalence of the Duffy 
antigen negative blood group could have arisen from evolutionary drive for a comparatively weak disease. 
However, the notion of vivax being a rather “benign” form of malaria is also a point of recent debate, with 
many arguing vivax infection takes a significant clinical toll even if it is not as deadly, plausibly enough to 
drive evolutionary adaptation for resistance to infection (reviewed in (164, 168, 174–176)). Other 
evidence has arisen suggesting vivax originated in Asia where it is most prevalent today, which again 
calls into question how vivax could have possibly influenced absence of the Duffy antigen across most of 
Africa ((177, 178) and discussed in (173)). Neither is this point uniformly agreed upon, however. In fact, 
very credible and compelling recent research claims the exact opposite, that vivax malaria originated in 
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non-human primates in Africa (179). If true, this of course allows for simple explanation of why DARC is 
absent from most Africans. 
Regardless of vivax origin and DARC prevalence, as Howes et al. extensively investigate and 
assess by meta-analysis, the belief that P.vivax is totally absent from Africa is far from accurate, with 
evidence for widespread (albeit quite low level) infection in many areas (180). Vivax existence in Africa is 
due to a combination of factors: a small population of Duffy positive individuals (particularly in parts of 
East Africa and Madagascar), possible zoonotic infection, and also parasite exploitation of alternative 
invasion routes in Duffy negative individuals (reviewed in (180)). In fact, definitive evidence has 
developed proving Duffy antigen negative individuals can support vivax infection – coming from such 
diverse regions as Mauritania, Equatorial Guinea, Cameroon, Ethiopia, Angola, Madagascar, Kenya, and 
even Brazil (reviewed and mapped in  (168, 180)), which is cause for renewed scrutiny of vivax burden 
potential in Africa.  
1.6 NEW AREAS OF RESEARCH REGARDING CHANGES IN RBC PHYSIOLOGY 
1.6.1 Nutritional Immunity, Iron Deficiency, and Anemia 
A newer area of research, at least in terms of framing it in the context of RBC alterations that 
impact malaria disease severity, has to do with nutritional immunity. Nutritional immunity refers to the host 
withholding essential nutrients from invading pathogens; often these nutrients are crucial growth or 
virulence factors for pathogens and the host gains an advantage by devising ways to make them less 
accessible. Though the term nutritional immunity can encompass several nutrients, particularly metal ions 
such as iron, zinc, copper, and manganese (reviewed in (181–183)), in the context of malaria, iron is 
central (183–185). In the bacterial field, the host-pathogen competition for iron is well-known to be a 
molecular arms race. To make it less freely available, the host binds iron in the blood and other 
secretions (either directly or as part of heme/hemoglobin, via proteins such as transferrin, lactoferrin, 
hemopexin, and haptoglobin), stores it in tissues (via the iron storage protein ferritin), and regulates 
dietary absorption and body storage (via inflammation-induced hepcidin signaling). Bacteria have devised 
several ways to sequester back iron from transport molecules or access intracellular iron stores. As 
examples, several bacteria express siderophore proteins or transferrin binding proteins that can chelate 
iron away from transferrin or access transferrin-bound iron in the blood. However, humans have further 
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evolved to possess the siderocalin/lipocalin2 protein which can sequester bacterial siderophores. And yet 
still, some bacteria have developed stealth siderophores to avoid siderocalin binding (reviewed in (186)). 
Such strong evidence of back and forth evolution over iron access is also seen with findings of specific, 
targeted, point mutations developing over time in host transferrin and bacterial transferrin binding protein 
(to either evade or improve binding each other, depending on the organism’s goal) (187). Clearly, iron 
access can play an important role in human and pathogen evolution.  
Beyond bacteria, iron is also a well-known growth factor for malaria (reviewed in (188)). Iron of 
course also directly effects erythropoiesis and is essential for hemoglobin formation. With growing 
epidemiological evidence over the past decades that iron deficient people are more resistant to malaria 
infection (189–192) and iron supplementation possibly puts them at increased risk for infection (193–197), 
the idea of nutritional immunity playing a role in malaria susceptibility is very plausible. Given the 
geographic overlap between prevalence of iron deficiency and malaria endemicity in the developing 
world, there exists a public health conundrum of how to best treat anemia (itself not an inconsequential 
health deficit that can significantly affect child development and pregnancy outcomes), if iron deficiency is 
protective and iron supplementation increases malaria risk. Yet, evidence from these epidemiological 
studies is inconclusive and questions remain about exactly how iron deficiency and iron supplementation 
may impact malaria pathogenesis. Iron is not just a growth factor for malaria; iron deficiency significantly 
impacts several physiological properties of the RBC and hence could alter malaria infection susceptibility 
in many ways. 
To better address this question, we have worked to model in vitro the growth of malaria in RBCs 
from relevant donor populations. The crux of this dissertation thus involves investigating the degree of 
protection of iron deficiency anemia and the safety of iron supplementation via in vitro characterization of 
infection and growth parameters of the malaria parasite in RBCs from iron deficient individuals before and 
after iron supplementation. This research is directly applicable to the concept of RBC alterations 
conferring resistance to malaria and contributes to our broader understanding of malaria pathogenesis. 
1.7 CONCLUSIONS 
In focusing on human RBC factors contributing to malaria infection, admittedly missing from this 
discussion are potential linkages of malaria protection to human genetic alterations and physiology 
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beyond the RBC. This would include immunity and inflammatory related factors, such as HLA haplotypes 
and MHC complexes (198, 199), TNF-α (200), CR1 (201), NOS2 (202), CD40L (203), and IL22 (204), or 
factors that affect binding of infected RBCs to the endothelium like CD36 (205), ICAM-1 (116), and EPCR 
(206) variants – all of which have been published as potentially affecting malaria susceptibility. Nor have I 
discussed new areas of research involving GWAS looking for novel RBC or other factors associated with 
reduced malaria severity that are as of yet unidentified or underappreciated.  
Still, as is clear from all of the above evidence, humans and Plasmodium species have been at 
war for centuries, and one of the most important battlegrounds is indisputably the human RBC. The work 
in this dissertation was designed to better understand the interaction of the falciparum malaria parasite 
with iron deficient and anemic RBCs, a relatively new line of interest in the long standing quest to 
characterize parasite-RBC interactions in the context of modified human physiology and genetic 
adaptations. Of further importance, the research described in this dissertation also addresses the 
important public health issue of how to safely correct anemia in malaria endemic areas. Better 
understanding of malaria pathogenesis in the face of altered RBC physiology will ultimately help improve 
our strategies to combat the disease. 
1.8 DISSERTATION OUTLINE 
To orient the reader, the work presented in the remainder of this dissertation includes: 
Chapter 2: Initial in vitro modeling using UNC-based blood donors to examine how iron deficiency 
and iron supplementation conspire to mediate host susceptibility to erythrocytic stage malaria infection; 
Chapter 3: Development of improved long-term RBC storage methods for in vitro falciparum 
culture in order to better utilize valuable RBC samples, in anticipation of initiating field work using blood 
donors enrolled in an iron supplementation clinical trial; 
Chapter 4: Evaluation of the degree of protection afforded by iron deficiency anemia and the 
safety of iron supplementation through in vitro erythrocytic stage infection modeling, using RBCs from 
anemic Gambian children enrolled in an iron supplementation trial; 
Chapter 5: Evaluation of the degree of protection afforded by iron deficiency anemia and the 
safety of iron supplementation through in vitro erythrocytic stage infection modeling, using RBCs from 
pregnant Gambian women enrolled in an iron supplementation trial; and 
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Chapter 6: Summary and discussion of ways to advance research regarding the relationship 
between iron deficiency, iron supplementation, and malaria infection. 
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CHAPTER TWO: HOST IRON STATUS AND IRON SUPPLEMENTATION MEDIATE MALARIA 
SUSCEPTIBILITY TO ERYTHROCYTIC STAGE PLASMODIUM FALCIPARUM1 
 
 
2.1 OVERVIEW 
Iron deficiency and malaria have similar global distributions, and frequently co-exist in pregnant 
women and young children. Where both conditions are prevalent, iron supplementation is complicated by 
observations that iron deficiency anemia protects against falciparum malaria, and that iron supplements 
increase susceptibility to clinically significant malaria, but the mechanisms remain obscure. Here, using 
an in vitro parasite culture system with erythrocytes from iron deficient and replete human donors, we 
demonstrate that Plasmodium falciparum infects iron deficient erythrocytes less efficiently. In addition, 
owing to merozoite preference for young erythrocytes, iron supplementation of iron deficient individuals 
reverses the protective effects of iron deficiency. Our results provide experimental validation of field 
observations reporting protective effects of iron deficiency and harmful effects of iron administration on 
human malaria susceptibility. Because recovery from anemia requires transient reticulocytosis, our 
findings imply that in malarious regions iron supplementation should be accompanied by effective 
measures to prevent falciparum malaria. 
2.2 INTRODUCTION 
The interactions between falciparum malaria and iron deficiency anemia (IDA) are complex and 
bi-directional. Malaria causes acute anemia by destroying both infected and uninfected red blood cells 
(RBCs) (1), whereas persistent sub-clinical infection causes a milder anemia of infection by blocking iron 
recycling to the bone marrow (2). Conversely, once established, IDA protects both pregnant women (3–5) 
and children (6–8) from malaria. In addition, supplemental iron, given alone or in combination with other 
micronutrients, predisposes children to malaria (8, 9) and other serious adverse outcomes (10). Iron 
homeostasis has been implicated in regulating liver stage P.falciparum infection; in murine studies,  
                                                          
1 First published in Nature Communications, 25 July 2014, 5:4446; doi:10.1038/ncomms5446 
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erythrocytic stage malaria infection initiates hepcidin-mediated hepatic hypoferremia, which blocks 
superinfections by sporozoites from competing plasmodial strains (11). Mathematical modelling suggests 
that this can explain the low levels of superinfections in young children (11), but this mechanism cannot 
account for observed reductions in the risk of primary malaria infection in children with IDA. It has also 
been speculated that transient peaks in non-transferrin-bound iron caused by administration of highly 
absorbable iron supplements (12) could promote intra-erythrocytic parasite growth (13) or bacterial 
septicemia (a common cause of death in malaria patients (14–16) but definitive evidence is absent. 
As iron deficiency and iron supplementation of iron deficient individuals profoundly alters 
erythropoiesis, RBC physiology, and RBC population structure, we hypothesized that iron deficiency and 
iron supplementation directly impact the disease causing erythrocytic stage of P.falciparum infection. In 
our investigations, we minimize the confounding factors that have complicated prior field studies of the 
relationship between host iron status, iron supplementation and falciparum malaria by utilizing an in vitro 
system with freshly isolated RBCs from donors with well-defined, physiologic iron states recruited through 
our US-based hospital clinic. This approach eliminated the influence of acquired and innate immunity to 
malaria, hemoglobinopathies and concurrent inflammation. Our study reveals that RBCs from donors with 
IDA confer malaria protection by impairing P.falciparum invasion and intra-erythrocyte propagation. This 
protective effect was reversed when donors with IDA received iron supplementation. We go on to show 
that when iron deficient RBCs are replaced with iron-replete (IR) RBCs in vitro (as occurs in individuals 
with IDA following iron supplementation) the susceptibility to P.falciparum infection is increased. These 
findings support well-described clinical patterns of differential susceptibility to malaria. Taken together, 
they indicate that therapeutic iron supplementation conspires with host iron status to mediate host RBC 
susceptibility to malaria infection by altering the dynamic structure of the host’s RBC population. 
2.3 MATERIALS AND METHODS 
Clinical: Study participants included healthy, HIV-negative, non-pregnant donors over 18 years 
of age with and without IDA. Exclusion criteria included: on-going inflammation or infection, previous 
history of malaria, travel to malaria endemic areas, malignancy, sickle cell disease (or trait), thalassemia 
(or trait for either thalassemia-α or -β). This study was approved by the University of North Carolina 
Institutional Review Board, Protocol #09-0559, and informed consent was obtained from all subjects. 
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Study participants with Hgb >11g/dl and ferritin >12 ng/ml were classified as IR and participants with Hgb 
<11g/dl and ferritin <12ng/ml were classified as IDA. IDA+Fe donors were identified by their personal 
physicians for participation in our study. Subjects were included in the IDA+Fe group if they fit the criteria 
for IDA and had been prescribed high-dose oral ferrous sulfate, 60 mg (9–12.6 mg/kg) elemental iron 
orally three times per day or intravenous iron at a dosage determined by their personal physician using 
the following equation: Dose=0.0442 [desired Hgb – observed Hgb] x LBW + [0.26 x LBW]. Healthy 
donors took 325 mg of ferrous sulfate once daily for the 2-month duration of the study. These donors 
donated 40 ml of blood on three occasions— at enrollment and two subsequent monthly intervals. An 
additional group of healthy donors served as the IR control group. Non-anemic donors with low-iron 
stores (Hgb >11g/dl, ferritin <12ng/ml) were excluded. Full iron panels were obtained for each study 
participant and mean values for each group are reported in Table 2.1. 
Parasite culture: P.falciparum parasite strains 3D7, Dd2 and FCR3-FMG were cultured in RBCs 
from O+, IR donors at 2–3% hematocrit and Albumax Complete Media (ACM)–RPMI 1640 (Sigma-
Aldrich) with 10% AlbuMAX II (Gibco), 1mM hypoxanthine (Sigma-Aldrich), 20mM L-glutamine (Cellgro), 
0.45% glucose (Cellgro) and 0.01 ng/ml gentamicin (Sigma-Aldrich). AlbuMAX II was used to supplement 
the media in place of human serum to isolate the effects of the RBCs from different experimental groups. 
All RBCs used for parasite culture were obtained from well-characterized IR O+ donors and used within 
14 days of being drawn. Cultured parasites were maintained between 0.5 and 10% at 37⁰C, in an 
atmosphere of 5% O2, 5% CO2 and 90% N2 with continuous shaking. Early ring stage parasites were 
synchronized with 5% (w/v) D-sorbitol. Synchronization was repeated at 20 and 40 h to achieve a tightly 
synchronized parasite population. 
Growth assay: P.falciparum parasites from routine cultures were seeded as rings at 0.5% initial 
parasitemia in 1% hematocrit in ACM in triplicate in 96-well plates. Parasites were maintained for 96 h 
under standard culture conditions and the media was changed daily. At 96 h, parasite cultures were split 
back to 0.5% parasitemia and maintained as described for an additional 96 h (Supplementary Fig. S2.1). 
Parasites were stained at all 0 and 96 h time points with 1X DNA dye SYBR Green I (Invitrogen) as 
described in ref. (17), and fixed in 1% paraformaldehyde and 0.0075% glutaraldehyde (Electron 
Microscopy Sciences) in Alsever’s Solution (Sigma-Aldrich) for 30 min at 4⁰C. Fixative was removed and 
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cells were stored in PBS at 4⁰C until analysis by flow cytometry. Growth rate reflects the fold increase in 
RBC parasitization between 0 and 96 h. To identify parasitized reticulocytes, cultures were stained with 
0.5 mM DNA dye SYTO 61 (Invitrogen) (13, 18) and PE-conjugated mouse anti-human CD71 antibody 
(Miltenyi Biotech) and analyzed by flow cytometry. 
Barcoded RBC invasion assay: RBCs were labelled with 5 mM of either CellTrace Violet or 
CellTrace Far Red DDAO-SE (Invitrogen) as described (18). Violet- and DDAO-labelled RBCs were 
combined in ACM and delivered in triplicate into 96-well plates and subsequently seeded with schizonts 
to achieve 1.5–2% parasitized RBCs. Parasites were maintained for 12–18 h under standard culture 
conditions to allow for schizont rupture and subsequent invasion of CellTrace-labelled RBCs. The 
invasion of P.falciparum into Violet- and DDAO-labelled RBCs was directly compared by measuring the 
SI, defined as the ratio of the prevalences of infected Violet RBCs to infected DDAO RBCs (19). Note that 
the SI is different from the previously described selectivity index (20, 21). The selectivity index has been 
used to report the number of multiply infected cells, whereas the SI defines the relative susceptibility to 
invasion of two different types of RBCs. 
Parasite erythrocyte multiplication rate assay: Trophozoite-infected cultures were magnetic 
activated cell sorting (MACS) purified and seeded into experimental RBCs to achieve 1.5–2% pRBCs and 
incubated for 48 h to allow for invasion of merozoites into experimental RBCs and their subsequent 
development into trophozoites inside the experimental RBCs. Experimental RBC parasite density was 
determined and the same number of infected experimental RBCs was seeded into separate wells 
containing target RBCs (from an IR donor) to achieve 1.5–2% pRBCs. Cultures were then incubated for 
12–18 h to allow merozoites produced within experimental RBCs to invade target RBCs, allowing for 
assessment of the PEMR (20, 22). Following invasion of target RBCs, cells were stained with SYBR 
Green I and analyzed by flow cytometry to determine the total number of ring pRBCs. PEMR reflects the 
number of merozoite invasions of target RBCs per schizont infected experimental RBC. 
Density separation: RBCs were separated into five fractions with a modified version of 
previously described density gradient centrifugation method (23). Briefly, blood was collected into acid 
citrate dextrose and plasma was subsequently removed by centrifugation for 15 min at 800g. Packed 
cells were resuspended at 50% hematocrit in RPMI, and passed over a 2:1 (w/w) α-
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cellulose/microcrystalline cellulose column to remove lymphocytes (24). Following lymphocyte depletion, 
RBCs were washed twice with RBC buffer (10mM HEPES, 12mM NaCl, 115mM KCl, 5% BSA). RBCs 
were layered onto a 65, 60, 55 and 50% discontinuous Percoll gradient and then centrifuged for 25 min at 
1,075g. Each of the five fractions was removed, washed twice with RBC buffer and stored at 4⁰C for up to 
5 days. Decreasing MCV, reticulocyte content and Calcein fluorescence (25) of the five fractions 
confirmed the age separation of RBCs (Supplementary Fig. 2.3c–g). For barcoded RBC invasion assays 
and growth assays, which utilized density separated RBCs, recombined RBCs were included as a ‘total’ 
RBC control.  
Flow cytometry: Growth, invasion and infectious merozoite production assays were analyzed by 
flow cytometry using either a modified FACS-Calibur with two lasers 30mW 488 Diode Pumped Solid 
State laser and a 25-mW 637 red diode laser (FACS-Calibur; Becton Dickinson, modified by Cytek 
Development) or a Beckman-Coulter (Dako) CyAn ADP. Channels and probes used on the FACSCalibur 
included: SYTO 61 (637 nM, 666/27 bandpass), PE (488 nM, 585/42 bandpass) and SYBR Green I (488 
nM, 530/30 bandpass). FACS-Calibur data were collected using FlowJo CE and analyzed with Summit 
v5.1. Channels and probes used on the Dako cyan included: CellTrace Violet (405 nM, 450/50 
bandpass), SYBR Green I (488 nM, 530/40 bandpass) and CellTrace DDAO-SE (635 nM, 665/20 
bandpass). Data from the Cyan cyotometer were collected and analyzed with Summit v4.3.01. Linear 
amplification of forward scatter was used to set event threshold in order to exclude cell debris, 
microparticles and doublets. Electronic volume of uninfected RBCs and pRBCs was assessed on a 
Beckman Coulter Cell lab Quanta (Beckman Coulter). Channels and probes used on the Quanta 
included: SYBR Green I (488 nM, 525/40 bandpass). National Institute of Standards and Technologies-
certified beads standard L2 2 mm, L5 5 mm and L10 10 mm (Beckman Coulter) were used to calibrate 
electronic volume. Calibrated data were expressed as both electronic volume (mm3) and diameter (mm). 
Quanta data were collected with Cell Lab Quanta Collection Software for Instrument Control and 
analyzed with Kaluza (Beckman Coulter). For all experiments, samples were diluted to 0.001–0.002% 
hematocrit and 100,000–500,000 total events were collected.  
Statistical methods: All experiments were performed in triplicate. Results are from either one 
representative experiment or the combined results of at least three independent experiments. Parasite 
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growth rate and infectious merozoite production experiments were analyzed with two-tailed Student’s t-
test and one-way analysis of variance (GraphPad Prism 5). Data from all in vitro growth studies were 
pooled and analyzed using random effects regression (Fig. 2.1d,e). The dependent variable in the 
analysis was the logarithm of the ratio of the percent pRBCs at 96 h (final) and 0 h (initial). In addition, to 
the usual variation independently affecting each observation, we fitted two higher levels of variance: 
variation between individuals and day-to-day variation in parasite ‘preparations’ taking account of the fact 
that in this data set these two variance components were cross (rather than the more usually encountered 
nested design). We fitted two exposure variables, iron status and iron supplementation, both as binary 
variables, and their interaction, focusing on three contrasts: supplemented IDA versus supplemented IR 
donors; supplemented versus non-supplemented IDA donors; supplemented versus non-supplemented 
IR donors. All experiments were performed in triplicate with three P.falciparum strains (3D7, Dd2 and 
FCR3-FMG) and consisted of three serial 96 h growth assays (Supplementary Fig. S2.1); P.falciparum 
strain, growth assay number and their (highly significant) interaction were fitted as binary covariates. We 
noted that when 0 h (initial) percent pRBCs was greater than 1, the second growth assay always gave 
anomalous low results (most likely due to a saturation effect). As these data were uninformative and yet 
added noise to the analysis, we omitted all such cases while noting that although their inclusion increased 
the standard errors, it did not change the same general conclusions of the analysis. This model was fitted 
using Stata’s xtmixed procedure (v12, Stata Corp). To compare the susceptibility of different RBC types to 
invasion by P.falciparum, an unadjusted odds ratio was used to calculate the SI. All statistical analyzes 
for invasion experiments were performed with Stata/IC (v10, Stata Corp). Linear regression was 
employed to investigate the associations between host iron status and parasite invasion in vitro using 
percent of RBCs from IDA or IR donors as the independent variable and total invasions/1x105 RBCs as 
the dependent variable (Fig. 2.3e). Analysis of covariance was conducted to determine whether the 
invasion into the two groups were the same. An α of 0.05 was set a priori to determine statistically 
significant differences. Similar analysis was done to better understand associations between RBC age 
and parasite invasion (Fig. 2.4e).  
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2.4 RESULTS 
2.4.1 Malaria growth is reduced in RBCs from individuals with IDA. 
To determine the effect of IDA on the growth of erythrocytic stage P.falciparum, we enrolled 
donors with and without IDA from a non-malaria endemic area through our US-based hospital clinic. 
Donors were classified as IR (hemoglobin (Hgb) >11g/dl, mean corpuscular volume (MCV) >80 fL, ferritin 
>12ng/ml) or as IDA (Hgb <11g/dl, MCV <80 fL, ferritin <12ng/ml) (Table 2.1). Non-anemic donors with 
low iron stores (Hgb >11g/dl, ferritin <12ng/ml) were excluded. P.falciparum (strains 3D7, Dd2 and FCR3-
FMG) were grown in either RBCs from the IR (n=10) or IDA (n=7) donors in up to three consecutive 96 h 
growth assays (Supplementary Fig. S2.1). We observed that parasite growth rates were reduced in RBCs 
from IDA donors as compared with growth in RBCs from IR donors by 48.8% (standard deviation 
(s.d.)±23.9), 34.3% (s.d.±22.2) and 50.0% (s.d.±20.4) for strains 3D7, Dd2 and FCR3-FMG, respectively 
(Fig. 2.1a). These findings clearly show that P.falciparum propagation is reduced within RBCs from IDA 
individuals, but that variability may exist in the degree to which different P.falciparum isolates are affected 
by IDA.  
2.4.2 Malaria growth is increased in RBCs from iron-supplemented donors.  
Given field evidence that supplementation of children with 12.5 mg of iron (1–1.5 mg/kg) and 50 
ng of folic acid may potentiate the risk of malaria (9), we next investigated the effects of iron 
supplementation of IDA and IR individuals on in vitro growth of erythrocytic stage P.falciparum. We first 
collected RBCs from IDA patients who were receiving iron supplementation (IDA+Fe); these individuals 
met the above criteria for IDA and were receiving either high-dose oral ferrous sulfate (60 mg elemental 
iron orally three times per day (9–12.6 mg/kg)) or intravenous iron (at a dosage determined by their 
personal physician using the following equation: Dose=0.0442 [desired Hgb—observed Hgb] x LBW + 
[0.26 x LBW]). IDA+Fe group Hgb values ranged from 6.6 to 9.8 g/dL and MCV values ranged from 75 to 
98 fL. Additionally reticulocyte counts and red cell distribution width (RDW) were elevated; and average 
mean corpuscular hemoglobin concentration (MCHC), total iron, and ferritin values were greater than that 
of the IDA group but still lower than that of the IR group (Table 2.1). Together, these values are indicative 
of an erythropoietic response to iron supplements, but not full recovery from IDA. Comparison of the 
growth rate of P.falciparum (strains 3D7, Dd2 and FCR3-FMG) within RBCs from the IDA+Fe donors to 
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the growth rate of parasites within RBCs from IR donors revealed increases in P.falciparum growth of 
17.3% (s.d.±22.7), 17.6% (s.d.±14.0) and 26.3% (s.d.±16.1) for 3D7, Dd2 and FCR3-FMG in RBCs from 
IDA+Fe donors (Fig. 2.1b). 
We additionally assessed the effect of iron supplementation of IR individuals on P.falciparum 
growth. For this study, IR individuals donated blood at enrollment (baseline) and were then prescribed 
daily oral iron supplementation (325 mg ferrous sulfate). Iron-supplemented IR study participants (IR+Fe) 
subsequently returned at one and two months following initiation of daily iron supplementation to donate 
blood. At each donation (enrollment, 1 month and 2 months), the growth rate of P.falciparum (strains 3D7, 
Dd2 and FCR3-FMG) within RBCs from IR+Fe donors was determined and then compared with the 
corresponding parasite growth rates within RBCs from a non-supplemented IR donor. Compared with 
RBCs from IR donors, we observed in RBCs from IR+Fe donors that 1 month of iron supplementation 
increases of 17.5% (s.d.±16.1), 11.3% (s.d.±15.7) and 6.6% (s.d.±8.1) in growth for 3D7, Dd2 and FCR3-
FMG, respectively. There was no change in parasite growth rate in RBCs collected 1 and 2 months after 
administering iron supplements (Fig. 2.1c). Analyzes of Hgb, hematocrit, MCV, MCHC, transferrin 
saturation, ferritin and reticulocyte count of IR+Fe donors revealed no significant change in their iron 
status following iron supplementation (Table 2.1). 
To comprehensively compare and ultimately quantify the impact of IDA and iron supplementation 
on the growth of P.falciparum in vitro, we integrated data from all growth experiments and fit a multilevel 
random effects model to the pooled data (Fig. 2.1d). The outputs of this analysis were growth rates of any 
parasite strain in experimental RBCs plotted against the growth rate in IR RBC controls. Values were 
adjusted for variation between study participants, day-to-day differences in parasite preparations and 
differences in P.falciparum strain growth rates. The Y=X line was fit to the growth rate of P.falciparum in 
RBCs from IR donors. Data above the Y=X line indicate growth rates greater than that of parasite growth 
in RBCs from IR donors and data below the Y=X line indicate growth rates lower than that of parasite 
growth RBCs from IR donors. Based on this analysis, we estimate that compared with IR RBCs, 
P.falciparum growth is reduced (59.8% (95% confidence interval (CI)=51.9–68.8)) in RBCs from IDA 
donors, and that there is a slight increase in the growth of P.falciparum in RBCs from IDA+Fe donors 
(22.8% (95% CI=2.7–46.7)) and RBCs from IR+Fe donors (18.9% (95% CI=5.0–33.9)); no difference was 
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observed between P.falciparum growth in RBCs from IRþFe donors and IDAþFe donors (Fig. 2.1e). 
These data clearly indicate that IDA substantially attenuates the growth of P.falciparum parasites and that 
iron supplementation of donors with IDA reverses the protection provided by IDA against falciparum 
infection. Furthermore, these data suggest that iron supplementation of IR individuals may slightly 
increase propagation of erythrocytic stage P.falciparum.  
2.4.3 RBCs from donors with IDA are refractory to malaria infection. 
Propagation of the erythrocytic stage of P.falciparum may be impeded at the point of (i) invasion, 
(ii) maturation or (iii) production of infectious daughter merozoites. To determine why P.falciparum 
infection of RBCs from IDA donors is reduced, we systematically assessed the capacity of P.falciparum to 
progress through each of these rate-limiting steps within RBCs from IDA donors compared with RBCs 
from IR donors. To assess invasion, we directly compare invasion of P.falciparum strains 3D7, Dd2 and 
FCR3-FMG into RBCs from IDA and IR donors with a barcoded RBC flow cytometry based invasion 
assay. To express the differential invasion of RBCs, we computed the susceptibility index (SI), which is 
the ratio of the relative risk of invasion of RBCs from IDA donors to that of RBCs from IR donors. An SI of 
1.0 indicates no difference in parasite invasion between two RBC populations. In experiments with strains 
3D7, Dd2 and FCR3-FMG, the mean SI of RBCs from IDA donors relative to RBCs from IR donors was 
0.56 (95% CI=0.56–0.57), 0.52 (95% CI=0.52–0.53) and 0.70 (95% CI=0.69–0.71), respectively, 
indicating consistently reduced invasion of RBCs from IDA donors (Fig. 2.2a). We next assessed parasite 
maturation within RBCs from IDA donors by analyzing Giemsa-stained thing blood smears, which were 
made every 6 h during the course of a 48-h intra-erythrocytic lifecycle. We observed that parasites 
matured normally in iron deficient RBCs, indicating that the reduced overall parasite growth in iron 
deficient RBCs did not result from delayed maturation (Fig 2.2b,c). Finally, we measured the parasitized 
erythrocyte multiplication rate (PEMR) (20, 22) of P.falciparum within RBCs from IDA donors as 
compared with RBCs from IR donors. For parasite strains 3D7, Dd2 and FCR3-FMG, RBCs from IDA 
donors (relative to RBCs from IR donors) had a reduced PEMR of 48.0% (s.d.±12.2), 25.7% (s.d.±2.2) 
and 39.9% (s.d.±9.3), respectively (Fig. 2d). In accordance with the PEMR data, we additionally observed 
fewer merozoites within IDA as compared with IR RBCs by microscopy (data not shown). Taken together, 
these data indicate that P.falciparum matures normally within RBCs from IDA donors, but that invasion 
46 
 
into and production of infectious merozoites within RBCs from IDA donors are significantly reduced. 
These data additionally reveal that different P.falciparum isolates may exhibit different invasion and 
PEMR phenotypes in RBCs of IDA individuals. 
2.4.4 Replacement of iron deficient RBCs increases malaria growth. 
The erythropoietic rate of iron deficient individuals increases dramatically in response to iron 
supplementation, and elevated erythropoietic rate is hypothesized to increase an individual’s susceptibility 
to malaria19. As the iron biomarkers of individuals in the IDA+Fe group were indicative of an 
erythropoietic response to iron (Table 2.1), we hypothesized that the replacement of iron deficient RBCs 
with IR RBCs would explain the recovered growth of P.falciparum in RBCs from IDAþFe donors (Fig. 2.1). 
To determine whether the replacement of iron deficient RBCs with young IR RBCs could explain the 
recovered growth of P.falciparum in RBCs donated by IDA+Fe individuals, we first compared P.falciparum 
infection of reticulocytes (CD71+) and mature RBCs (CD71-) from IDA+Fe donors. Consistent with 
P.falciparum’s reported preference for young RBCs, we observed 8.6% (s.d.±0.1) parasitization of 
reticulocytes (CD71+) and 4.5% (s.d.±0.4) parasitization of mature RBCs (CD71-) (Fig. 2.3a). However, 
(CD71+) reticulocytes accounted for only 1.6% (s.d.±0.9) of all RBCs and parasitized (CD71+) 
reticulocytes only contributed to 3.0% (s.d.±0.1) of the total number of parasitized RBCs (Fig. 2.3b).  
Having clearly demonstrated that reticulocytes from IDA+Fe donors are more highly infected by 
P.falciparum, but that reticulocytes themselves only contribute marginally to the total infection, we next 
sought to definitively determine whether the replacement of iron deficient with IR RBCs could explain the 
recovered growth of P.falciparum in RBCs from IDA+Fe donors. However, low incidence of IDA in our 
study setting, the difficulty of following iron-supplemented IDA individuals longitudinally through full 
recovery from iron deficiency, as well as the inability to use the common surrogates of RBC age (volume 
and density) against the background of changing host iron status, prevented us from studying the impact 
of an elevated erythropoietic rate on erythrocytic stage P.falciparum infection. Therefore, we modelled the 
effect of iron supplementation- mediated changes in RBC population dynamics on erythrocytic stage 
P.falciparum infection by assessing the impact of replacing RBCs from IDA donors with RBCs from IR 
donors on in vitro P.falciparum growth. Replacing 10, 25, 50 and 75% of the RBCs from IDA donors with 
RBCs from IR donors resulted in a steady increase in parasite growth rate; 75% replacement recovered 
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3D7, Dd2 and FCR3-FMG P.falciparum growth rate to 88.2% (s.d.±2.0), 89.7% (s.d.±2.5) and 92.3% 
(s.d.±1.1) that of the growth rate of in RBCs from IR donors, respectively (Fig. 2.3c). 
As the first step in the erythrocytic life cycle of the malaria parasite, erythrocyte invasion is a 
pivotal determinant of the magnitude of infection. Therefore, we utilized the barcoded RBC invasion assay 
to determine how iron deficient and IR RBCs interact to shape P.falciparum invasion. Like growth rate, 
P.falciparum invasion rate increased as IDA RBCs were replaced with IR RBCs. Rate of invasion was 
fully recovered to IR levels once 80% of IDA RBCs were replaced with IR RBCs for all three parasite 
strains (Fig. 2.3d and Supplementary Fig. S2.2a). Furthermore, employment of the barcoded RBC 
invasion assay allowed for the full characterization of the kinetics of P.falciparum invasion into IDA and IR 
RBCs, as the frequency of each changed relative to the total RBC population. We observed that the 
number of P.falciparum FCR3-FMG invasions into IDA and IR RBCs increased linearly, as each RBC 
population increased in frequency, R2=0.984 and 0.931, respectively, and P.falciparum invasion as a 
function of IDA RBC abundance was significantly less than that of IR RBCs (Fig. 2.3e). Similar trends 
were observed for P.falciparum strains 3D7 and Dd2 (Supplementary Fig. S2.2b and c). Together, these 
results support the hypothesis that replacing an individual’s iron deficient RBC population with IR RBCs 
would increase the host’s susceptibility to erythrocytic stage P.falciparum infection and clearly illustrate 
the impact RBC population dynamics have on potential parasite biomass and pathogenesis. Moreover, 
our use of the barcoded RBC invasion assay allowed for the definitive determination and characterization 
of the distribution of parasites in IDA and IR RBC populations, as the frequency of each changed.  
2.4.5 Effect of RBC population age structure on malaria infection. 
Reticulocytes and young RBCs are preferentially invaded by P.falciparum (26, 27), and 
theoretical models predict that elevated reticulocytosis may increase the risk of high parasite density (28, 
29). Because of the shortened lifespan of iron deficient RBCs, there is a period in the course of an 
individual’s recovery from IDA at which point protective iron deficient RBCs have been cleared from 
circulation and the remaining circulating RBCs are on average younger than that of an IR individual. To 
determine the capacity of young RBCs to shape P.falciparum infection, we (i) directly compare 
P.falciparum infection of young RBCs and RBCs of increasing age and (ii) model the effect of replacing 
young IR RBCs with old IR RBCs on P.falciparum growth and invasion in vitro. For these studies, we 
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utilized two proxies for RBC age: RBC volume, which decreases with age (23) and is unaffected by ring 
stage parasitization (30), and RBC density, which increases with increasing RBC age (23). We observed 
that when RBCs from an IR donor were infected with P.falciparum, parasite infection increased with 
increasing RBC volume (Fig. 2.4a). To directly compare P.falciparum invasion of RBCs of different ages, 
we density separated RBCs from IR donors into four fractions of increasing RBC age: young, young adult, 
mature adult and old (Supplementary Fig. S2.3A). Decreasing MCV, reticulocyte content and Calcein 
fluorescence (25) confirmed the age separation of the RBCs (Supplementary Fig. S2.3b–d). We observed 
that the SI of young adult, mature adult and old RBCs to parasite invasion as compared with young RBCs 
was 0.85 (95% CI=0.82–0.90), 0.58 (95% CI=0.56–0.62) and 0.28 (95% CI=0.27–0.30), respectively (Fig. 
2.4b). In accordance with previous reports (22, 26, 31), young RBCs sustained a significantly greater 
growth rate than young adult, mature adult and old RBCs, with young RBCs supporting a growth rate 
50% greater than old RBCs (Supplementary Fig. S2.3e), and compared with young RBCs the PEMR was 
reduced by 10% (s.d.±4.78), 15% (s.d.±1.16) and 19% (s.d.±2.23) in young adult, mature adult and old 
RBCs, respectively (Supplementary Fig. S2.3f). These data clearly demonstrate the preferential invasion 
of P.falciparum into young RBCs and show that the risk of RBCs to P.falciparum invasion relative to 
young RBCs decreases with increasing RBC age. All together we have confirmed (i) P.falciparum 
infection is more prevalent in young RBCs (ii) the increased capacity of young RBCs to support 
P.falciparum invasion and growth.  
To determine the capacity of the age distribution of a RBC population to shape P.falciparum 
infection, we examined the effect of replacing young IR RBCs with old IR RBCs on P.falciparum growth in 
vitro. We observed 15.7% (s.d.±3.1) greater growth of P.falciparum in young IR RBCs as compared with 
density separated and then recombined (total) IR RBCs, and growth remained significantly greater when 
10% of young RBCs were replaced with old RBCs. Following replacement of 33, 50, 66, 80 and 90% of 
young RBCs with old RBCs, P.falciparum growth rate steadily decreased (Fig. 2.4c). Consistent with 
P.falciparum growth, we observe that the rate of P.falciparum invasion into young RBCs is significantly 
greater than that of total IR RBCs (29.0% (s.d.±2.1)). Furthermore, we observed that as the frequency of 
young RBCs decreased from 100 to 50% and the frequency of old RBCs increased from 0 to 50%, the 
total rate of invasion decreased by only 4.9% (s.d.±0.7), maintaining a P.falciparum invasion rate 
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significantly greater than that of the invasion rate of total RBCs. However, when the frequency of young 
RBCs fell from 50 to 0% and old RBCs increased from 50 to 100%, P.falciparum infection decreased 
steadily, ultimately falling by 45.7% (s.d.±1.9) (Fig. 2.4d).  
As young IR RBCs are at the greatest risk of P.falciparum invasion, we speculated that an 
insufficient merozoite inoculum might be responsible for the observed plateau in P.falciparum invasion. 
However, invasion experiments with double the inoculum of merozoites also resulted in a plateau in the 
rate of P.falciparum invasion when young RBCs accounted for more than 50% of the total RBCs 
population (Supplementary Fig. S2.4a). Moreover, the rate of P.falciparum invasion achieved with the 
higher inoculum was less than that of the lower inoculum invasion experiments (Fig. 2.4d and 
Supplementary Fig. S2.4a). We subsequently characterized the kinetics of P.falciparum invasion into 
young and old RBCs as the frequency of each changed relative to the total RBC population. We observed 
that like P.falciparum invasion of IDA and IR RBCs, the number of P.falciparum invasions into old IR 
RBCs increased linearly as old IR RBCs increased in frequency, R2=0.991. In contrast, the number of 
P.falciparum invasions into young IR RBCs as a function of young IR RBC abundance was best fit by a 
logarithmic function, R2=0.976 (Fig. 2.4e). The same kinetics of P.falciparum invasion were observed 
when experiments were performed with double the merozoite inoculum (Supplementary Fig. S2.4b). 
These results demonstrate that replacement of young IR RBCs with old IR RBCs reverses the elevated 
growth and invasion rate sustained by young IR RBCs. In addition, we show that the rate of P.falciparum 
invasion only begins to dramatically drop off once 50% of young IR RBCs have been replaced with old IR 
RBCs, and that this can be attributed to the logarithmic nature of P.falciparum invasion of young IR 
RBCs. Together, these data support the hypothesis that the effects of iron deficiency and iron 
supplementation on RBC physiology and erythropoietic rate are at least partially responsible for 
determining an individual’s risk of malaria infection (Fig. 2.5). 
2.5 DISCUSSION 
Iron supplementation has clear nutritional benefits for children and pregnant women (2), but iron 
is also an essential nutrient for most pathogens and as a result is a critical mediator of host–pathogen 
interactions (32). Activation of the host innate immune system by the malaria parasite or other infectious 
organisms triggers reduction in iron absorption, redistribution of existing iron stores and decreases 
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erythropoiesis, which effectively limits the availability of iron to invading pathogens. It is unknown what 
host iron (mosquito or human) P.falciparum is able to access and utilize nor how the parasite circumvents 
the host’s attempt to restrict iron. It has been previously postulated that as occurs with other pathogens 
(33), iron deficiency inhibits P.falciparum infection via iron deprivation. Although the malaria parasite may 
find iron less readily available in an iron deficient host, our work reveals an alternate cellular mechanism 
by which iron deficiency may protect against malaria. Our study of the relationship between iron 
deficiency, iron supplementation and erythrocytic stage P.falciparum infection highlights how by altering 
the dynamics of the human hosts RBC population iron deficiency and iron supplementation shape 
erythrocytic stage P.falciparum infection.  
Clinical studies in different field sites have reported that iron deficiency correlates with protection 
from malaria. In Malawian children, baseline iron deficiency was associated with significant reductions in 
the subsequent risks of both parasitemia (45%) and malaria (51%) (34). Similarly in Tanzanian children, 
baseline iron deficiency significantly decreased the odds of subsequent parasitemia (23%) and severe 
malaria (38%) (6). In addition, in two studies of pregnant women, iron deficiency was associated with a 
decreased prevalence of placental malaria, a major cause of neonatal and maternal morbidity (4, 5). Our 
results—that iron deficient RBCs impair parasite propagation in vitro (Fig. 2.1)—are consistent with these 
clinical findings, and provide valuable insight into a cellular mechanism for the observations made in the 
clinical setting. In our study of P.falciparum growth in RBCs from IDA donors, we reveal that RBCs from 
IDA donors are refractory to P.falciparum invasion and support a lower PEMR but that parasite 
maturation is normal (Fig. 2.2). There are multiple physiological differences between iron deficient and IR 
RBCs that may contribute to the impaired invasion into and replication within iron deficient RBCs. These 
include greater osmotic fragility and membrane rigidity, accelerated ageing in vivo (35–38), lower Hgb 
content and smaller size (microcytosis). 
Iron supplementation has long been hypothesized to increase malaria risk, and this issue has 
garnered recent attention after a large-scale nutritional supplementation study in Tanzanian children was 
halted owing to significantly increased mortality among those receiving iron (8). Although it remains 
unclear whether the increased mortality rate was secondary to malaria, this potential for harm has 
complicated recommendations for widespread supplementation and has caused iron supplementation 
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programs in malaria endemic countries to be suspended. In a more recent randomized trial of Tanzanian 
children, iron supplementation increased the risk of malaria by 41% in iron deficient but not in IR children 
(8). Notably, our studies are consistent with the Tanzania study. Specifically, we observed increased 
parasite growth in RBCs donated by iron-supplemented IDA individuals and a modest effect in RBCs 
donated by iron-supplemented IR individuals (Fig. 2.1). As individuals in the iron-supplemented IDA group 
were observed to be undergoing an erythropoietic response to iron supplementation (Table 2.1), we 
proceeded to investigate the effect of replacing iron deficient RBCs with IR RBCs and young RBCs with 
old RBCs on P.falciparum erythrocyte infection. We demonstrate that P.falciparum growth and invasion 
rates increase when iron deficient RBCs are replaced with IR RBCs (Fig. 2.3). Furthermore, we show that 
young RBCs support greater P.falciparum growth and invasion rates than total IR RBCs and that the 
replacement of young RBCs with old RBCs reverses the effect of young RBCs on parasite growth and 
invasion (Fig. 2.4). Finally, in the course of these experiments, our use of barcoded RBC flow cytometry 
invasion assay has provided novel insight into the relationship between the frequency of a RBC subset in 
the total RBC population and P.falciparum infection (Figs 2.3e and 2.4e). In summary, our results 
demonstrate that the changes in the RBC population that occur during recovery from IDA enhance 
parasite propagation.  
It should be noted that our work exclusively focuses on the influence of iron deficiency and iron 
supplementation on the susceptibility of the human host’s RBC to malaria infection, and does not address 
the potential effect of serum iron (13) or additional factors, which may function in vivo, including growth of 
the hepatic stage of the parasite (39), rosetting and cytoadherence to the endothelium, accelerated 
clearance of parasitized RBCs (40, 41), effects of innate immune factors such as hepcidin (11) and 
lipocalin 2 (42), or adaptive immune function. We have previously reported that both transferrin and ferric 
citrate increase the bioavailable iron pool of trophozoite-infected RBCs but not that of uninfected RBCs 
(13). It is possible that parasite growth may be enhanced by the transient increase in serum iron that is 
observed in IR individuals who are given oral iron supplementation (12). Further investigations need to be 
conducted to explore the extent to which iron deficiency and iron supplementation shape other aspects of 
malaria pathogenesis.  
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Our findings, taken together with those from field studies, raise the important medical and public 
health question: How can iron supplementation be safely administered to IDA children in malarious 
areas? A critical implication of these observations is that reconstitution of red cell mass in anemic patients 
would be expected to transiently enhance susceptibility to malaria (Fig. 5), which may inform the on-going 
debate as to whether fortification with iron would be safer than supplemental iron. Our data implies that, 
where P.falciparum is endemic, treatment of anemia with iron supplementation should be accompanied 
by malaria preventive measures, such as malaria prophylaxis, bed nets and increased active surveillance 
and access to health care. Additional questions raised by this study are: Does iron deficiency in African 
children represent an evolutionarily advantageous phenotype that derives from polymorphisms in iron 
homeostasis? What molecular mechanisms confer protection from malaria in the setting of microcytosis, 
and can these protective mechanisms be exploited by medical interventions? Future clinical and 
translational studies will be needed in order to design safe and effective interventions to address the twin 
burdens of iron deficiency and falciparum malaria. 
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2.6 TABLES AND FIGURES 
Table 2.1. Iron parameters and values of study participants. Tests were performed by McClendon 
Clinical Laboratory on samples taken from each donor at the same time points that blood samples were 
drawn for experiments. Values in the Normal Range column are the normal or healthy range for each 
parameter as defined by the McClendon Clinical Laboratory. Numerical values reflect the mean value of 
all individuals in each group and values in parentheses indicate standard deviation. 
 
Variable 
Normal 
Range 
Iron 
Deficiency 
Anemia 
(IDA) 
(N = 7) 
Iron 
Deficiency 
Anemia on 
Iron 
supplementati
on (IDA+Fe) 
(N = 6) 
Iron 
Replete 
(IR) 
(N = 10) 
Iron Replete 
after 1 
month Iron 
supplementa
tion (IR+Fe) 
(N = 4) 
Iron Replete 
after 2 
months Iron 
supplementa
tion (IR+Fe) 
(N = 4) 
White Blood Cell 
(x109/L) 
4.5-11.0 4.84 
(1.78) 
4.45 
(1.15) 
6.40 
(1.61) 
6.3 
(1.41) 
6.2 
(1.12) 
Red Blood Cell 
(x1012/L) 
4.0-5.2 3.96 
(0.60) 
3.42 
(0.35) 
4.78 
(0.52) 
4.94 
(0.52) 
4.91 
(0.39) 
Hemoglobin (g/dL) 12.0-
16.0 
8.2 
(1.56) 
8.73 
(1.23) 
14.60 
(1.40) 
14.9 
(0.57) 
14.63 
(0.53) 
Hematocrit (%) 36.0-
46.0 
28.13 
(4.32) 
29.11 
(4.25) 
42.80 
(4.31) 
43.85 
(2.62) 
42.88 
(2.81) 
Mean Corpuscular 
Volume (fL) 
80-100 71.20 
(6.63) 
84.78 
(8.28) 
89.80 
(2.74) 
89.67 
(4.24) 
87.75 
(2.50) 
Mean Corpuscular 
Hemoglobin (Pg) 
26-34 20.79 
(2.54) 
25.50 
(2.35) 
30.70 
(0.95) 
30.5 
(2.12) 
30.0 
(1.83) 
Mean Corpuscular 
Hemoglobin Content 
(g/dL) 
31-37 29.20 
(1.50) 
30.27 
(0.86) 
34.20 
(0.63) 
34.50 
(0.71) 
34.25 
(0.96) 
Red Cell Distribution 
Width (%) 
12.0-
15.0 
17.41 
(1.44) 
18.13 
(2.71) 
13.22 
(0.85) 
13.90 
(0.28) 
13.2 
(0.45) 
Mean Platelet 
Volume (fL) 
7.0-10.0 8.56 
(1.05) 
8.78 
(0.65) 
7.63 
(0.54) 
8.45 
(0.92) 
8.15 
( 0.52) 
Platelet Count 
(x109/L) 
150-440 294.57 
(59.70) 
344.0 
(168.63) 
251.80  
(36.70) 
212.5 
(89.80) 
256 
(79.31) 
Iron Total (mg/dL) 35-165 21.60 
(10.55) 
32.0 
(16.79) 
103.60 
(43.34) 
105.75 
(32.71) 
87.5 
(17.99) 
Transferrin (mg/dL) 200-380 343.60  
(74.72) 
305.20 
(63.55) 
264.30  
(41.33) 
275 
(29.50) 
276.75 
(31.83) 
TIBC (mg/dL) 252-479 438.67 
(92.08) 
384.60 
(80.29) 
333.0 
(52.20) 
346.0 
(37.43) 
348.75 
(40.07) 
Transferrin 
Saturation (%) 
15-50 4.71 
(3.15) 
8.0 
(7.45) 
31.60 
(13.04) 
31.0 
(9.49) 
25.75 
(7.63) 
Ferritin (ng/mL) 30-151 5.71 
(2.75) 
17.17 
(25.44) 
42.01 
(24.28) 
46.75 
(38.75) 
33.33 
(18.45) 
Reticulocyte (%) 0.5-2.7 1.42 
(0.55) 
3.52 
(1.62) 
1.48 
(0.48) 
2.4 
(0.71) 
1.4 
(0.38) 
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Figure 2.1. P.falciparum growth is reduced in iron deficient RBCs and iron supplementation 
eliminates growth attenuation. (a–c) Growth experiments with RBCs from IDA donors (n=7), IDA+Fe 
donors (n=5) and IR+Fe donors (n=4) were performed. Growth rate in RBCs from an IR donor served as 
the control. Bars represent growth of P.falciparum (strains 3D7, Dd2 and FCR3-FMG) in indicated RBCs, 
normalized to growth in RBCs from IR donors (% Pf growth in IR RBC). Error bars represent the s.d. (a) 
Bars represent growth in RBCs from IDA donors. Significance was determined by two-tailed paired 
Student’s t-test. *P<3E-10 as compared with P.falciparum growth in RBCs from IR donors. (b) Bars 
represent growth in RBCs from IDA+Fe donors. Significance was determined by two-tailed paired 
Student’s t-test. *P<0.0003 as compared with P.falciparum growth in RBCs from IR donors. (c) Bars 
represent growth of P.falciparum in RBCs from IR+Fe donors at enrollment, 1 month and 2 months on 
iron, normalized to growth in RBCs from IR donors (% Pf growth in IR RBC). Significance was determined 
by one-way analysis of variance. +P<0.02 for strain 3D7and nonsignificant (n.s.) for strains Dd2 and 
FCR3-FMG. (d) Mean growth rate of P.falciparum in RBCs from each individual IDA (white square), 
IR+Fe (x) and IDA+Fe (black square) donor plotted against the growth rate of P.falciparum in 
corresponding control RBCs from non-supplemented IR donors. Data were analyzed by mixed effects 
regression. The Y=X line was fit to the growth rates (in RBCs from IR donors). Points below the Y=X line 
indicate growth rates less than that within RBCs from IR donors. (e) Graphical summary of the mixed 
effects regression analysis shown in d. Donor and parasite preparation were fitted as crossed random 
effects. The bars show the estimated parasite growth of P.falciparum in RBCs from the IDA, IDA+Fe and 
IR+Fe donors as a percent of P.falciparum growth in RBCs from non-supplemented IR donors. Error bars 
represent the 95% confidence interval. 
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Figure 2.2. P.falciparum invasion and growth are reduced in RBCs from IDA donors. (a) Direct 
comparison of invasion into RBCs from either IDA or IR donors. Invasion experiments for RBCs from all 
IDA donors were performed independently and each experiment was performed in triplicate. Data show 
the mean SI of six independent experiments performed with RBCs from six IDA donors. The marker 
represents the SI point estimate and the bar represents the 95% CI. An SI of 1.0 indicates no difference 
in parasite invasion of the two RBC populations. (b,c) Comparison of the maturation of P.falciparum in 
RBCs donated by IDA and IR donors. Geimsa-stained thin blood smears were made every 6 h and 1,000 
RBCs were counted by light microscopy to determine the percent of pRBCs as well as parasite intra-
erythrocytic stage of maturation. Data are from a representative experiment (with strain FCR3-FMG) of 
three independent experiments performed with RBCs from three IDA donors infected with either 
P.falciparum strain 3D7, Dd2 or FCR3-FMG. (b) Giemsa-stained thin blood smears of P.falciparum ring, 
trophozoite and schizont stage parasites in RBCs from an IDA and an IR donor. (c) Bars indicate percent 
frequency of parasite ring, trophozoite and schizont stages in RBCs from an IDA and IR donor at each 6 h 
time point. Error bars represent the s.d. (d) Comparison of the parasite erythrocyte multiplication rate 
(PEMR) of P.falciparum within RBCs from IDA and IR donors. Bars represent PEMR of P.falciparum in 
RBCs from IDA donors, normalized to the PEMR of parasites in RBCs from IR donors (% IR PEMR). Data 
are the mean of three independent experiments performed in triplicate with RBCs from three IDA donors. 
Error bars represent the s.d. Significance determined by two-tailed paired Student’s t-test.*P<3E-6, 
compared with PEMR in RBCs from IR donors. 
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Figure 2.3. Replacement of iron deficient RBCs with iron-replete RBCs increases P.falciparum 
infection. (a,b) P.falciparum (strain 3D7) infection of reticulocytes (CD71+) and mature RBCs (CD71-) 
from an IDA+Fe donor. (a) Bars represent the percent of parasitized reticulocytes (CD71+) and mature 
RBCs (CD71-). Error bars represent the s.d. *P<0.0001. (b) Contribution of parasitized reticulocytes 
(CD71+) and parasitized mature RBCs (CD71-) to the total infection. Error bars represent the standard 
deviation. (c) Growth rate of P.falciparum in RBC populations in which IDA RBCs were replaced with IR 
RBCs. RBCs were inoculated individually or together in the same wells at different ratios (100% IDA; 90% 
IDA and 10% IR; 75% IDA and 25% IR; 50% IDA and 50% IR; 25% IDA and 75% IR; 100% IR) and 
subsequently infected. Elongated triangles below the x axis represent the percentage of 
IDA RBCs (white triangle) and IR RBCs (grey triangle) in the total RBC population. Bars represent 
parasite growth rates after one 96 h growth assay. Error bars represent the s.d. *P<0.01 and **P<0.0003. 
(d and e) Invasion rate of P.falciparum into RBC populations in which IDA RBCs were replaced with IR 
RBCs. Differentially labelled RBC donors were inoculated individually or together in the same wells at 
different ratios (100% IDA; 90% IDA and 10% IR; 80% IDA and 20% IR; 50% IDA and 50% IR; 20% IDA 
and 80% IR; 10% IDA and 90% IR; 100% IR). Each invasion condition contained 20x106 total RBCs. (d) 
Bars represent parasite invasion rate. Elongated triangles below the x axis represent the percentage of 
IDA RBCs (white triangle) and IR RBCs (grey triangle) in the total RBC population. Error bars represent 
the s.d. *P<0.001, compared with P.falciparum invasion rate into 100% IR RBCs. (e) Number of invasions 
events into IDA (diamonds) and IR (circles) RBCs as the frequency of each increases. Linear regression 
was used to determine the best fit lines for the data (IR R2=0.9842 and IDA R2=0.9305). Analysis of 
covariance was performed to compare the slopes of the lines and calculated P<0.0001. The null 
hypothesis was no difference between the two RBC types (H0: βIron replete = βIron deficient, α=0.05) n.s., 
nonsignificant. 
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Figure 2.4. The elevated P.falciparum infection supported by young RBCs is reversed as young 
RBCs are replaced with old RBCs. (a) Percent P.falciparum (strain 3D7) infection of RBCs of increasing 
diameter. Data points represent the % pRBCs of five gated RBC populations of increasing volume. Error 
bars represent the s.d. (b) Direct comparison of P.falciparum (strain FCR3-FMG) invasion into RBCs of 
increasing age. IR RBCs were separated into five fractions of increasing density, a proxy for increasing 
RBC age (Supplementary Fig. S2.3a–d). The markers represent the SI point estimate and the bar 
represents the 95% CI. (c) Growth rate of P.falciparum (strain FCR3-FMG) in RBC populations in which 
young IR RBCs were replaced with old IR RBCs (0%, 10%, 20%, 33%, 50%, 66%, 80%, 90% and 100% 
replacement young RBCs with old RBCs). Elongated triangles represent the percentage of young IR 
RBCs (gray triangle) and old IR RBCs (white triangle) in the total RBC population. Bars represent parasite 
growth rates after 96 h. Error bars represent the s.d. *P<0.004 and **P<0.0003, compared to growth rate 
in 100% total IR and 100% young RBCs, respectively. (d and e) Invasion into RBC populations in which 
young IR RBCs were replaced with old IR RBCs. Differentially labelled young and old RBCs were 
inoculated individually or together in the same wells at different ratios (0%, 10%, 20%, 33%, 50%, 66%, 
80%, 90% and 100% replacement young RBCs with old RBCs). (d) Bars represent invasion rates. 
Elongated triangles represent the percentage of young IR RBCs (gray triangle) and old IR RBCs (white 
triangle) in the total RBC population. Error bars represent the s.d. *P<0.05 and **P<0.003 (e) Number of 
invasions events into young (circles) and old (triangles) RBCs as the frequency of each increases. Linear 
regression was used to determine best fit lines. A linear function best fit old RBC data (R2=0.9788) and a 
logarithmic function best fit young RBC data (R2=0.9786). Analysis of covariance was performed to 
determine whether invasion data of old and young RBCs differed significantly, P<0.0001. The null 
hypothesis was no difference between the two RBC types (H0: βIron replete = βIron deficient, α=0.05) n.s., 
nonsignificant. 
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Figure 2.5. Hypothesized impact of iron deficiency and iron supplementation on host RBC 
population dynamics and susceptibility to erythrocytic stage malaria infection. Recovery from IDA 
is a complex process, which varies between individuals. Iron supplementation of an individual with IDA (0 
weeks) will result in reticulocytosis and the production of young iron-replete RBCs (6 weeks). 12 weeks 
after the initiation of supplementation, the majority of the iron deficient RBCs, will have been cleared from 
circulation (iron deficient and iron-replete RBCs have 90 and 120 day lifespans respectively). After 16 
weeks of iron supplementation, iron status has been corrected and the age structure of the RBC 
population will be restored. As shown above, we hypothesize that individuals with IDA will be less 
susceptible to erythrocytic stage malaria. The induction of erythropoiesis in these individual by iron 
supplementation and subsequent replacement of the iron deficient RBCs with young iron-replete RBCs 
will increase the susceptibility of the individual to erythrocytic stage malaria infection. The susceptibility to 
infection is predicted to peak at the point when all iron deficient RBCs have been replaced, but the age 
distribution of iron-replete RBCs is on average younger than a fully recovered iron-replete individual. 
Finally, restoration of the normal distribution of RBC age will return an individual’s susceptibility to a 
normal level. 
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2.7 SUPPLEMENTARY FIGURES 
Supplementary Figure S2.1. Serial in vitro growth assay design for P.falciparum. Synchronized 
P.falciparum cultured in RBCs from O+ iron replete donors were seeded as rings at 0.5% initial 
parasitemia at 1% hematocrit in triplicate into 96 well plates. Parasites were maintained for 96 h at 37ºC 
in 5% O2, and media was changed daily. At 96 h, the parasite cultures were split back to 0.5% 
parasitemia and maintained for an additional 96 h in Growth Assay 2. At 192 h, the parasite cultures were 
split back again to 0.5% parasitemia and maintained for an additional 96 h in Growth Assay 3. Growth 
rate was determined for each growth assay independently. *seed experimental cultures with 0.5% ring 
stage pRBC. **parasites invade experimental cells of interest. 
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Supplementary Figure S2.2. Replacement of RBCs from IDA donors with RBCs from IR donors 
increases the invasion rate of erythrocytic stage P.falciparum in vitro (additional strains 3D7 and 
Dd2). (A – C) Invasion of P.falciparum (strains 3D7 and Dd2) into RBC populations in which DDAO 
labeled RBCs from an IDA donor were replaced with Violet labeled RBCs from an IR Donor. Differentially 
labelled RBCs from and IDA and an IR donors were inoculated individually or together in the same wells 
at different ratios (100% IDA; 90% IDA and 10% IR; 80% IDA and 20% IR; 50% IDA and 50% IR; 20% 
IDA and 80% IR; 10% IDA and 90% IR; 100% IR). Each invasion condition contained 20x106 total RBCs 
and was subsequently inoculated with 0.3x106 pRBCs. Data is from a representative experiment of three 
independent experiments performed in triplicate with RBCs from three different IDA and IR donors. (A) 
Bars represent parasite invasion rates into 100% IDA; 90% IDA and 10% IR; 75% IDA and 25% IR; 50% 
IDA and 50% IR; 25% IDA and 75% IR; and 100% IR RBCs. Elongated triangles below the X-axis 
represent the percentage of IDA RBCs (white triangle) and IR RBCs (gray triangle) in the total RBC 
population. Error bars represent the standard deviation. Significance determined by two-tailed paired 
Student’s t test (GraphPad, Prism, v. 5.04, La Jolla, CA). *p<0.0009, compared to P.falciparum invasion 
rate into 100% IR RBCs. (B and C) Data shows the number of P.falciparum strains 3D7 (B) and Dd2 (C) 
invasions events into IDA and IR RBCs as the frequency of each increases in a RBC population 
containing 100,000 total RBCs. Circles and triangles represent the number of P.falciparum invasion 
events into IR and IDA RBCs respectively as each increases in frequency from 10% to 100% of the total 
RBC population. Linear regression was used to determine the best fit line for the data, IR R2=0.9924 and 
IDA R2=0.9789 for 3D7 and IR R2=0.9884 and IDA R2=0.9899 for Dd2. ANCOVA was performed to 
compare the slopes of the lines fit to the IDA and IR invasion data. The null hypothesis was no difference 
between the two RBC types (H0: βIron replete = βIron deficient, α=0.05). ANCOVA performed with GraphPad, 
Prism, v.5.04, La Jolla, CA calculated a p value of <0.0001. 
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Supplementary Figure S2.3. Reticulocytes and young RBCs support greater P.falciparum growth 
rates and PEMRs in vitro than increasingly older RBCs. (A) Percoll density separation of RBCs from 
an IR donor into five fractions of increasing age: very young (VY), young(Y), young adult (YA), mature 
adult (MA) and old (O). Briefly, 1mL of RBCs at 50% hematocrit in RPMI were layered on top of a 
discontinuous Percoll gradient and spun at 1075g for 25 min. Layers were removed, washed, and stored 
at 4ºC for up to two days prior to use. Density age separation of RBC was confirmed by: (B) MCV, as 
measured by Beckman Coulter AcT diff2 (Brea, CA), (C) percent reticulocytes, as determined by new 
methylene blue staining and counting, and (D) fluorescence of density separated RBCs stained with 5 μM 
calceinAM for 30 min and assessed by flow cytometry. For P.falciparum experiments the very young RBC 
population was combined with the young RBC population and subsequently referred to as young. (E) 
Growth of P.falciparum (strain FCR3-FMG) within age separated RBCs. Data is from a representative 
experiment of three independent experiments performed in triplicate. Bars represent parasite growth rate 
after one 96 h growth assay in young, young adult, mature adult and old RBCs. Error bars represent the 
standard deviation. Significance determined by two-tailed paired Student’s t-test (GraphPad, Prism, 
v.5.04, La Jolla, CA). *p<0.001, compared to P.falciparum growth rate in young RBCs. (F) Comparison of 
the Parasite Erythrocyte Multiplication Rate (PEMR) of P.falciparum (strain FCR3-FMG) within age 
separated RBCs. PEMR experiments were performed as described previously for RBCs from IDA and IR 
donors. Data is from a representative experiment of three independent experiments performed in 
triplicate. Bars represent PEMR of P.falciparum in young, young adult, mature adult and old RBCs. Error 
bars represent the standard deviation. Significance determined by two-tailed paired Student’s t-test 
(GraphPad Prism 5, La Jolla, CA). *p<0.001, compared to infectious merozoites produced within young 
RBCs. 
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Supplementary Figure S2.4. P.falciparum plateau in invasion rate of RBC populations containing 
50% to 100% young RBCs is independent of merozoites inoculum. (A and B) Invasion of 
P.falciparum (strain FCR3-FMG) into RBC populations in which Violet labeled young IR RBCs were 
replaced with DDAO labeled old IR RBCs. Differentially labeled young and old RBCs were inoculated 
individually or together in the same wells at different ratios (100% young; 90% young and 10% old; 80% 
young and 20% old; 67% young and 33% old; 50% young and 50% old; 33% young and 67% old; 20% 
young and 80% old; 10% young and 90% old; 100% old). Each invasion condition contained 20x106 total 
RBCs and was subsequently inoculated with 0.6x106 pRBCs. The invasion rate of P.falciparum into total 
IR RBCs was additionally assessed. Data is from a representative experiment of two independent 
experiments performed in triplicate with RBCs with P.falciparum strains 3D7 and FCR3-FMG. (B) Data 
shows the number of P.falciparum invasions events into young and old RBCs as the frequency of each 
increases in a RBC population containing 100,000 total RBCs. Circles and squares represent the number 
of P.falciparum invasion events into young and old RBCs respectively as each increases in frequency 
from 10% to 100% of the total RBC population. Linear regression was used to determine the best fit line 
for young and old RBC data. A linear function best fit old RBC data (R2=0.9906) and a logarithmic 
function best fit young RBC data (R2=0.9764). ANCOVA was performed to compare to determine whether 
invasion data of old and young RBCs differed significantly. The null hypothesis was no difference 
between the two RBC types (H0: βIron replete = βIron deficient, α=0.05). ANCOVA performed with GraphPad, 
Prism, v.5.04, La Jolla, CA calculated a p value of <0.0001. 
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CHAPTER THREE: BIOPRESERVATION OF RBCS FOR IN VITRO PLASMODIUM FALCIPARUM 
CULTURE2 
 
3.1 OVERVIEW 
The in vitro culture of P.falciparum in red blood cells (RBCs) is essential to studying the molecular 
and cell biology of the parasite. Current methodologies utilize RBCs within 4 weeks of collection. Here we 
show that storage of RBCs for greater than two weeks at 4⁰C in each of four different media known to 
preserve RBC integrity, decreases the growth rate of the parasite. The decrease in growth is secondary 
to decreased invasion of the stored RBCs; there is no impact on the parasite erythrocyte multiplication 
rate. Finally, we show cryopreserved RBCs support growth of P.falciparum and are invaded equally well 
as freshly drawn RBCs. These data indicate that use of RBCs stored longer than 2 weeks may affect in 
vitro experimentation with P.falciparum, but that biopreservation of RBCs at -80⁰C is an effective 
technique for preserving RBCs for P.falciparum culture. Our findings demonstrate the utility of 
biopreservation for RBCs obtained from individuals with rare blood types and for RBCs obtained during 
field studies. 
3.2 INTRODUCTION 
Falciparum malaria remains a devastating infectious disease, killing nearly 700,000 people 
annually. Further understanding of malaria pathogenesis will help identify molecular and cellular targets of 
next-generation therapeutics. The morbidity and mortality of malaria infection occur during the 
erythrocytic stage. Study of erythrocytic stage malaria is critical not only for new anti-malarial 
development, but also for increasing our understanding of the host pathogen relationship. For example, 
many host genetic polymorphisms known to impact red blood cell (RBC) physiology also alter malaria 
susceptibility. Methods for culturing erythrocytic stage Plasmodium falciparum were developed more than 
30 years ago (1, 2). However, optimization of in vitro P.falciparum culture is still under investigation. The 
                                                          
2 First published as a Short Report in The British Journal of Haematology, 15 Jan 2016, doi: 
10.1111/bjh.13882. The version that appears in this chapter includes extended methods descriptions.  
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aspects of intra-erythrocytic development that are impacted by RBC storage, as well as the effects of 
RBC biopreservation on the intra-erythrocytic life cycle, remain unknown. Studies on RBC storage for 
human clinical use reveal a relationship between RBC storage and transfusion complications (3). Current 
blood banking standards involve RBC storage in SAGM (a solution containing saline, adenine, mannitol 
and glucose) or closely related solutions for up to 42 d at 4°C (4). Many RBC storage lesions have been 
documented in these acidic medias, including decreased intracellular ATP, 2,3-diphosphoglycerate (2,3-
DPG) and potassium; increased intracellular NaCl; oxidative damage; lipid peroxidation; membrane 
phospholipid changes and vesiculation; decreased deformability; reduced glycolytic capacity; decreased 
vasodilatory capacity; and increased cytoadhesion (3, 5). Overall, these storage lesions are similar to 
physiological changes occurring with normal RBC ageing in the blood-stream (6) and could also impact 
parasite growth, as P.falciparum preferentially infects younger RBCs in circulation (7, 8). The use of 
biopreserved RBCs for human transfusion has been validated (9) and cryopreserved umbilical cord blood 
cells can propagate Plasmodium vivax (10). Here we examine the impact of RBC storage and 
biopreservation on P.falciparum growth and development in vitro. Prolonged RBC shelf-life and 
biopreservation could enhance malaria research by: (i) enabling standardization of the RBC source for 
multiple experiments, and (ii) increasing access to RBCs from individuals with unusual blood types, 
nutritional deﬁciencies, or from remote locations. 
3.3 MATERIALS AND METHODS 
P.falciparum culture. P.falciparum parasite lines FCR3-FMG (MR4, MRA-736) and Dd2 (MR4, 
MRA-156) were routinely cultured in O-positive (O+) RBCs obtained from healthy individuals at the 
Clinical and Translational Research Center at the University of North Carolina, Chapel Hill, NC (IRB #09-
0559, approved by the University of North Carolina Institutional Review Board). Cultures were maintained 
with 2% Hematocrit (hct) in complete media containing RPMI 1640 with 10% Albumax II, 1 mM 
hypoxanthine, 20 mM L-glutamine, 0.45% glucose, and 10 µg/l gentamicin (ACM). Cultures were 
incubated on a shaker at 37⁰C in 5% O2, 5% CO2 and 90% Nitrogen. Parasite density was maintained 
between 0.5% and 10% P.falciparum-parasitized RBCs (pRBCs). pRBC cultures were synchronized to 
within 4-6 hours of each other by first treating cultures with 5% D-sorbitol to select for ring stage 
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parasites, followed by MACS (Miltenyi Biotec) isolation of hemozoin-containing trophozoite and schizont 
stage pRBCs. 
Growth assay. Cultures were seeded as rings at 0.5% pRBCs and 1% hct in ACM in triplicate 
into 96 well plates and maintained for 96 hrs before staining. Duplicate plates were also stained at 0 hrs. 
Plates were stained with 1X DNA dye SYBR green I (Invitrogen) for 30 min at 37⁰C and fixed in 1% 
paraformaldehyde and 0.0075% glutaraldehyde in Alsever’s solution (Sigma) for 30 minutes at 4°C for 
flow cytometry analysis of pRBCs present. Parasite growth rates were determined by dividing final 
parasitemia at 96 hrs by initial parasitemia at 0 hrs (8). 
Parasite erythrocyte multiplication rate (PEMR). Production of infectious daughter merozoites 
of FCR3 and Dd2 within fresh and stored RBCs was assayed beginning with trophozoite infected O+ 
cultures MACS purified and seeded into experimental RBCs to achieve 1.5-2% infected RBCs and 
maintained for 72 hrs to allow for a full growth cycle within each experimental RBC population. 
Trophozoites in experimental RBCs were MACS isolated and subcultured into a 96 well plate with 2% 
pRBC at 1% hct in fresh control RBCs in triplicate and maintained for 12-18 hrs to allow for invasion of 
control RBCs and comparison of infectious merozoites produced within different experimental RBCs. 
Wells were stained, fixed and analyzed by flow cytometry as above; calculating invasion events divided 
by initial schizonts seeded provides PEMR data, which represents replication efficiency within each blood 
condition (8).   
RBC barcoding assay. As described in (11), RBCs were labeled at 2% hct in RPMI with 5 µM of 
either CellTrace Violet or DDAO-SE (Invitrogen) for 2 hrs with shaking at 37°C, washed twice with ACM, 
incubated 30 minutes in ACM with shaking at 37°C, and finally washed twice with RPMI and stored in 
RPMI at 4°C. All invasion assays were performed with within two days of labeling. For three color 
invasion assays, DDAO-SE and Violet labeled RBCs were combined in ACM and delivered in triplicate 
into a 96 well plate and subsequently seeded with MACS purified trophozoite pRBCs from standard, 
unlableled O+ cultures to achieve 1.5-2% pRBCs. Parasites were maintained for 12-18 hrs to allow for 
subsequent invasion of DDAO-SE and Violet RBC populations. Following invasion, cells were stained, 
fixed, and analyzed by flow cytometry as described above. P.falciparum invasion into Violet and DDAO-
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SE labeled RBCs was directly compared by measuring the Susceptibility Index (SI), defined as the ratio 
of the prevalence of infected Violet RBCs to infected DDAO RBCs (8).  
Flow cytometry analysis. Flow cytometry was performed at the UNC Flow Cytometry Core 
Facility on a Beckman-Coulter (Dako) CyAn ADP cytometer. Channels and probes used on the Dako 
cyan included: CellTrace Violet (405nM excitation, 450/50 bandpass), SYBR Green I (488nm excitation, 
530/40 bandpass), and CellTrace DDAO-SE (635nm excitation, 665/20 bandpass). Detector gain settings 
varied between experiments to optimize signal but were kept constant within individual experiments and 
spectral overlap compensation was not necessary with this configuration. P.falciparum pRBCs were 
gated on SYBR Green I signal. Dako CyAn data was collected and analyzed with Summit v4.3.01. Linear 
amplification of forward scatter was used to set event threshold in order to exclude cell debris, 
microparticles and doublets. For all experiments, samples were diluted to 0.001-0.002% hct and 100,000 
total events were collected. 
RBC storage conditions. Blood for cultures was routinely drawn into ACD, packed by 
centrifugation with plasma removed, and stored at 4°C for 2 weeks; aliquots were washed with Alsever’s 
Solution (4.2 g/l NaCl, 9.0 g/l  Na-citrate, 20.5 g/l glucose) (Sigma) 3X prior to use, and used for 
experiments and culture within 4 days after washing. Variations in blood storage included storing packed 
RBCs at 4°C for up to 6 weeks, or after removal of plasma, overlaying packed RBCs with alternative 
storage buffers (CPDA, Alsever’s Solution, a RBC Buffer (10 mM HEPES, 12 mM NaCl, 115 mM KCl, 5% 
BSA)) at a ratio of 2:1 packed RBCs:storage media. 
RBC cryopreservation. To freeze RBCs, 200µl of fresh packed RBCs was mixed with 300µl 
plasma, then 500µl freezing media (28% glycerol, 3% sorbitol, 0.65% NaCl) was slowly added and cells 
were immediately frozen in liquid nitrogen. To use frozen RBCs, cells were quickly thawed, then 200µl of 
12% NaCl was added dropwise, and cells were incubated at RT 5 min. Following addition of 10mL 1.6% 
NaCl, cells were centrifuged 10 min at 2500g. Pellets were mixed with 10ml 0.9% NaCl, and similarly 
centrifuged. Final pellets were washed 3X in Alsever’s Solution prior to immediate culture use. Variations 
included washing in Alsever’s Solution or ACM before freezing, using RBCs without washing post thaw, 
and storing RBCs at 4°C post-thaw before culture use.  
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Statistical Methods.  All experiment conditions were tested in triplicate. Results depicted are 
from either one representative experiment of at least three independent experiments or the combined 
results of at least three independent experiments. Growth rates and PEMR were compared with two-
tailed Students t-test and one way ANOVA using GraphPad Prism 5. Invasion assays utilize the SI 
(described above), an unadjusted odds ratio which allows the determination of the relative risk of the two 
RBC populations to P.falciparum invasion. All statistical analyses for invasion experiments were 
performed with Stata/IC (v10, Stata Corp, College Station, TX). 
3.4 RESULTS 
3.4.1 P.falciparum growth rates decline proportional to RBC storage length.  
Given lingering discrepancies in standard P.falciparum culture protocols, we sought to deﬁnitively 
assess RBC shelf-life. To begin, fresh RBCs were collected into acid citrate dextrose (ACD) and stored in 
aliquots as packed RBCs at 4°C for up to 6 weeks. At 2-week intervals, fresh RBCs were obtained and 
identically stored to allow for simultaneous comparisons of parasite growth in vitro using blood stored for 
0, 2, 4 and 6 weeks. Growth in RBCs stored for 2 weeks showed no decrease in standard 96 h growth 
assays (8). After 4 weeks of storage, growth rates diminished signiﬁcantly (42% decline for Dd2, 65% for 
FCR3-FMG). In RBCs stored for 6 weeks, there was very little growth (over 90% decline for both strains 
Dd2 andFCR3-FMG) (Fig 3.1A). 
3.4.2 Differential storage media does not prolong longevity of RBCs for use in P.falciparum growth 
assays. 
We next compared parasite growth in RBCs stored for 0, 2 and 4 weeks at 4°C in four different 
storage buffers. Buffers tested were: (i) ACD; (ii) citrate-phosphate-dextrose-adenine (CPDA), commonly 
used for malaria culture; (iii) Alsever’s Solution, a balanced salt solution routinely used for RBC washing 
prior to parasite culture; and (iv) “RBC buffer,” an alternative balanced salt solution. Growth rates 
decreased proportionally to storage length in each of the buffers, with a signiﬁcant decrease after 4 
weeks of storage (62% for ACD,56% for CPDA, 54% for Alsever’s and 51% for “RBC buffer”) (Fig 3.1B). 
This conﬁrms RBCs destined for parasite culture must be used within 2 weeks of collection and that 
differential storage media does not prolong their shelf-life fo rP.falciparum culture.  
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3.4.3 The decline in P.falciparum growth rates in stored RBCs is primarily due to decreased 
invasion. 
We next sought to determine whether parasite replication and/or invasion were decreased in 
stored RBCs. To assess replication, we measured the parasite erythrocyte multiplication rate (PEMR), 
which reﬂects the number of infectious merozoites produced per schizont (8). We found no statistically 
signiﬁcant differences in replication between RBCs stored for 0–4 weeks (Fig 3.1C). Invasion rates were 
assayed using a RBC barcoding assay (11) in which differentially labelled RBCs (with CellTrace 
membrane dyes; Life Technologies Corp., Grand Island, NY,USA) were combined in the same wells and 
seeded with unlabeled trophozoite stage parasitized RBCs. This assay allows direct comparison of 
parasite invasion into two different RBC populations. Invasion rates decreased as RBC storage time 
increased (Fig 3.1D). We hypothesize that this reduction in invasion is due to decreases in intracellular 
ATP content and RBC deformability, which are associated with RBC storage.  
3.4.4 Biopreserved RBCs remain suitable for P.falciparum growth and invasion assays. 
In an effort to increase the shelf-life of RBCs for malaria culture, we turned to biopreservation. 
RBC freezing/thawing resulted in minimal RBC lysis (Fig 3.2A). Biopreserved RBCs were able to support 
equally high rates of P.falciparum growth as fresh RBCs (Fig 3.2B). No variation of washing before or 
after freezing/thawing consistently increased biopreserved RBC shelf-life. Successful merozoite invasion 
of biopreserved RBCs was conﬁrmed using the RBC barcoding assay. No differences were observed 
between invasion of fresh versus biopreserved RBCs (Fig 3.2C). 
3.5 DISCUSSION 
Regarding P.falciparum in vitro experimentation, the use of extensively stored RBCs could 
artiﬁcially indicate growth differences between donors with divergent RBC phenotypes, when, in reality, 
differential RBC storage length might primarily contribute to any observed difference. Routine use of 
outdated RBCs could also result in the artiﬁcial selection of strains that preferentially invade atypical 
RBCs. Our ﬁnding that biopreserved RBCs are suitable for P. falciparum assays has vast practical 
applications. Using biopreserved RBCs minimizes the need to obtain fresh blood, as fresh RBCs could be 
frozen in aliquots and individually thawed when needed. Our biopreservation method could also facilitate 
ﬁeld studies in areas where immediate parasite growth is difﬁcult. Additional studies are needed to 
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determine if this technique can be applied to ‘variant’ RBCs, such as RBCs from individuals with sickle 
cell trait or glucose-6-phosphate dehydrogenase deﬁciency. Freezing RBCs also allows for extensive 
evaluation of parasite growth in unique blood types and standardization in gene expression assays. 
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3.6 FIGURES 
Figure 3.1. Effects of RBC storage conditions on Plasmodium falciparum growth in vitro. (A) 
Growth assays in RBCs stored 0, 2, 4, or 6 weeks in ACD a t4°C. Growth rates in stored RBCs are 
normalized to fresh RBCs. Error bars represent the standard deviation (SD). *P<0.01, compared to 
growth rates in fresh RBCs. (B) Growth rates in RBCs drawn into ACD and packed were either stored as 
is, or in alternative storage media (Alsever’s, ACD,CPDA, RBC Buffer). *P<0.01, compared to growth 
rates in fresh RBCs (RBC Buffer = 10 mmol/l HEPES, 12 mmol/l NaCl, 115 mmol/l KCl, 5% BSA). (C) 
PEMR in RBCs stored 0, 2, and 4 weeks. PEMR is normalized to that in fresh RBCs. Error bars represent 
the SD. (D) Susceptibility Index (SI) for fresh RBCs compared to RBCs stored for 0, 2, 4 and 6 weeks. An 
SI of 1.0 indicates no invasion difference between two RBC populations. The marker represents the SI 
point estimate and the bars represent the 95% conﬁdence intervals. RBCs, red blood cells; ACD, acid 
citrate dextrose; CPDA, citrate-phosphate-dextrose-adenine; PEMR, parasite erythrocyte multiplication 
rate; Dd2, P.falciparum Dd2 strain; FCR3-FMG, P.falciparum FCR3-FMG strain. 
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Figure 3.2. Biopreserved red blood cells (RBCs) are suitable for Plasmodium falciparum growth. 
(A) Biopreserved RBCs show minimal lysis after deglycerolization and centrifugation. (B) Comparison of 
growth rates between fresh RBCs and biopreserved RBCs differentially washed. To freeze RBCs, 200µl 
of fresh RBCs were mixed with 300µl human plasma, then 500µl freezing media (28% glycerol, 3% 
sorbitol, 0.65% NaCl) was added and cells were frozen in liquid nitrogen. To thaw, 200µl of 12% NaCl 
was added to the frozen RBCs, incubated for 5 minutes and pelleted by centrifugation. Subsequently, 
RBCs were washed with 1.6% NaCl, followed by 0.9% NaCl and used immediately for culture. Variations 
tested included: washing with Alsever’s Solution (BioP-1) or parasite culture media (BioP-2) three times 
prior to freezing. Cells pre-washed in Alsever’s solution were either used directly (BioP-1) or rewashed 
three times after thawing in Alsever’s solution (BioP-3). Error bars represent the standard deviation. (C) 
Susceptibility Index (SI) for fresh versus biopreserved RBCs. The marker represents the SI point estimate 
and the bars represent the 95% confidence interval.  
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CHAPTER FOUR: ANEMIA OFFERS STRONGER PROTECTION THAN SICKLE-CELL TRAIT 
AGAINST ERYTHROCYTIC STAGE MALARIA IN VITRO AND THIS PROTECTION IS REVERSED BY 
IRON SUPPLEMENTATION3 
 
4.1 OVERVIEW 
Background: Iron deficiency causes long-term adverse consequences for children and is the most 
common nutritional deficiency worldwide. Observational studies suggest that iron deficiency anemia 
protects against P.falciparum malaria and several intervention trials have indicated that iron 
supplementation increases malaria risk through unknown mechanism(s). This poses a major challenge for 
health policy. We investigated how anemia inhibits blood stage malaria infection and how iron 
supplementation abrogates this protection. 
Methods: This observational cohort study occurred in a malaria-endemic region where sickle-cell 
trait is also common. We studied fresh RBCs from anemic children (135 children; age 6-24 months; 
hemoglobin <11g/dl) participating in an iron supplementation trial (ISRCTN07210906) in which they 
received iron (12mg/day) as part of a micronutrient powder for 84 days. Children donated RBCs at 
baseline, Day 49, and Day 84 for use in flow cytometry-based in vitro growth and invasion assays with 
P.falciparum laboratory and field strains.  
Findings: Anemia substantially reduced the invasion and growth of both laboratory and field 
strains of P.falciparum in vitro (~10% growth reduction per standard deviation shift in hemoglobin). The 
population level impact against malaria was 15.9% from anemia compared to 3.5% for sickle-cell trait. 
Parasite growth was 2.4 fold higher after 49 days of iron supplementation relative to baseline (p<0.001) 
paralleling increases in erythropoiesis.  
                                                          
3 This work was submitted to EBioMedicine on 30 Aug 2016 and was conditionally accepted on 13 Oct 
2016 dependent upon formatting revisions (which have not yet been finalized and given back to the 
journal). The version that appears in this chapter is the version submitted to the journal on 30 Aug 2016, 
and also includes an extended discussion of data analysis and statistical methodology. 
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Interpretation: These results confirm and quantify a plausible mechanism by which anemia 
protects African children against falciparum malaria, an effect that is substantially greater than the  
protection offered by sickle-cell trait. Iron supplementation completely reversed the observed protection 
and hence should be accompanied by malaria prophylaxis. Lower hemoglobin levels typically seen in 
populations of African descent may reflect past genetic selection by malaria.  
4.2 INTRODUCTION 
Malaria and iron deficiency anemia impact the same geographic and demographic groups and 
the pathophysiological relationship between the two is complex. Acute malaria can cause severe anemia 
due to hemolysis of infected and uninfected RBCs, and chronic or subclinical malaria can induce anemia 
of inflammation (1). There is clear epidemiological evidence in both children (2–4) and pregnant women 
(5, 6) that, once established, iron deficiency anemia (IDA) is protective against malaria infection. In fact, in 
pregnant women, iron deficiency has been shown to reduce risk of placental malaria to a greater extent 
than multiparity (5). 
Multiple studies have raised concern that iron supplementation in malaria-endemic areas may put 
people at increased risk of acquiring malaria (7–11). Most importantly, a large childhood nutritional 
supplementation study in Zanzibar was halted due to increased morbidity and mortality in the children 
receiving iron (12). Subsequently, the WHO abandoned its recommendation for universal iron 
supplementation and now recommends that, in malarious regions, iron supplements only be given where 
malaria management and prevention services are present (13, 14). This has severely disrupted iron 
supplementation campaigns in malaria endemic areas, despite IDA being the leading cause of years lived 
with disability among children and adolescents according to the 2013 Global Burden of Disease Study 
(15). Reducing the prevalence of IDA is one of the six priorities of the WHO’s Comprehensive 
Implementation Plan on Maternal, Infant, and Young Child Nutrition (16). Further complicating research in 
this area, it is now difficult to ethically study the safety of iron supplementation in malarious areas. In most 
developing countries iron supplements cannot be withheld during a study and all children in iron 
supplementation studies must be provided insecticide-treated bed nets and monitored closely for illness. 
As a result, recent studies evaluating the safety of iron supplementation have done so in the context of 
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providing malaria prevention services and extensive medical care (17, 18) – a scenario that would not 
necessarily exist in reality.  
In an effort to assess the magnitude of protection from anemia and the safety of iron 
supplementation in a malaria endemic area where sickle-cell trait is common, we have systematically 
characterized P.falciparum growth in RBCs from anemic African children before, during, and after 12 
weeks of iron supplementation. 
4.3 MATERIALS AND MEHTODS 
Subject recruitment, study design, and blood samples for parasite assays. The children 
were recruited from the control arm of a randomized trial testing the efficacy and safety of a hepcidin-
guided screen-and-treat strategy for combatting anemia (see published protocol for full details) (19). 
(Note we also recruited children in the other two arms of this trial, but only for observation at baseline, 
pre-randomization/pre-intervention.) As per current WHO recommendations, children in the control arm 
received 12mg/d iron as ferrous fumarate, given within a micronutrient powder (modified MixMeTM 
supplied by DSM Nutritional Products). Field workers visited children daily in order to supervise the 
micronutrient powder administration and check the children’s health status. For baseline population 
characteristics, see Supplemental Table S4.1. Fresh RBCs were obtained from these anemic 
(Hgb<11g/dl) but otherwise healthy children (6-24m) living in rural Gambia (19). Blood was collected at 
Days 0 (baseline), 49, and 84 during 12wks of iron supplementation (Figure 4.1) with the primary 
objective of evaluating in vitro P.falciparum growth characteristics to model malaria susceptibility in 
anemic subjects before and after iron supplementation. We compared subject characteristics of those 
whose blood was and was not able to be used for growth rate data to ensure no sampling bias occurred 
(Supplemental Table S4.2). For a full description of this embedded observational study, please reference 
the published protocol (19). 
P. falciparum culture. Parasite lines FCR3-FMG (MR4, MRA-736) and 3D7 (MR4, MRA-102) 
were routinely cultured in RBCs from healthy donors using standard methods (1). Parasite strains 952, 
998, and 1029 were isolated from patients presenting with symptomatic malaria infections at the Jammeh 
Foundation for Peace hospital in Serekunda and the outpatient clinic at MRC Fajara, both located within 
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the urban/periurban coastal area of The Gambia. Isolates were collected as part of a larger study during 
the annual malaria transmission seasons (September–January) from 2005–2011, as described in (20).  
Growth assay. In vitro growth was assessed in fresh, washed RBCs as in (1) for 96h (performed 
in triplicate for RBCs from each study participant). RBCs from healthy, iron replete adult donors of normal 
hemoglobin genotype and G6PD status not undergoing iron supplementation served as controls for inter-
assay variability. Growth rates represent final 96h parasitemia divided by initial 0h parasitemia (1), 
analyzed by flow cytometry (see Supplemental Methods). Growth rates in subjects’ RBCs were 
normalized to that in control RBCs assayed simultaneously.  
RBC barcoding invasion assay. The assay was performed and analyzed as in (21) using two 
different concentrations of CellTrace Far Red DDAO (Invitrogen Life Technologies/Molecular Probes): 
1uM (high) or 0.1uM (low) (see Supplemental Methods and Supplemental Figure 2 for flow cytometry 
analysis).   
Reticulocyte quantification. Reticulocyte (CD71+) levels in fresh subject RBCs were assessed 
using PE-conjugated anti-human CD71 antibody (Clone M-A712, BD) and isotype control (Clone G155-
178, BD), and analyzed by flow cytometry (see Supplemental Methods) for reticulocyte percent relative to 
non-anemic control.  
Statistics. All experiments were done in triplicate. Growth rates, invasion assays, and 
hematological data were compared by two-tailed Student’s t-test, one-way ANOVA, and/or 95% CI values 
using GraphPad Prism 5. 
Multivariate modelling. We employed linear regression to estimate the effect of hematological 
characteristics on in vitro parasite growth rates. First, bivariate associations and their respective 95% CI 
were calculated between growth rates and hematological and patient characteristics at Day 0. We then 
used multivariate linear regression – specifically, we estimated the effect of hemoglobin and hemoglobin 
genotype on growth rate along with their respective 95% CI. We used directed acyclic graphs to identify 
potential confounders and controlled for them in our modelling approach (22). An a priori alpha of 0.05 
was used to determine statistical significance. All statistical analyses were performed using R software 
(RStudio Version 0.99.902).  
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Population level impact. We compared, at the population level, the relative protection offered by 
sickle-cell trait carriage and anemia using the following formula: pp(RG-1)/RG (modified from (22)), where 
pp is the proportion of the population exposed to the protective factor and RG is the relative growth rate 
associated with that factor. The RG values for sickle-cell trait and hemoglobin were based on the adjusted 
β coefficients from our multivariate modelling results. In this population the pp for anemia is 0.75 (derived 
from 688 children <3y in the Kiang West Longitudinal Population Study) (23) and the prevalence of AS is 
0.159 (24), and there is no detectable confounding between AS and hemoglobin level.  
Ethics approval. The trial from which children were recruited was approved by the MRCG 
Scientific Coordinating and The Gambia Government/MRC Joint Ethics Committees (SCC 1358) and the 
UNC IRB (#14-1551). Parents/guardians were given a full description of the study in their native language 
and provided written signed consent. 
Role of the funding source. None of the funding sources had a role in study design, data 
collection or interpretation, writing of the manuscript, or the decision to submit for publication. The 
corresponding author had full access to all the data included in the study and assumed final responsibility 
for the decision to publish; all authors reviewed the report and agreed to submit for publication. 
4.4. RESULTS 
4.4.1 P.falciparum growth is reduced in RBCs from anemic children.  
Evaluating in vitro parasite growth in RBCs from anemic children at baseline, we consistently 
found lower parasite growth rates than in RBCs from iron replete individuals. Furthermore, growth was 
lower in RBCs from those donors with the lowest hemoglobin concentrations (Hgb 7-9g/dl=mean relative 
growth rate (GR) 32.6%; Hgb 8.1-10g/dl=GR 45.9%; Hgb 10.1-11=GR 55.9%; p<0.05 by ANOVA) (Figure 
4.2A). Iron panel data indicated some degree of iron deficiency in most participants (Table 4.1). However, 
as the diagnosis of iron deficiency in children with ongoing inflammation is controversial, we grouped 
subjects using several common definitions of IDA in an attempt to uncover any further differential impacts 
on malaria susceptibility. We observed decreased parasite growth in all anemic children independent of 
the type (e.g. with inflammation or without) and severity of iron deficiency, with no significant differences 
between groups (Supplemental Figure S4.1).  
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To further investigate potential confounding effects of inflammation and host genetics on parasite 
growth, we performed bivariate analysis using P.falciparum in vitro growth, hematological, iron, and 
inflammatory data obtained for subjects prior to iron supplementation to determine which variables 
influenced parasite growth in anemic children (Table 4.2). Several key variables commonly assumed to 
affect anemia and/or blood-stage malaria growth were tested. Hemoglobin genotype influence was 
evaluated solely based on β-globin sickle-cell trait (AS) mutation versus normal β-globin (AA), as other β-
globin genotypes (homozygous sickle-cell anemia (SS), hemoglobin C (AC), and a heterozygous 
combination (SC)) were rare. Hemoglobin concentration, hemoglobin genotype, and mean corpuscular 
volume (MCV) all significantly influenced parasite growth. G6PD status (normal versus deficient) did not 
significantly affect parasite growth, nor did age, sex, ferritin, hepcidin, or CRP (Table 4.2). Parasite growth 
rate decreased 10.7% for every 1g/dl hemoglobin decrease. Additionally, we found parasite growth rate 
decreased 1.4% for every 1fL decrease in MCV and 18.3% in RBCs from children carrying sickle-cell trait. 
In order to compare the magnitude of these growth rate effects, we standardized the growth rate 
differences per standard deviation (SD) of each exposure variable, finding 8.6% and 10.8% decreased 
parasite growth per SD of hemoglobin and MCV, respectively (Table 4.2). Next, we performed 
multivariate analysis to determine if the effect of hemoglobin on malaria growth rate was confounded by 
hemoglobin genotype and vice versa. These variables retained significant effects on malaria growth 
independently of one other, highlighting the independent impact of both microcytic anemia and sickle-cell 
trait on malaria growth.  
4.4.2 The population level impact on parasite growth is greater from anemia than from sickle-cell 
trait genotype. 
Using our multivariate modelling results, we estimated the population level impact on parasite 
growth from both sickle-cell trait genotype and anemia in order to assess overall the risk of malaria 
infection in our study population. Given the prevalence of AS (15.9%) (24) and anemia (75%) (23), we 
thus calculated the population level impact of malaria growth reduction to be 3.5% from sickle-cell trait 
and 15.9% from anemia in these Gambian children. Note that this underestimates the protection by 
anemia because it simply compares anemic (defined as Hgb<11g/dl, 2 SD below the mean) versus non-
anemic children. In fact, our population mean Hgb is 3.6 standard deviations below normative data (mean 
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12g/dl) from healthy African-American children (25); using this comparator the protection offered to the 
average Gambian child would be a 31% reduction in parasite growth rate (see Table 4.2). 
4.4.3 P.falciparum clinical isolates exhibit decreased growth in RBCs from anemic children.  
We additionally evaluated the growth of Gambian clinical P.falciparum isolates (952, 998, and 
1029) to ensure the observed decreased parasite growth in anemic RBCs was not solely a phenomenon 
of laboratory adaptation. These field isolates assayed in parallel in RBCs from 5 randomly chosen anemic 
subjects at baseline (with normal hemoglobin genotype and CRP<5mg/ml) all exhibited decreased growth 
compared to RBCs from non-anemic individuals (Figure 4.2B). Mean growth rates for all strains were 
consistently below 100% (FCR3-FMG=51.88% CI= 29.33-74.43%; 952=74.43%, CI= 55.04-93.83%; 
998=59.34%, CI= 42.51-76.16%; and 1029=74.94%, CI= 53.31-96.57%).  
4.4.4 RBCs from anemic children are resistant to invasion by laboratory and clinical strains of 
P.falciparum.  
Next, we used a RBC barcoding assay (21) adapted for field use (Supplemental Figure S4.2) to 
directly compare parasite invasion into RBCs from anemic children (n=15 for strain FCR3-FMG and n=10 
for strain 3D7) versus non-anemic donors. Susceptibility Indices (SI) of RBCs from the anemic donors 
were significantly decreased using both strains (FCR3-FMG SI=0.77, CI=0.70-0.84; 3D7 SI=0.66, 
CI=0.54-0.78) (Figure 4.2C). P.falciparum clinical isolates from The Gambia (strains 952, 998, and 1029) 
also exhibited decreased invasion into RBCs from anemic donors (952 SI=0.65, CI=0.58-0.73; 998 
SI=0.57, CI=0.42-0.77; and 1029 SI=0.62, CI=0.49-0.75) (Figure 4.2D). These assays confirm the clinical 
relevance of previous in vitro work examining laboratory parasite strains and iron deficient RBCs (1). 
4.4.5 Malaria susceptibility increases transiently with iron supplementation.  
 In order to assess malaria susceptibility following iron supplementation, we investigated in vitro 
parasite growth 49d and 84d after daily iron supplementation compared to baseline. The children were 
monitored daily for changes in health status and underwent weekly malaria testing. Consistent with the 
fact that malaria incidence is now low in The Gambia (26), only two malaria cases occurred during our 
study. Hence, in vitro assays offered a way to examine the relationship between growth of malaria 
parasites in RBCs and changing hematological parameters and capture the window of increased 
susceptibility. Parasite growth rates in RBCs from study subjects were low on Day 0 (n=158, mean GR 
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48.51%, CI=42.88-54.14%), increased markedly by Day 49 (n=91, mean GR 120.3%, CI=106.6-133.9%), 
and then by Day 84 decreased back to levels closer to those seen in non-anemic individuals (n=87, mean 
GR 80.26%, CI=57.27-103.3%). One-way ANOVA confirmed significant differences in parasite growth 
rates across Days 0, 49 and 84 (p<0.0001) and post-hoc analysis using Tukey’s test indicated significant 
differences between Days 0 and 49 (p<0.001), Days 0 and 84 (p<0.01), and Days 49 and 84 (p<0.001) 
(Figure 4.3A). Restricting the analysis to paired comparisons within the 35 children with growth 
measurements at all 3 timepoints, we confirmed the increased growth rate from Day 0 to Day 49 
(p<0.001) (Supplemental Figure S4.3A).  
 To further confirm changes in malaria pathogenesis in RBCs from anemic children taking iron, we 
performed invasion assays to assess subjects’ RBC susceptibility before and after iron supplementation 
in a subset of randomly selected subjects (n=8). The mean SI values of these donors before iron 
supplementation (SI=0.72; CI=0.60-0.84) and post iron (SI=1.58, CI=1.17-1.99) were significantly different 
by student’s t-test (p<0.01) (Supplemental Figure S4.3B).  
4.4.6 The population of young RBCs increases in anemic children undergoing iron 
supplementation.  
To assess RBC population age structure, we evaluated levels of CD71-positive early reticulocytes 
in circulation at Days 0, 49, and 84 for a subset of anemic children undergoing iron supplementation. 
Relative percent of CD71-positive cells at Day 0 (mean=129%, CI=82-175%) was comparable to non-
anemic controls (standardized as 100%), and increased at Day 49 (mean=224%, CI=166-286%) and Day 
84 (mean=180%, CI=148-211%). Means were significantly different by one-way repeated measures 
ANOVA (p<0.01), and Tukey’s test showed significant difference between Days 0 and 49 only (p<0.01) 
(Figure 4.3B; Supplemental Figure S4.3C).  
Further probing host factors which could increase parasite growth rates in RBCs from children 
undergoing iron supplementation, we assessed RBC surface markers from the same children over time 
(n=8). We examined changes in surface expression of: glycophorin A (GPA), a sialoglycoprotein affecting 
RBC charge; CD47, an anti-phagocytic RBC marker; C3b deposition on RBC surfaces; CD35, 
complement receptor 1; CD55, a decay accelerating factor regulating complement on the cell surface; 
CD147; and sialic acid, all of which can reflect RBC age and overall membrane integrity and/or have been 
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implicated in malaria merozoite invasion. We found significantly increased GPA, CD47, CD35 and CD147 
levels and significantly decreased C3b deposition at Day 49 (p<0.01 for all analyzing means between Day 
0 and Day 49 by ANOVA and Tukey’s test) (Supplemental Figure S4.4). We were unable to detect 
differences in CD55 and sialic acid levels. Taken together, these surface marker findings support the idea 
that overall RBC population age and membrane physiology has shifted toward a younger, healthier RBC 
population following iron supplementation of anemic children.    
4.5 DISCUSSION 
Use of in vitro growth assays as our primary outcome provided a rare opportunity to 
systematically examine the cellular determinants of parasite growth in anemic and iron-supplemented 
children. We demonstrate here that blood stage in vitro P.falciparum growth is decreased in RBCs from 
anemic children and this effect is reversed by iron supplementation. 
Defining iron deficiency in children with ongoing infections or inflammation is difficult, and has 
confounded previous clinical studies trying to determine the protective effect of iron deficiency on malaria 
susceptibility. Here we show protection offered by anemia is substantial (~10% per standard deviation 
shift in hemoglobin), and RBCs from children with iron deficiency – no matter the definition criteria nor the 
presence of potential confounders such as inflammation – consistently reduce parasite growth compared 
to RBCs from non-anemic individuals. The protection was mediated by anemia rather than iron 
deficiency. Additionally, the use of clinical parasite isolates from The Gambia confirm this is not merely an 
artefact of laboratory strains. Notably, at the population level, anemia was estimated to confer at least 
four times as much protection against blood stage parasite growth than sickle-cell trait. Taken together, 
this data is evidence that anemia exhibits a profound natural influence on parasite growth beyond even 
the mostly commonly studied and referenced RBC polymorphisms which evolved due to malaria 
pressure.  
Furthermore, we demonstrate parasite growth increases dramatically relative to baseline in RBCs 
taken from children during iron supplementation, transiently rising at Day 49 to exceed growth rates in 
non-anemic controls and remaining elevated at Day 84 relative to baseline. Iron deficient RBCs have a 
shorter circulation lifetime (90 vs 120 days, on average) and exhibit physiological differences such as 
microcytosis, decreased deformability, and increased oxidative membrane stress, among other effects – 
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similar to changes in aged RBCs (27). As parasites preferentially infect young RBCs and reticulocytes (1, 
28), we assessed surface markers reflecting RBC age and integrity to provide a picture of the overall 
health of RBCs in anemic children undergoing iron treatment. Our data suggests that erythropoiesis 
increased in response to iron, creating a younger population of circulating RBCs. These younger RBCs 
are most prevalent at Day 49, which matches the largest shifts in malaria growth rates and supports our 
hypothesis that parasite growth transiently increases following iron supplementation due to P.falciparum’s 
preference for young RBCs (1). The study was constrained by the wide intervals between venous bleeds 
selected for the intervention. At Day 49, it is possible the main iron-induced erythropoietic surge already 
passed, in which case our data would underestimate the true extent of increased malaria risk. 
We also examined merozoite invasion into RBCs from anemic and non-anemic individuals, as our 
previous work found invasion differences contributed significantly to reduced malaria pathogenesis in iron 
deficient RBCs (1). We expanded our previous findings to show that RBCs from anemic African children 
were resistant to invasion with both laboratory and clinical P.falciparum strains and that iron 
supplementation increased invasion susceptibility. Our RBC surface marker data corroborating a shift 
towards younger, healthier RBCs corresponds with our hypothesis that changes in RBC population 
structure influence overall malaria risk.  
The public health implications of our study are significant, shedding light on the overarching 
question of whether iron supplements cause harm. We acknowledge that in vitro parasite growth might 
not translate directly to malaria susceptibility. Yet there are no other viable alternatives for addressing this 
safety aspect regarding iron supplementation in malarious regions. While our system only examined the 
RBC impact of anemia on malaria growth, eliminating the impact of serum iron or immune cells, the fact 
that we still observe such profound growth effects highlights the protection afforded by anemia and the 
need for caution regarding iron supplementation. Furthermore, our results provide insight into why other 
clinical studies on this topic produce such variable results – given we find increased malaria susceptibility 
is transient, other studies may miss the window of enhanced susceptibility. We detect significant changes 
in parasite growth rates despite relatively small changes in hemoglobin levels, emphasizing the impact of 
iron and RBC population dynamics on P.falciparum pathogenesis. Our data clearly show that the safety of 
iron supplementation must be addressed, even if additional unknown mechanisms contribute to increased 
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malaria susceptibility. We thus advocate temporary malaria prophylaxis should always accompany iron 
supplementation for anemic children in malaria endemic areas, though the period of enhanced 
susceptibility has not been accurately identified by this study. Finally, quantifying the sizeable contribution 
of anemia to population level protection against malaria, our research raises the question of whether 
consistently reduced hemoglobin and MCV values in people of African descent are genetic signatures of 
evolution under significant malaria pressure, much like the hemoglobinopathies.     
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4.6 TABLES AND FIGURES 
Table 4.1: Blood, inflammatory, and iron parameters of anemic donors whose RBCs were used for 
parasite growth assays before (Day 0), during (Day 49), and after (Day 84) iron supplementation. 
Tests were performed in MRC Keneba laboratories using a Medonic M20M GP and Cobas Integra 400 
plus, or in the field using a HemoCue 301. Values in the Normal Range column are the normal or healthy 
range for each parameter for 6-24 month-olds as defined by standard guidelines (29). Numerical values 
reflect the mean value of all individuals and values in parentheses indicate standard deviation. Note that 
control non-anemic donors had an average hemoglobin of 14.13 g/dl (standard deviation 0.85).  
 
Variable Normal 
Range 
Day 0 
n=158 
Mean (SD) 
Day 49 
n=91 
Mean (SD) 
Day 84 
n=87 
Mean (SD) 
White Blood Cell (x10^9 per l) 6-17.0 12.11 (4.34) 12.35 (4.80) 12.22 (3.86) 
Hemoglobin (g per dl) 11.0-13.5 9.88 (0.81) 10.68 (0.94) 10.78 (1.04) 
Hematocrit (%) 33-39 28.88 (6.34) 28.57 (3.68) 29.67 (5.97) 
Mean Corpuscular Volume (fl) 70-86 62.90 (7.66) 64.39 (6.40) 64.80 (6.15) 
Mean Corpuscular Hemoglobin 
Concentration (g per dl) 
30-36 34.98 (1.47) 35.16 (1.32) 35.44 (1.18) 
Red Cell Distribution Width (%) 12-14 18.06 (2.51) 18.24 (2.38) 17.52 (2.17) 
Platelet Count (x10^9 per l) 150-300 430.01 
(200.10) 
417.44 
(172.28) 
372.45 
(155.27) 
Iron Total (µ mol per l) 9-21 4.99 (5.10) 9.24 (5.25) 14.97 (7.21) 
Transferrin (g per l) 2-36 3.08 (0.62) 2.91 (0.52) 2.88 (0.56) 
Transferrin Saturation (%) 15-39 8.10 (8.76) 13.22 (6.73) 21.75 (11.04) 
Ferritin (ng per ml) 12-140 16.55 (17.30) 28.81 (46.50) 22.78 (23.74) 
Alpha 1 Anti-glycoprotein (g per l) <1 1.29 (0.52) 1.27 (0.46) 1.29 (0.46) 
C Reactive Protein (mg per dl) 0.8-3.1 6.30 (13.70) 5.19 (7.90) 4.56 (7.61) 
Soluble Transferrin Receptor (nmol per l) 
(30) 
1.26-1.23 8.83 (3.84) 8.21 (2.67) 7.36 (3.17) 
Soluble Transferrin Receptor: log Ferritin 
Index  
N/A 8.57 (18.24) 7.95 (9.10) 5.62 (7.39) 
Hepcidin (ng per ml) N/A 12.07 (13.73) 13.23 (12.76) 14.42 (12.37) 
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Table 4.2. Effect of host hemoglobin, iron status, and other hematological characteristics on in 
vitro P. falciparum growth in RBCs from anemic children (Hgb<11g/dl) at baseline. Growth rates 
(GR) were calculated relative to growth in healthy, non-anemic donors. Growth assays were performed in 
triplicate for each donor and the average value was used for linear regression modelling; multivariate 
analyses represent the estimated association for a given variable while controlling for potential 
confounders. Hgb genotype was evaluated solely based on AA vs. AS classification (too few individuals 
for statistical evaluation of SS genotypes) and G6PD status was evaluated solely based on normal vs. 
deficient classification. For continuous variables, the β1 value represents the %GR change (x100) for 
every 1 unit increase in the primary variable. For categorical variables, the β1 value represents the %GR 
change (x100) based on yes-no genotype. For example, for Hgb AS, the %GR change is -18.3% relative 
to Hgb AA. Significant p values (<0.05) are bolded. The adjusted %GR change for Hgb and MCV is 
calculated based on the SD for the exposure variable of interest (see Table 1) multiplied by β1 (x100%), to 
give the %GR change for every 1 SD change in the exposure variable; for Hgb genotype the adjusted 
%GR change is simply β1 (x100%). 
 
Condition β1 Value Lower CI Upper CI p Value Adjusted 
% GR 
Change 
Bivariate analysis of measures affecting 
parasite growth 
     
Hgb (g/dl) 0.107 0.039 0.174 0.002 8.6% 
Hgb genotype (AA vs AS) -0.183 -0.318 -0.047 0.009 -18.3% 
MCV (fL) 0.014 0.007 0.021 <0.001 10.8% 
G6PD status (normal vs deficient) 0.051 -0.206 0.309 0.696 
 
Ferritin  (ng/ml) 0.002 -0.002 0.005 0.290  
Hepcidin (ng/ml) 0.004 0.000 0.008 0.074  
CRP (mg/dl) -0.002 -0.006 0.002 0.360  
sTfR:log ferritin ratio -0.001 -0.004 0.003 0.702  
Transferrin saturation (%) 0.431 -0.307 1.169 0.255  
Multivariate analysis of significant 
measures affecting parasite growth 
controlling for possible confounders 
     
Hgb affects parasite growth controlling 
for Hgb genotype 
0.103 0.036 0.170 0.003 8.3% 
Hgb genotype affects parasite growth 
controlling for Hgb 
-0.179 -0.312 -0.047 0.009 -17.9% 
 
  
91 
 
Figure 4.1: Description of subjects and flow chart of sample collection and assays performed. 
Blood samples for hematological, biochemical, and parasite growth analyses were drawn at Day 0, as 
well as Day 49 and Day 84 for those taking iron. A full hematology panel was measured in EDTA-
stabilized blood (Medonic M20M GP). We also assayed plasma ferritin, soluble transferrin receptor 
(sTfR), serum iron, transferrin saturation (TSAT), C-reactive protein (CRP), alpha 1-acid glycoprotein 
(AGP) (Cobas Integra 400 plus); and hepcidin (Hepcidin-25 (human) EIA Kit (Bachem)). Genotyping for 
hemoglobinopathies was performed using hemoglobin electrophoresis. Glucose-6-phosphate 
dehydrogenase (G6PD) enzyme activity was measured by commercial kit (R&D Diagnostics Ltd). For 
malaria assays, 2.5mL of venous blood was drawn directly into microvette tubes containing CPDA-1 
(Sarstedt, Germany). Unavailable donors include safety exclusion (Hgb<7g/dl or positive malaria test 
(RDT pos) or general loss to follow up (withdrawal and travel). Failure to collect blood from subjects (e.g. 
from phlebotomy failure, subject moved or withdrew, or became significantly ill) was 9.3% at Day 0, 
17.0% at Day 49, and 20.7% at Day 84. RBCs from study subjects were evaluated with in vitro P. 
falciparum growth assays (using strain FCR3-FMG) as a proxy measure for malaria susceptibility. In order 
to standardize the growth assays, control for inter-assay variability and variability between parasite 
preparations, assays on clinical samples were run in parallel with and reported relative to growth assays 
done using RBCs from non-anemic donors. Each available blood sample at every time point was 
subjected to growth assays but not all produced growth data, as some blood was unusable (e.g. clotted, 
hemolysed, contaminated). Further growth data exclusions (e.g. parasites died or control blood did not 
provide a readable output for comparison) do not represent population sampling bias, as subject 
characteristics are the same between those with and without corresponding growth data (Supplemental 
Table 2). 
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Figure 4.2: Parasite growth and invasion in RBCs from anemic children (Hgb<11g/dl) at baseline. 
A) P.falciparum (strain FCR3-FMG) growth rates are proportional to hemoglobin concentration. Growth 
assays were performed in RBCs drawn from anemic children at baseline (Day 0) and values are 
presented relative to growth in RBCs from non-anemic donors. Each dot represents the mean result of 
triplicate growth assays from each donor and the error bars represent 95% CI. One-way ANOVA indicates 
the means are significantly different between Days (p<0.05); specifically, post-hoc analysis with Tukey’s 
test indicates significant differences between Hgb levels 7-9g/dl and 10.1-11g/dl (*p<0.05). B) 
P.falciparum clinical isolates from The Gambia exhibit decreased growth in RBCs from anemic children at 
Day 0. Growth of 3 different clinical strains (952, 998, 1029) was compared to growth of a laboratory 
strain (FCR3-FMG) in RBCs from five anemic children. Each dot represents the mean result of triplicate 
growth assays from each donor relative to growth in non-anemic RBCs and error bars represent the 95% 
CI. The mean relative growth rate in anemic RBCs for each strain is decreased compared to 100% growth 
in non-anemic RBCs. C) Direct comparison of invasion into RBCs from anemic and non-anemic donors 
using P.falciparum laboratory strains. Invasion experiments for RBCs from all anemic donors (drawn at 
Day 0) were performed independently and each experiment was performed in triplicate. Data show the 
mean SI using RBCs from 10 anemic donors for strain 3D7 and 15 for FCR3-FMG. The SI defines the 
relative susceptibility to invasion of two different types of RBCs. The marker represents the SI point 
estimate and the bar represents the 95% CI. An SI of 1.0 indicates no difference in parasite invasion of 
two RBC populations. Both strains 3D7 and FCR3-FMG give SI values significantly decreased from the 
control value of 1.0. D) Direct comparison of invasion into RBCs from either anemic or non-anemic donors 
using clinical strains of P.falciparum. Invasion experiments for RBCs from all anemic donors (drawn at 
Day 0) were performed independently and each experiment was performed in triplicate. Data show the 
mean SI using RBCs from 5 anemic donors for all strains (FCR3-FMG, 952, 998, 1029). The marker 
represents the SI point estimate and the bar represents the 95% CI. An SI of 1.0 indicates no difference 
in parasite invasion of two RBC populations. 
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Figure 4.3: Malaria susceptibility increases transiently during iron supplementation and anemic 
children receiving iron supplements have increased numbers of young RBCs. A) P. falciparum in 
vitro growth rates in RBCs from anemic children increase over time with iron supplementation (12mg iron 
daily for 84d). Parasite growth assays were conducted in RBCs from children at Day 0, Day 49, and Day 
84 using strain FCR3-FMG. Growth rates are reported relative to growth in RBCs from non-anemic 
donors. Each dot represents the mean of triplicate assays and error bars represent the 95% CI. 
Differences between growth rates at the different timepoints were significant (p<0.0001 by one-way 
ANOVA); specifically, post-hoc analysis with Tukey’s test indicates significant differences between Day 0 
and Day 49 (***p<0.001) and Day 49 and Day 84 (***p<0.001), as well as Day 0 and Day 84 (**p<0.01). 
n=158 children at Day 0, n=91 children at Day 49, and n=87 children at Day 84. B) Levels of CD71 
positive RBCs increase over time in anemic children undergoing iron supplementation. Percent CD71-
positive RBCs was measured by flow cytometry analysis of CD71 surface expression. Error bars 
represent the 95% CI; one-way repeated measures ANOVA indicates the means are significantly different 
between Days (p<0.01, n=31); post-hoc analysis with Tukey’s test indicates significant differences 
between Day 0 and Day 49 (**p<0.001) but not between Day 49 and Day 84, nor Day 0 and Day 84. 
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4.7 SUPPLEMENTAL INFORMATION 
4.7.1 Supplemental Methods 
Micronutrient power. The iron supplementation product used in this trial is a micronutrient 
powder (MNP, MixMe WHO) produced by the DSM Company and distributed routinely by the United 
Nations Children’s Fund and the World Food Program (contains 10mg of iron). For our study purposes 
the iron concentration was altered to contain 12mg iron/sachet (daily dose). The MNP contained Vitamin 
A (400µg RE), Vitamin D (5µg), Vitamin E (5mg), Vitamin C (30mg), Thiamine B1 (0.5mg), Riboflavin B2 
(0.5mg), Niacin B3 (6g), Pyridoxine B6 (0.5mg), Cobalamine B12 (0.9µg), Folate (150g), Zinc (4.1mg), 
Copper (0.56mg), Selenium (17µg), and Iodine (90g).   
Flow cytometry analysis. Flow cytometry was performed onsite at MRCG using a BD Accuri C6 
flow cytometer. Channels and probes used included: SYBR Green I, FITC, and Alexa Fluor® 488 (488nm 
excitation with a 530/30nm bandpass emission filter, detector FL1); PE (488nm excitation with a 
585/40nm bandpass emission filter, detector FL2); and CellTrace Far Red DDAO and Alexa Fluor® 647 
(640nm excitation with a 675/25nm bandpass emission filter, detector FL4). Detector gain setting 
changes and compensation were not necessary with this configuration. Accuri C6 data was collected and 
analyzed with Accuri software (BD Accuri CSampler Analysis Software). Linear amplification of forward 
scatter was used to set event threshold in order to exclude cell debris, microparticles and doublets. For all 
experiments, samples were diluted to 0.001-0.002% hematocrit and ≥ 100,000 total events were 
collected.  
RBC surface marker assessment. RBC surface protein levels were determined by staining with 
fluorescently tagged antibodies followed by flow cytometry analysis. The relative expression fluorescence 
of each surface marker for each study sample was calculated using the MFI values (corrected for 
background), relative to MFI in the non-anemic donor. The exception was C3b for which the relative 
expression was reported as a percent of positively stained RBCs relative to the non-anemic donor.  
Antibodies. The following antibodies were used: for CD35 (Mouse Anti-Human CD35 Clone E11 
(BD) primary 1:2000; Alexa Fluor® 647 Rabbit Anti-Mouse IgG secondary 1:2000); for CD47 (Mouse Anti-
Human CD47 Clone B6H12 primary 1:2000; Alexa Fluor® 647 Rabbit Anti-Mouse IgG secondary 1:500); 
for CD55 (Mouse Anti-Human CD55-PE conjugate Antibody NaM16-4D3 (Santa Cruz Biotechnologies) 
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1:10); for CD147 (Mouse Anti-Human CD147 Clone HIM6 (BD) primary 1:500; Alexa Fluor® 647 Rabbit 
Anti-Mouse IgG secondary 1:500); for Glycophorin A (GPA) (primary Rabbit Anti-Human 
CD235a/Glycophorin A (ThermoFisher Scientific/Pierce) 1:500 and secondary Alexa Fluor® 647 Goat 
Anti-Rabbit 1:2000); for sialic acid residues (Wheat Germ Agglutinin Alexa Fluor® 488 Conjugate 
(ThermoFisher Scientific/Molecular Probes) 1:2000); and for C3b deposition (primary Mouse Anti-Human 
Complement C3b Antibody 10C7 (ThermoFisher Scientific) 1:200; Alexa Fluor® 647 Rabbit Anti-Mouse 
IgG secondary 1:500). 
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4.7.2 Supplemental Tables and Figures 
Supplemental Table S4.1: Description of subjects. Hemoglobin genotyping was performed by 
electrophoresis. G6PD enzyme activity was performed by commercial kit. *A portion of subjects (% of 
total) were unable to be tested for G6PD status or hemoglobin genotype so are not included in the 
denominator for other % of total calculations. 
 
Description of study population at baseline 
 
 
All participants (n=407) Those to receive 12 mg iron daily 
(n=135) 
Age, months, mean (SD) 15.4 (4.4) 15.5 (4.4) 
Sex (%) 
  
 
Female 209 (51.2) 71 (52.6) 
 
Male 198 (48.5) 64 (47.4) 
Z score, Wt for ht, mean (SD) -0.91 (0.89) -0.76 (0.84) 
G6PD Status, n (% of those tested) 
  
 
Normal 312 (93.7) 99 (93.3) 
 
Deficient 21 (6.3) 7 (6.6) 
 
Untested* 74 (18.2) 29 (21.3) 
Hemoglobin genotype, n (%) 
  
 
AA 326 (81.5) 110 (83.3) 
 
AS 66 (16.5) 19 (14.4) 
 
SS 6 (1.5) 2 (1.5) 
 
AC 1 (0.3) 0 (0.0) 
 
SC 1 (0.3) 1 (0.8) 
 
Untested* 7 (1.7) 3 (2.2) 
 
 
  
97 
 
Supplemental Table S4.2: Blood, inflammatory, and iron parameters of study participants with 
reportable parasite growth rate data versus those without. Numerical values reflect the mean value of 
all individuals of a particular category and time point, and values in parentheses are the SD. 
 
Variable D0 w/ 
GR 
n=158 
Mean 
(SD) 
D0 no 
GR 
n=249 
Mean 
(SD) 
D49 w/ 
GR 
n=91 
Mean 
(SD) 
D49 no 
GR 
n=35 
Mean 
(SD) 
D84 w/ 
GR 
n=87 
Mean 
(SD) 
D84 no 
GR 
n=33 
Mean 
(SD) 
White Blood Cell (x10^9 per l) 12.11 
(4.34) 
11.83 
(3.82) 
12.35 
(4.80) 
11.21 
(2.69) 
12.22 
(3.86) 
10.86 
(2.54) 
Red Blood Cell (x10^12 per l) 4.62 
(1.00) 
4.38 
(0.63) 
4.64 
(0.62) 
4.58 
(0.42) 
4.59 
(0.85) 
4.34 
(0.33) 
Hemoglobin (g per dl) 9.88 
(0.81) 
9.85 
(0.82) 
10.68 
(0.94) 
11.05 
(1.21) 
10.78 
(1.04) 
11.32 
(1.04) 
Hematocrit (%) 28.88 
(6.34) 
27.30 
(3.90) 
28.57 
(3.68) 
30.35 
(3.93) 
29.67 
(5.97) 
29.44 
(3.00) 
Mean Corpuscular Volume 
(fl) 
62.90 
(7.66) 
62.72 
(6.84) 
64.39 
(6.40) 
66.27 
(6.21) 
64.80 
(6.15) 
67.84 
(5.72) 
Mean Corpuscular 
Hemoglobin (pg) 
22.02 
(2.92) 
22.17 
(2.84) 
22.66 
(2.56) 
23.11 
(2.43) 
22.97 
(2.33) 
23.63 
(2.20) 
Mean Corpuscular 
Hemoglobin Concentration (g 
per dl) 
34.98 
(1.47) 
35.29 
(1.39) 
35.16 
(1.32) 
34.88 
(1.11) 
35.44 
(1.18) 
34.82 
(1.30) 
Red Cell Distribution Width 
(%) 
18.06 
(2.51) 
17.58 
(2.68) 
18.23 
(2.38) 
18.13 
(2.46) 
17.52 
(2.17) 
18.69 
(2.21) 
Mean Platelet Volume (fl) 7.62 
(0.62) 
7.70 
(0.48) 
7.76 
(0.60) 
7.85 
(0.55) 
7.90 
(1.19) 
7.62 
(0.44) 
Platelet Count (x10^9 per l) 430.00 
(200.10) 
459.21 
(196.49) 
417.44 
(172.28) 
386.64 
(187.22) 
372.45 
(155.27) 
370.35 
(152.33) 
Iron Total (µ mol per l) 4.99 
(5.10) 
6.18 
(4.88) 
9.24 
(5.25) 
9.53 
(4.89) 
14.97 
(7.21) 
17.23 
(12.77) 
Transferrin (g per l) 3.07 
(0.62) 
3.22 
(0.66) 
2.91 
(1.52) 
2.90 
(0.48) 
2.88 
(0.56) 
2.94 
(0.54) 
Transferrin Iron Binding 
Capacity (µ mol per l) 
66.31 
(11.50) 
72.06 
(16.95) 
69.21 
(12.40) 
76.19 
(11.88) 
70.27 
(13.62) 
74.82 
(11.45) 
Transferrin Saturation (%) 8.10 
(8.76) 
9.04 
(7.01) 
13.22 
(6.72) 
12.60 
(6.43) 
21.75 
(11.04) 
23.12 
(15.31) 
Ferritin (ng per ml) 16.55 
(17.30) 
20.89 
(28.33) 
28.80 
(4.50) 
20.88 
(13.58) 
22.78 
(23.74) 
30.95 
(27.07) 
Alpha 1 Anti-glycoprotein (g 
per l) 
1.29 
(0.52) 
1.24 
(0.52) 
1.27 
(0.46) 
1.02 
(0.40) 
1.29 
(0.46) 
1.04 
(0.30) 
C Reactive Protein (mg per 
dl) 
6.30 
(13.70) 
6.27 
(14.99) 
5.19 
(7.90) 
4.87 
(11.55) 
4.56 
(7.61) 
3.15 
(5.76) 
Soluble Transferrin Receptor 
(nmol per l) 
8.83 
(3.84) 
8.99 
(3.84) 
8.21 
(2.67) 
7.84 
(2.47) 
7.36 
(3.17) 
6.91 
(2.13) 
Soluble Transferrin Receptor: 
log Ferritin Index  
8.57 
(18.24) 
7.09 
(28.79) 
7.95 
(9.10) 
4.43 
(13.08) 
5.62 
(7.39) 
4.51 
(4.80) 
Unsaturated Iron Binding 
Capacity (µ mol per l) 
61.33 
(13.17) 
66.54 
(17.17) 
60.97 
(11.91) 
66.80 
(11.75) 
55.53 
(15.23) 
57.59 
(15.47) 
Hepcidin (ng per ml) 12.07 
(13.73) 
11.79 
(11.61) 
13.23 
(12.78) 
11.49 
(12.89) 
14.42 
(12.37) 
12.12 
(10.95) 
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Supplemental Figure S4.1: Parasite growth rates in RBCs from children categorized by different 
definitions of anemia at baseline. In analysis of parasite growth rates in RBCs from children at Day 0, 
we stratified participants (all anemic) using four different definitions to categorize the severity and type of 
iron deficiency in the presence or absence of inflammation: those with 1) hepcidin<5.5ng/ml (n=82); 2) 
ferritin<12ng/ml (n=69); 3) ferritin12-30ng/ml with CRP>5mg/ml (n=17); 4) hemoglobin increase of 
>0.5g/dl from baseline after 49d or 84d of daily iron supplementation (n=46); definitions 1-4 are not 
necessarily mutually exclusive. Of note, everyone in our population had a raised serum transferrin 
receptor (sTfR):log ferritin index >2 which is highly suggestive of iron deficiency. Growth rate values are 
presented relative to growth in RBCs from non-anemic donors. Each dot represents the mean result of 
triplicate growth assays from each donor and the error bars represent 95% CI. Mean growth rate results 
(with 95%CI) are: hepcidin<5.5ng/ml=42.89% (37.11-48.67%); ferritin<12ng/ml=43.34% (36.01-50.68%); 
ferritin 12-30ng/ml with CRP>5mg/ml=49.08% (29.16-69.00%), ΔHgb>0.5g/dl=44.04% (35.14-52.93%). 
There are no significant differences between the means.  
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Supplemental Figure S4.2: Gating strategy to highlight adaptation of RBC barcoding assay to the 
field setting using basic two-color flow cytometry. A) RBCs from different blood donors are 
differentially labelled with CellTrace Far Red DDAO (1 µM (R3) or 0.1 µM (R4)) to distinguish between 
donor populations. Late stage purified parasites grown in unlabeled RBCs (R5) are seeded into the 
differentially labelled RBCs which have been combined in equal proportion. B) M10 represents the 1 µM 
Far Red DDAO labelled RBCs from a non-anemic donor and M11 represents the 0.1 µM Far Red DDAO 
labelled RBCs from an anemic donor. Gating cells on M11 (C) or M10 (D) allows for Sybr Green I DNA 
dye detection of parasite infected RBCs in the RBCs from anemic donors (M12, C) or from non-anemic 
donors (M13, D). Parasitemia in each cell population is compared to calculate the invasion SI. 
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Supplemental Figure S4.3. Changes in parasite growth, invasion, and reticulocytosis in RBCs 
from anemic children before and after daily iron supplementation. A) Levels of parasite growth rates 
increase over time in anemic children undergoing iron supplementation, as depicted by line graph in order 
to highlight changes for each individual that had data available at all timepoints (n=35 children with 
complete repeat growth measures at Day 0, 49, and 84, with 86% having increased growth rate at Day 
49) One-way repeated measures ANOVA of growth rate values indicates the means are significantly 
different between Days (p<0.0001); post-hoc analysis with Tukey’s test indicates significant differences 
between Day 0 and Day 49 means (p<0.001) and Day 49 and Day 84 means (p<0.001), but no 
significance between Day 0 and Day 84 for those children with repeat measures. B) Direct comparison of 
invasion into RBCs from non-anemic donors to RBCs from 8 anemic children either before or during 
12mg daily iron supplementation. Each experiment was performed in triplicate for each blood donor. The 
marker represents the SI point estimate and the bar represents the 95% CI. An SI of 1.0 indicates no 
difference in parasite invasion of the two RBC populations. Student’s t-test indicates significant 
differences between pre- and post-iron SI values (**p<0.01). C) Line graph of CD71 repeated measures 
(n=31 children with complete repeat CD71 measures at Day 0, 49, and 84). In 21 of these children, the 
relative percent CD71 positive cells increased from Day 0 to Day 49. See Figure 3B for repeated 
measures ANOVA statistics.  
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Supplemental Figure S.4.4: Surface markers of RBC age and integrity change in a pattern 
consistent with an increase in erythropoiesis in anemic children undergoing iron supplementation 
(12mg daily). We measured GPA (an abundant sialoglycoprotein which contributes to RBC surface 
charge and is found at higher levels on younger RBCs (31)), CD47 (an anti-phagocytic marker which 
influences RBC senescence and is found in lower levels in RBCs that have been in circulation longer or 
are less healthy (32)), surface deposition of complement factor C3b (higher levels of which would 
correlate with increased RBC time in circulation, or less healthy RBC membranes (33)), and levels of 
P.falciparum merozoite receptors (CD35, CD147, CD55, and sialic acid residues). Note that GPA is also a 
merozoite receptor, and CD35 and CD55 involved in the complement system have also been described 
as reflecting RBC age (more abundant on younger/healthier RBCs (33)), as has sialic acid abundance 
(reduced on older RBCs) (32). CD147, known as basigin, is the only known essential P.falciparum 
invasion receptor (34). Data represent relative expression based on anemic donor RBC MFI values (GPA, 
CD47, CD35, CD147, CD55, and sialic acid residues) or percent positive population values (C3b), 
compared to RBCs from a non-anemic donor not receiving iron supplementation (relative 
expression=1.0). RBCs from the same 8 donors were examined over time. Error bars represent the 95% 
CIs. If indicated, one-way repeated measures ANOVA with post-hoc Tukey’s test analysis indicates 
significant difference between expression levels (*p<0.05, **p<0.01, ***p<0.001).  
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4.8 DISCUSSION ADDENDUM 
4.8.1 Linear regression and population level impact: results, interpretations, and alternative 
analyses. 
Dr. Meshnick and his Ph.D. student Jordan Cates have kindly offered some very specific points 
about the analytical approach used in the previous chapter. Below, we address these issues point by 
point and present the same data as analyzed by suggested alternative methods. 
 
You are extrapolating from an in vitro finding (parasite growth) to a disease (malaria).  
We understand this comment, and will modify the final published manuscript to make it clearer 
that this is a translational research study that was a sub-study within a clinical trial. It is not an 
epidemiological study; we did in vitro assays with clinical samples. We are not trying to make policy 
statements or clinical recommendations. We are contributing to the evidence base on malaria and iron. 
These results will help people design future clinical trials on the impact of iron supplementation and risk of 
clinical malaria and/or on the interaction of sickle-cell trait and anemia. 
 
Instead of adjusting the β effect to be based on standard deviation, can you use something like 
“every 10 units” of a given variable? This might make your results more applicable to a broader 
population because currently your presentation of growth rate changes for every standard 
deviation of a given variable amongst your subjects is only relevant to your specific study 
population. 
We see the point that it would be nice to have our growth rate changes be interpretable to any 
population of anemic children, not just the kids in our study. However we disagree with this method 
because attempting to compare 10 units of MCV (femtoliters) to 10 units of Hgb (g/dl), for example, the 
degree of growth rate changes become very difficult to interpret in relation to one another as the units of 
measurement can be so vastly different and have such different normal spread. Thus, results presented 
in this manner would not be clinically interpretable. We have renamed our “adjusted” growth rate which 
represents the change for every one degree of standard deviation change of that variable in our 
population to be the “standardized” growth rate to better fit with epidemiological terminology.  
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Multivariate linear regression analysis of growth rate versus hemoglobin or hemoglobin genotype, 
controlling for one another, doesn’t completely make sense because hemoglobin cannot influence 
hemoglobin genotype. 
As was correctly pointed out, hemoglobin cannot influence sickle-cell trait genotype because it is 
not possible for an individual’s genotype to change based on hematological variables. However, in 
reverse, we do need to control for sickle-cell trait when examining the effect of hemoglobin on parasite 
growth, because sickle-cell trait carrier status can in fact influence hemoglobin levels. Fortunately, as our 
multivariate results controlling for hemoglobin and hemoglobin genotype do not affect the relationship of 
parasite growth to hemoglobin or sickle-cell trait genotype, in our case we can effectively ignore this 
issue. 
 
It is impossible for you to say anything about the influence of “anemia” on parasite growth since 
all of your subjects are anemic, so you do not have growth rate data from non-anemic people 
within your dataset. 
We understand this comment and it is certainly a limitation for our in vitro parasite study that the 
enrollment criteria for the clinical trial from which we obtained RBC samples was for children to be anemic 
(Hgb 7-11g/dl). We can make this distinction clearer in the final manuscript text, including statements like 
“within our study population of people with anemia, we find the degree of anemia affects parasite growth 
rate.” The same statement would apply for the sickle-cell genotype: “within our study population of people 
with anemia, those with sickle-cell trait have lower growth rates than those without.”   
Non-anemic subjects were not enrolled in the iron supplementation study, but RBCs from non-
anemic control donors were independently included as a reference in all of our experiments. The 
dependent variable of parasite growth in our linear regression model is a calculated number. Growth 
assays were incubated for 96 hours and parasite growth is calculated by dividing the final 96h 
parasitemia by the initial 0h parasitemia. The relative growth rate for each individual experimental RBC 
sample is then calculated by dividing the parasite growth rate in the experimental RBCs by the parasite 
growth rate in RBCs from control non-anemic RBCs assayed in parallel. Every growth assay we set up 
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included parasites grown in control non-anemic RBCs to be able to make these comparisons. We 
ultimately agree we must make it clear we were restricted to looking at people with anemia, even though 
all our data is normalized to non-anemic controls. Normalizing the data to non-anemic controls does not 
fully take care of the problem. Thus to make a specific inference about someone with Hgb>11 based on 
our linear regression results is wrong because we do not have data collected on subjects with Hgb>11; 
we only generally know that parasite growth at Day 0 prior to iron supplementation is lower in anemic 
versus non-anemic individuals. However this general knowledge, which relates back to our date being 
reported as “relative” growth rates, does allow us to still make statements saying that parasite growth is 
lower in RBCs from anemic study subjects than from non-anemic controls. There is further discussion of 
this point below in relation to our “population level impact” calculations. 
 
Comparing the continuous variable “Hgb” and the dichotomized variable “Hemoglobin genotype” 
in your linear regression model is like comparing apples and oranges. 
We chose to compare Hgb (continuous) vs. genotype (dichotomized) because we were interested 
in reporting our output as the effect on parasite growth per unit= 1g/dl of change in Hgb, similar to how we 
were using the unit=genotype for the genotype. We only analyzed AA and AS genotypes in our study 
population. For both Hgb and genotype, the dependent variable was parasite growth. We also wanted to 
begin by analyzing our results with hemoglobin as a continuous variable because sometimes categorizing 
a variable can mask its significance. Finally, we are aware of many other studies and statisticians who 
use both continuous and categorical variables in the same linear regression modeling (35). 
In an attempt to make it easier for the reader to compare the impact of the various factors on the 
parasite growth, we presented information on the standardized %GR change for each of the variables. 
For Hgb and MCV this was calculated based on the SD for the exposure variable of interest (using the 
data from Table 1 in this chapter) multiplied by the β1 effect (x100%), to give the %GR change for every 1 
SD change in the exposure variable; for Hgb genotype the adjusted %GR change is simply β1 (x100%). 
Please refer to Table 2 in this chapter for a refresher of the results. 
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Please reanalyze results with hemoglobin as a categorized variable, for the sake of comparison. 
We have now redone the multivariate analysis using Hgb as a categorical variable and present 
the results here below. For comparison, we tried several different ways of breaking down the hemoglobin 
into categories. Admittedly, it makes the most sense to have the categories be clinically relevant or 
otherwise justifiable, in order to best demonstrate the clinical relevance of the results and interpretations. 
The WHO categories for anemia are severe (Hgb<7g/dl), moderate (Hgb 7-10g/dl), and mild (Hgb 10-
10.9g/dl). The population of children enrolled in our study had hemoglobin values between 7-11g/dl. 
Thus, our data exclusively represents parasite susceptibility in children with mild and moderate anemia, 
and if we categorized hemoglobin based on these WHO-defined distinctions, we dichotomize the Hgb 
variable.  
Below are the linear regression results assessing impact of moderate versus mild anemia on 
parasite growth rates (dichotomizing Hgb into two categories). Note that now the growth rate change for 
hemoglobin is negative, reflecting the difference between those with moderate anemia compared to those 
with mild anemia (the reference category). Also, standardizations for growth rate here are simple 
conversions of the β1 effect to percent growth rate changes, and do not take into account SD of Hgb. 
 
Addendum Table A4.1: Multivariate modeling with Hgb dichotomized 
Condition B1 
value 
Lower CI Upper CI p Value Standardize
d % GR 
change 
Hgb dichotomized 
    
 
Hgb affects growth at Day 0 -0.130 -0.241 -0.020 0.0223 -13.0% 
Hgb genotype affects growth at Day 0 -0.183 -0.318 -0.047 0.0091 -18.3% 
Hgb affects growth at Day 0 
independently of Hgb genotype 
-0.126 -0.236 -0.016 0.0260 -12.6% 
 
 
 
The effect of hemoglobin is thus still significant when dichotomized, although the overall spread 
between categories in terms of both Hgb means (10.45g/dl average amongst mildly anemic versus 
9.19g/dl average amongst moderately anemic) and also potential growth rate differences (now only 
13.0%) within our population is now much smaller. We know the potential spread of hemoglobin within 
our population is much greater, as is the growth rate spread, so this analysis minimizes the size of our 
results. Not only that, but the p value greatly increases compared to Hgb as a continuous variable.  
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If we further categorize Hgb values into tertiles, quartiles, or quintiles (or even slightly different 
divisions of tertiles and quintiles), we still see an effect of Hgb on parasite growth that is independent of 
genotype. Finally, we did not include Hgb genotype linear regression results in these tables because this 
remains the same no matter the Hgb classification (see main chapter text and Table 2 for results). 
Complete results for different Hgb categorizations are as follows: 
 
 
Addendum Table A4.2: Combinations of hemoglobin categories tested 
Hemoglobin categories 
Several different category groupings of hemoglobin were tried, to see if different divisions affected the 
data. Average hemoglobin values for each division are in parentheses. 
Category 
label** 
Quintiles 1: Quintiles 2: Quartiles: Tertiles 1: Tertiles 2: Dichotomized: 
0 10.6-11 
(10.74) 
10.5-11 
(10.69) 
10.5-11 
(10.69) 
10.1-11 
(10.50) 
10.5-11 
(10.69) 
10-11 (10.45) 
1 10.1-10.5 
(10.33) 
10-10.4 
(10.22) 
9.9-10.4 
(10.17) 
9.1-10 
(9.64) 
9.6-10.4 
(10.05) 
<10 (9.19) 
2 9.6-10 
(9.84) 
9.5-9.9 
(9.75) 
9.3-9.8 
(9.61) 
<9.1 (8.38) <9.6 
(8.83) 
 
3 9.1-9.5 
(9.30) 
9.0-9.4 
(9.22) 
<9.3 
(8.60) 
   
4 <9.1 (8.38) <9.0 (8.29) 
    
**Note here "0" is always the highest Hgb value – so for every unit change in Hgb category in linear 
regression analyses, growth rate should decrease (as Hgb also decreases)  
 
 
 
Addendum Table A4.3: Number of people in each group for different Hgb categories 
Quintiles 1: n Quintiles 2: n Quartiles: n Tertiles 1: n Tertiles 2: n Dichotomized: n 
10.6-11 24 10.5-11 34 10.5-11 34 10.1-11 68 10.5-11 34 10-11 77 
10.1-10.5 44 10-10.4 43 9.9-10.4 50 9.1-10 58 9.6-10.4 70 <10 72 
9.6-10 36 9.5-9.9 31 9.3-9.8 33 <9.1 23 <9.6 45     
9.1-9.5 22 9.0-9.4 21 <9.3 32             
<9.1 23 <9.0 20                 
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Addendum Table A4.4: Linear regression results for different Hgb categories 
Linear Regression Results 
Condition B1 value St Err Lower CI Upper 
CI 
p Value %GR 
change* 
Hgb by quintiles 1  
Hgb affects growth at Day 0 -0.072 0.021 -0.112 -0.031 0.001 -7.16 
Hgb affects growth at Day 0 
independently of Hgb 
genotype 
-0.068 0.021 -0.108 -0.027 0.001 -6.75 
  
      
Hgb by quintiles 2 
Hgb affects growth at Day 0 -0.065 0.021 -0.106 -0.025 0.002 -6.52 
Hgb affects growth at Day 0 
independently of Hgb 
genotype 
-0.064 0.020 -0.103 -0.024 0.002 -6.36 
  
      
Hgb by quartiles 
Hgb affects growth at Day 0 -0.084 0.026 -0.134 -0.033 0.001 -8.35 
Hgb affects growth at Day 0 
independently of Hgb 
genotype 
-0.080 0.025 -0.129 -0.030 0.002 -7.97 
  
      
Hgb by tertiles 1 
Hgb affects growth at Day 0 -0.108 0.039 -0.184 -0.032 0.006 -10.83 
Hgb affects growth at Day 0 
independently of Hgb 
genotype 
-0.102 0.039 -0.178 -0.025 0.010 -10.16 
  
      
Hgb by tertiles 2 
      
Hgb affects growth at Day 0 -0.124 0.037 -0.197 -0.052 0.001 -12.42 
Hgb affects growth at Day 0 
independently of Hgb 
genotype 
-0.117 0.037 -0.189 -0.044 0.002 -11.65 
  
      
Hgb dichotomized 
      
Hgb affects growth at Day 0 -0.130 0.056 -0.241 -0.020 0.022 -13.03 
Hgb affects growth at Day 0 
independently of Hgb 
genotype 
-0.126 0.056 -0.236 -0.016 0.026 -12.58 
 
 
 
While many of these categorizations are not as easily justifiable in practical terms, it is true that 
the more groups of hemoglobin we have, the more significant our results are in terms of spread of 
parasite growth in people within our population. We retain statistical significance for Hgb influencing 
parasite growth for every categorization we tried, but we lose the ability to report the impact of anemia in 
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terms of g/dl, which we feel is more relevant clinically. It is true the dichotomization of Hgb into mild and 
moderate is a well-known definition, but this distinction is still not clinically relevant as, at least in The 
Gambia, treatment regimens for children with mild and moderate anemia are the exact same. 
Overall, we have proven with these additional analyses that categorizing hemoglobin maintains 
the significance of association versus parasite growth (which remained true for every permutation of 
hemoglobin categories we assessed). This speaks to the significance of our results in terms of the effect 
of hemoglobin, as sometimes categorizing a variable can even mask its effect.  
Given the results from the different categorizations together show a linear response in 
comparison to one another, this further validates the original use of Hgb as a continuous variable. To 
simply dichotomize Hgb into mild and moderate anemia categories is statistically wasteful and 
furthermore it only compares the effect of a difference in Hgb between 10.45-9.19g/dl which vastly 
underestimates the predicted effect of anemia versus no anemia. These alternative analyses were very 
useful in helping validate our results, but overall we clearly show our initial results finding significant 
association between continuous Hgb and the degree of the effect were real. 
 
 
It is not possible to extrapolate linear regression results from this dataset to a “population level 
impact” because you didn’t measure parasite growth in non-anemic people. 
This relates to the discussion above about how we need to be careful making statements about 
effects of certain variables on parasite growth within the entire population versus within our population of 
anemic subjects. We understand the point that our linear regression model does not give any specific 
output/results for the effect of anemia on parasite growth. Presumably if we had included data from non-
anemic people, we would certainly get a different β estimate. And we understand the point that therefore, 
we cannot calculate the “population attributable fraction”. However, we are not in fact calculating the 
“population attributable fraction” – to be discussed further in the next item. 
Furthermore, as argued above, we do still know everyone in our dataset has lower parasite 
growth than those who are non-anemic – because the definition of the “relative” growth rate we reported 
is that it was normalized relative to non-anemic controls. Also, given our extensive in vitro 
characterizations of parasite growth in RBCs from iron deficient versus iron replete donors previously (1), 
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it is not like we question that the parasite growth might potentially be greater in anemic than non-anemic 
Gambian children. Thus we feel it is still justifiable to argue for our attempt to use the population 
prevalence of anemia to make some conclusions about our growth rate changes seen with different Hgb 
levels in anemic children and extrapolate to what that could mean across the population. We are not 
calculating the “population attributable fraction.” 
In order to calculate a population attributable fraction for a subpopulation (i.e., anemic 
individuals), you need an odds ratio (or risk ratio) explicitly for that subpopulation, which involves 
information and measurements we do not have regarding this population. To be explicitly clear, here we 
use the β coefficient from our linear regression modeling as a proxy measurement for an odds ratio to 
generate our “population level impact” results, understanding that is not directly comparable to methods 
required for calculating population attributable fraction. 
 
If you are not calculating the “population attributable fraction,” the term “population level impact” 
is too easily confused with this well-known epidemiological calculation. 
We acknowledge this criticism and agree that the terms are easily confusable and that our 
citation of “population attributable fraction” as inspiration for our own “population level impact” equations 
was less than ideal. Our equation for population level impact is: prevalence of given trait x (relative growth 
rate for that trait – 100%/relative growth rate for that trait). We are trying to look at something similar to 
the relative risk for a trait, multiplied by the prevalence for that trait. As was pointed out, we should not 
reference Rothman for the epidemiological equation of “population attributable fraction” as inspiration, 
because for one thing he uses the prevalence of exposure among cases multiplied by the relative risk, 
and thus when our prevalence refers to the whole population (not just cases) it is not equitable. We fully 
recognize we are not calculating a “population attributable fraction” and that we should further distance 
ourselves from that term as we continue to include the “population level impact” calculations in our 
manuscript. 
With our creation and use of the “population level impact” equation, we were simply trying to find 
a logical way to quantitatively compare the impact of anemia versus sickle-cell trait on malaria growth as 
measured in our in vitro system and to expand the significance of these effects in order to infer 
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information about malaria protection in Gambian children. Knowing that the growth rates are reduced 
comparably in those with anemia versus those with sickle-trait, and also knowing prevalence of anemia is 
much greater in Gambian children than sickle-cell trait, then it makes logical sense to conclude the overall 
protection from anemia is greater in the population. We do not think that this interpretation is wrong, and 
we will make an effort to further clarify the “population level impact” calculation in our manuscript. 
 
Please reanalyze “population level impact” with categorized hemoglobin linear regression results. 
Taking the suggestion of using hemoglobin as a categorical variable will allow you to make more 
official “population attributable fraction”-like calculations, for the sake of comparison. 
As just stated, we accept that we may have inadvertently led the readers to mistakenly think that 
our “population level impact” calculations were comparable to the “population attributable fraction” term. If 
we take the suggestion to categorize hemoglobin in our linear regression model, then we do have the 
ability to calculate “population level impact” of protection for each of the categories of hemoglobin, which 
does much more closely relate to the concept of “population attributable fraction.” It is worthwhile to see 
these results in order to evaluate the relative effect of genotype versus level of anemia on growth rate in 
another light.  
In order to do these calculations, we have to take into account the prevalence of each Hgb 
“category” amongst the population as a whole, not just general anemia prevalence, nor the prevalence of 
mild versus moderate anemia within our study population. We do, in fact, have population data that allows 
us to calculate this. This population data comes from the study enrollment screening done for children in 
the capture area for our study – all children were screened by Hgb test, and only those with Hgb 7-11g/dl 
were included in the study. 651 children in the study area were screened for possible enrollment. Of 
those, 30.3% were moderately anemic (hgb 7-9.9g/dl), 41.3% were mildly anemic (hgb 10-11g/dl), 0.5% 
were severely anemic (hgb <7g/dl), and 27.9% were non-anemic (hgb>11g/dl). This is an accurate 
representation of the children in this area, because another larger study a few years ago determined 
anemia prevalence (all levels) to be 75%, which is very close to our screening data (72% anemia 
prevalence) (23).  
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Addendum Table A4.5: Frequency of anemia type in Gambian children  
Population data – categories of anemia 
Screened population - 651 total Prevalence 
3 with Hgb<7g/dl 0.46% 
197 moderate anemia Hgb 7-9.9g/dl 30.26% 
269 mild anemia Hgb 10-10.9g/dl 41.32% 
182 with no anemia Hgb>10.9g/dl 27.96% 
With mild or moderate anemia (study population) 71.58% 
With any anemia (mild, moderate, or severe) 72.04% 
 
To calculate the population level protection for Hgb categories, we have to use the new β1 effects 
and standardized %GR changes presented above. To begin with dichotomized Hgb categories, there is a 
prevalence of 30.3% for moderate anemia at the population level, and we determined a 13.0% decrease 
in parasite growth comparing moderately anemic to mildly anemic children in our study population 
(p=0.023). Thus, the new “population level impact” calculation becomes (30.3*(13-100)/87) which is a 
4.53% population level protection in moderately anemic kids. 
 
 
Addendum Table A4.6: Population level impact using continuous versus dichotomized Hgb 
Population Level Impact  
This is how we reported population level impact in our paper. 
Factor Prevalence Growth reduction Population Impact 
Sickle trait 15.90% 18.30% 3.50% 
Anemia (Hgb<11 g/dL)* 75% 17.20% 15.90% 
*This assumes anemic individuals are by definition 2 SD below the mean in healthy children, hence the 
growth reduction represents the effect across 2 SD in our population 
  
This is based on dichotomized Hgb, producing results only for those who aremoderately anemic. 
Factor Prevalence Growth reduction Population Impact 
Moderate anemia (Hgb 7-9.9g/dL) 30.30% 13.00% 4.50% 
 
 
Therefore, the “population level impact” from sickle-cell trait and moderate anemia is roughly 
comparable, 3.5% vs. 4.5%, respectively. However, by doing the calculation this way, we ignore the effect 
on kids with mild anemia because they become our comparison group. In essence, we are using the 
“mild” anemia Hgb category as the denominator for calculating the risk ratios for moderate anemia, but 
this prevents us from doing any population level impact calculations for the mildly anemic group.. Not only 
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that, but by comparing those with moderate anemia to those with mild anemia, the growth rate difference 
becomes much smaller than we know it is in reality in our population. If we do use these “population 
attributable fraction”-like results based on dichotomized Hgb categories, we can still make a statement 
about how those with moderate anemia have comparable levels of protection in terms of malaria growth 
as those with sickle-cell trait. But, we would have to revert to descriptions to emphasize the importance of 
our findings, reminding readers that there are other levels of anemia which also provide some degree of 
protection against malaria not measured in this calculation (thus looking only at those with moderate 
anemia underestimates the effect), and that anemic people encompass a much greater portion of the 
population than do people with sickle-cell trait. Using the dichotomized Hgb categories for the population 
level equation and finding a condition (moderate anemia) that provides the same amount of protection 
against malaria as sickle-cell trait is still a very interesting statement, since sickle trait is the known gold 
standard for malaria protection. However, ultimately we dislike this method of categorizing Hgb to 
calculate something closer to a “population attributable fraction” because we know it vastly 
underestimates the true effect of anemia as a whole on the growth rate reductions in our study 
population. 
It is possible we could calculate the “population level impact” for all other permutations of Hgb 
categorization we tried and add up the effects from each category, to try and reduce the loss of data from 
the highest level comparison Hgb category by expanding the number of categories used. However, we 
ultimately still believe that our original analysis (in which we keep Hgb as a continuous variable) is better, 
as it captures much more data describing the effect of anemia on parasite growth and is therefore a much 
more realistic and accurate representation. (Of course it goes without saying we all have to remember 
that these results are based on specific in vitro erythrocytic stage malaria cultures.)  
 
The meaning of the “population level impact” results needs to be clarified – what does 3.5% or 
15.9% protection mean? 
We recognize that our in vitro parasite growth data are difficult to translate to clinical protection 
levels in terms of malaria, and this is not what we were trying to accomplish. Again, this speaks to the 
reason why we need to focus on distancing ourselves from the clinical epidemiology “population 
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attributable fraction” term. Reduction in relative growth rate in vitro might very plausibly be reflective of 
reduction in parasite burden in a population, and thus perhaps relate to clinical malaria cases – but this is 
not at all an official statement we can attempt to make, as there are obviously so many other factors 
involved in malaria infection in the real world that we have not even begun to account for in our in vitro 
system. All we can describe is sickle-cell trait affords a 3.5% reduction in parasite growth and anemia 
affords a 15.9% reduction in parasite growth relative to one another. In essence this “population level 
impact” is a completely artificial concept and we are ultimately just comparing relative units, simply as a 
means of evaluating the impact of anemia versus genotype on parasite growth. 
 
Please summarize appropriate alternative options for data presentation and analysis.  
We wish to thank Jordan Cates for her assistance in discussing epidemiological methods and 
concerns regarding our data presentation. Together, she agreed these were plausible solutions for us 
going forward: 
1) Change our “population level impact” results to be purely descriptive, arguing the impact of 
anemia on parasite growth must surely be greater than sickle-cell trait given what we know 
about in vitro growth rates and prevalence of these traits, but avoiding any attempts at 
quantitative calculations 
2) Break our Hgb data into mild/moderate categories for linear regression analyses and use 
“population attributable fraction”-like calculations to make quantifiable statements about 
differences in parasite growth between mild and moderate anemics (but not anemia as a 
whole). 
3) Continue using our current “population level impact” calculations, but make sure it is explicitly 
clear we are not attempting to make official epidemiology calculations (rather we have 
devised our own way to take into account the prevalence of a given condition and the relative 
growth rate for a that condition in our in vitro system using the β coefficient from the linear 
regression modeling), and better describe the interpretation of the outcome of X% population 
level protection as a relative unit merely providing a means of comparing our results from 
different traits. 
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4.8.2 Conclusions 
Working with epidemiologists to better comprehend clinical epidemiological methods of data 
analysis and interpretation has been very useful in helping us interpret and clarify our own results and 
objectives, use alternative epidemiological analyses to confirm our data has significance, and gain more 
perspective on clinical epidemiological methods. Having extensively re-examined our results and 
interpretations, we feel confident the results we are presenting have real meaning based on the in vitro 
data we obtained. Naturally, any translation to population level clinical malaria only represents logic-
based descriptions and hypotheses, which are not based on actual results, as we did not use clinical 
malaria as an outcome. It is useful to note that our linear regression data from a parallel study conducted 
in pregnant women (which included both anemic and non-anemic women and is presented in the 
following chapter) found correlations with growth rate and Hgb level at baseline exactly on par with the 
level of growth rate changes seen at baseline in this children’s population. This gives us additional 
confidence that we are not inaccurately making assumptions about parasite growth in a non-anemic 
children’s population being greater than that in our anemic population. However, this extensive 
conversation has certainly improved our presentation of results, knowledge of the topics at issue, and 
understanding of the importance of being able to back up your claims, and we are grateful for the critique 
and thoughtfulness dedicated to our work. 
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CHAPTER FIVE: ERYTHROCYTES FROM GAMBIAN PREGNANT WOMEN ARE PROTECED 
AGAINST MALARIA IN VITRO AND THIS PROTECTION IS REVERSED BY IRON 
SUPPLEMENTATION4 
 
5.1 OVERVIEW 
Anemia, particularly iron deficiency anemia, is highly prevalent amongst pregnant women in the 
developing world and exhibits a profound health burden on both the mother and the developing fetus. The 
World Health Organization thus commonly recommends iron supplementation for pregnant women where 
anemia is common. Pregnant women are also particularly susceptible to placental malarial infection, 
which again affects both mother and fetus. Paradoxically, epidemiological studies suggest iron deficiency 
protects against malaria and administering iron to iron-deficient individuals may increase malaria risk. 
This has generated much debate in the public health field about how to best distribute iron supplements 
to pregnant women in malaria endemic areas. Our previous laboratory work demonstrated decreased P. 
falciparum growth in iron deficient red blood cells (RBCs) and increased infection susceptibility in young 
RBCs and reticulocytes in vitro. Here, our objective was to comprehensively evaluate P. falciparum 
pathogenesis in RBCs from pregnant women before, during, and after iron supplementation. We also 
sought to evaluate the hypothesis that malaria risk increases as erythropoiesis increases in response to 
iron supplementation. To do so, we investigated P. falciparum in vitro growth characteristics in RBCs from 
pregnant Gambian women participating in an iron supplementation trial. RBCs were collected from 165 
pregnant women (2nd and 3rd trimester) before, during, and upon completion of 12 weeks of iron 
supplementation (60 mg daily, respectively). We used in vitro flow cytometry based assays to examine 
effects of iron deficiency and iron supplementation on overall parasite growth and merozoite RBC 
invasion. Our results demonstrate P. falciparum erythrocytic stage growth in vitro is low in pregnant  
                                                          
4 We would like to emphasize to the reader that all of the research presented in this chapter remains a 
work in progress in terms of data analysis and presentation. We are awaiting our collaborators to officially 
lock the “Hepcidin and Pregnancy” iron supplementation study database before we can draft a manuscript 
for this work.   
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Gambian women at baseline but increases during supplementation. The elevated growth rates parallel 
increases in circulating reticulocytes and other markers of young RBCs which are suggestive of increased 
erythropoiesis. We conclude malaria growth in vitro corresponds with elevated erythropoiesis, an 
inevitable consequence of iron supplementation during pregnancy. Our findings imply iron 
supplementation of pregnant women in malarious regions should be routinely accompanied by effective 
preventative measures against falciparum malaria. 
5.2 INTRODUCTION 
Pregnant women represent one of the most susceptible populations to P. falciparum malaria 
infection, particularly primagravida women. This is because the parasite protein exported to the surface of 
trophozoite- and schizont-infected RBCs that allows for cytoadherence to the peripheral endothelium, Pf 
Erythrocyte Membrane Protein 1 (PfEMP1), has a variant (var2csa) that specifically binds to chondroitin 
sulfate A (CSA) on syncytiotrophoblasts present in the placental intervillous spaces. Thus parasites  can 
accumulate in the placenta and cause severe consequences for both the mother and fetus, including a 
risk of severe maternal malaria and death, as well as stillbirth, preterm delivery, intrauterine growth 
restriction and low birth weight, and perinatal morbidity and mortality (1). Risk of placental malaria 
infection diminishes with subsequent pregnancies, as women develop immunity against the PfEMP1 
variant that allows the parasite to cytoadhere in the placenta (2, 3). Because placental malaria can often 
go undetected for long periods, negative health consequences can become compounded and malaria in 
pregnancy is estimated to account for over 100,000 annual infant deaths in Africa as recently as 10 years 
ago (1), with tens of millions of pregnancies at high risk for malaria infection (4). 
Another important risk factor for pregnant women, particularly in the developing world, is anemia: 
over 50% of pregnant women globally are estimated to have anemia, with the rates even higher for Africa 
and other developing regions(5). Iron deficiency anemia accounts for 50-75% of those anemia cases, 
largely due to inadequate diet and increased nutritional requirements during pregnancy (6) (and reviewed 
in (7)). Adequate maternal iron stores are essential as the mother’s blood volume must expand 
accordingly to provide for a growing fetus, and erythropoiesis is heavily dependent on iron. In total, the 
maternal blood volume expands by 1-1.5 L, though plasma volume expands more so than red cell mass, 
such that there is an effective hemodilution peaking in the 2nd trimester which drops blood hemoglobin 
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concentrations by 1-2 g/dl (reviewed in (7, 8)). There are significant dangers associated with anemia for 
the mother, as the anemic woman is at much greater risk for life-threatening complications if excessive 
blood loss occurs during birth – as can be especially common in low resource settings (reviewed in (7)). 
Furthermore, anemia in the pregnant women is also very detrimental to the fetus, contributing to low birth 
weight and premature births (7, 9, 10). Not only that, but iron plays an essential role in developmental 
health, so babies born to anemic mothers begin life at increased risk for cognitive impairment and inability 
to reach their full potential – consequences of which can last far beyond time of birth (reviewed in (7)).  
Given that pregnant women are vulnerable to malaria and also to iron deficiency, understanding 
the relationship between iron and malaria in pregnancy is important. Providing evidence of the profound 
impact that iron deficiency anemia has on reducing malaria infection, the effect of anemia on reducing 
placental malaria risk has been documented in observational studies (11–13). Despite the malaria 
protection afforded by anemia, anemia and iron deficiency during pregnancy must be treated – especially 
considering the lasting detrimental health defects on infants born to anemic and iron deficient mothers. 
Further complicating matters is the difficulty in accurately diagnosing iron deficiency anemia in pregnancy 
in the context of changing physiology, especially in developing world settings where many tests are not 
routinely available and high rates of inflammation due to infection and environmental exposures exist. 
Many routinely used markers of iron status are impacted by inflammation (e.g. ferritin, zinc 
protoporphyrin, transferrin saturation) (14). 
Of course, ideally women would have adequate iron stores before becoming pregnant. But how to 
address iron deficiency complications in already pregnant woman? The obvious solution would appear to 
be iron supplementation. The WHO recommends 60mg iron daily as a supplement taken throughout 
pregnancy in areas where iron deficiency anemia is greater than 40% (i.e. much of the developing world) 
(15). A 2015 Cochrane review on iron supplementation in pregnancy concludes iron supplementation 
decreases rates of low birth weight and pre-term deliveries, though not at a statistically significant level, 
and that there was no evidence of differences in neonatal death (16). Women taking iron supplements 
during pregnancy had a 70% reduction in risk of anemia and 57% reduction in iron deficiency at birth, as 
well as higher Hgb levels at birth. Although there were no detectable differences regarding maternal 
infection rates, maternal mortality, or side effects, meta-analysis of these parameters was based on 
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studies determined to provide “low quality evidence” according to the Cochrane review (16). It should be 
noted that a 2009 Cochrane review on the same topic determined there was no evidence to conclude iron 
supplementation improved maternal and neonatal health outcomes despite improved anemia and iron 
status (17), and a 2012 Cochrane review did find evidence for reduction in low birth weight (18). Clearly 
the topic is open for research and discussion. 
Despite the facts that iron supplementation during pregnancy does improve maternal anemia 
status and iron stores and likely also improves infant birth outcomes, there are still some areas of concern 
regarding negative health outcomes. Those who take iron during pregnancy are also at greater risk for 
hemoconcentration (Hgb >13g/dL) during late pregnancy (slight physiologically normal hemodilution 
during pregnancy serving to increase blood flow in the placenta) (16), potentially impacting maternal 
hypertension and birth weight for those non-anemic women receiving excess iron. Elevated iron stores in 
pregnancy may also be associated with preeclampsia and gestational diabetes (discussed in (19, 20)). 
Secondly, of particular concern in developing world settings, there is also reason to believe that iron 
supplementation during pregnancy may impact the risk of infection, particularly malaria.  
The potential dangers of iron supplementation and the hypothesis that increased morbidity and 
mortality with iron was associated with malaria infection was most famously brought to light by a large 
nutritional intervention study in Tanzanian children (21). Other studies have also come to similar 
conclusions. The question about the impact of iron supplementation on malaria pathogenesis has not 
been definitively answered, but a 2016 Cochrane review concludes that iron supplementation in children 
in malaria endemic areas is safe if appropriate antimalarial public health measures are available (22). For 
pregnant women, less research has been done, but a full review of studies can be found in a 2014 meta-
analysis on iron and malaria and pregnancy (23). This meta-analysis found association between iron 
deficiency and reduced malaria infection risk if iron deficiency was measured by ferritin; transient 
increased incidence of vivax malaria with iron supplementation; and no increased risk of falciparum 
malaria infection with iron supplementation (though ultimately the study concluded there was insufficient 
evidence to fully answer this question) (23). A few recent studies have also attempted to address this. 
Mwangi et al. concluded in pregnant Kenyan women there was a beneficial effect on birth weight and no 
differences in malaria infection rates for those taking 60mg daily iron versus those taking placebo (24). 
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Etheredge et al. found in Tanzanian pregnant women taking 60mg daily iron that there were increases in 
iron stores and hemoglobin versus those taking placebo, and no differences between placebo and iron 
groups in terms of placental malaria infection rates (25). However, as the authors of both papers 
discussed, it is nearly impossible to conduct a purely observational clinical trial regarding iron 
supplementation and malaria, ethically speaking, because of past evidence suggesting iron 
supplementation might put people at increased risk for malaria – hence they must work hard to provide 
extensive antimalarial prevention measures and may in fact bias their own results (24, 25).  
As the level of risk of malaria infection with iron supplementation remains an important public 
health question, we thus attempted to better understand the precise relationship between iron deficiency, 
iron supplementation, and malaria in pregnancy. We have systematically assessed malaria susceptibility 
in vitro in RBCs drawn from pregnant women before, during, and after 12 weeks of iron supplementation 
initiated during the 2nd trimester of pregnancy. Having complete iron panels, full blood counts, and 
inflammatory marker data to match the malaria growth parameters at Day 0, 14, 49, and 84 of iron 
supplementation has allowed us to comprehensively evaluate the effect of iron supplementation on 
malaria risk in pregnancy. Our previous in vitro work led us to hypothesize that RBC population structures 
drive malaria susceptibility, given that iron deficient RBCs and older RBCs are more resistant to malaria 
infection and that younger RBCs are more susceptible. Hence, with iron supplementation in pregnant 
women we also hypothesized increased numbers of young RBCs following iron-induced elevated 
erythropoiesis rates would increase malaria growth rate in vitro, our proxy measure for malaria 
susceptibility (26). This is exactly what we observe in the data presented in this Chapter. Our work with 
pregnant women has taken place in The Gambia and was a sub-study within a larger iron 
supplementation trial (19). 
5.3 MATERIALS AND METHODS 
Subject recruitment. The pregnant women were recruited from the control arm of a randomized 
trial testing the efficacy and safety of a hepcidin-guided screen-and-treat strategy for combatting anaemia 
(see published protocol for full details (19)) and are 18-45 years old with estimated 14-22 weeks gestation 
at recruitment. (Note we also recruited pregnant women in the other two arms of this trial, but only for 
observation at baseline, pre-randomization/pre-intervention.) As per current WHO recommendations, 
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pregnant women in the control arm received 60mg/d iron as ferrous fumarate, given within a micronutrient 
capsule (UNIMMAP). Field workers visited the women frequently (biweekly) in order to check their health 
status and deliver the supplements. For baseline population characteristics, see Supplemental Table 
S5.1.  
UNIMMAP Capsules. The iron supplementation product used in this trial is a micronutrient 
mixture (UNICEF/WHO/UNU international multiple micronutrient preparation (UNIMMAP)) produced by 
the DSM Company (South Africa) and previously determined to be safe in pregnancy. It contains: 60 mg 
iron, 400 µg folic acid, Vitamin A (800µg RE), Vitamin D (200 IU), Vitamin E (10mg), Thiamine B1 (1.4 
mg), Riboflavin B2 (1.4mg), Niacin B3 (18g), Vitamin B6 (1.9mg), Vitamin B12 (2.6µg), Vitamin C (70mg), 
Zinc (15mg), Iodine (150µg), Selenium (65µg), and Copper (2mg). 
Blood samples for parasite assays. Fresh RBCs were obtained from otherwise healthy 
pregnant women (age 18-45 years, gestational age 14-22 weeks at enrolment) enrolled in an iron 
supplementation study in rural Gambia (19). Venous blood was collected at Days 0 (baseline), 14, 49 and 
84 during 12wks of iron supplementation (Figure 5.1). We compared subject characteristics of those 
whose blood was and was not able to be used for growth rate data to ensure no sampling bias occurred 
(Supplemental Table 5.2). 
P. falciparum culture. Parasite lines FCR3-FMG (MR4, MRA-736) and 3D7 (MR4, MRA-102) 
were routinely cultured in RBCs from healthy donors using standard methods (26). Parasite strains 
ΔPfRh1 B9, ΔPfRh2a, and ΔPfRh2b were kindly provided by the laboratory of Alan Cowman (WEHI, 
Australia).  
Growth assay. In vitro growth was assessed in fresh, washed RBCs as in (26) for 96 h 
(performed in triplicate for RBCs from each study participant). RBCs from healthy, non-pregnant, adult 
iron replete donors of normal hemoglobin genotype and G6PD status not undergoing iron 
supplementation served as controls. Growth rates represent final 96 h parasitemia divided by initial 0 h 
parasitemia (26), analyzed by flow cytometry. Growth rates in subjects’ RBCs were normalized to that in 
control non-anemic RBCs assayed simultaneously.  
RBC barcoding invasion assay. The assay was performed and analyzed as in (27) using two 
different concentrations of CellTrace Far Red DDAO (Invitrogen Life Technologies/Molecular Probes): 
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1uM (high) or 0.1uM (low). Labeling took place at 1% hematocrit in serum-free RPMI for 90 minutes with 
thorough rocking at 25°C, followed by washing twice with ACM, incubating an additional 30 minutes in 
ACM with rocking at 25°C, and finally washing twice with RPMI before storage in RPMI at 2% hematocrit 
at 4°C. All invasion assays were performed with fluorescently labeled RBCs within four days of labeling. 
Differentially labeled RBCs were combined in equal density in triplicate into a 96 well plate and seeded 
with MACS purified (Miltenyi Biotec) late stage parasites to achieve 1.5-2% pRBCs in 1% hematocrit. 
Plates were maintained for 12-18 hours under standard culture conditions to allow for schizont rupture 
and subsequent invasion of labeled RBCs. Invasion into high and low DDAO RBCs was detected by DNA 
dye Sybr Green I, as analyzed by flow cytometry (see Chapter 4 for pictorial flow cytometry analysis 
strategy), and the ratio of the prevalences of infected high to low DDAO RBCs was calculated to generate 
the “Susceptibility Index” (described in (28)). Note that we also report data from some invasion assays 
which were performed without barcoding, which instead assesses invasion rates into anemic and non-
anemic RBCs in parallel (not in the same well). 
Reticulocyte quantification. Reticulocyte (CD71+) levels in fresh subject RBCs were assessed 
using PE-conjugated anti-human CD71 antibody (Clone M-A712, BD) and isotype control (Clone G155-
178, BD), and analyzed by flow cytometry for reticulocyte percent relative to non-anemic control.  
RBC surface marker assessment. RBC surface protein levels were determined by staining with 
fluorescently tagged antibodies and analyzed by flow cytometry. The following antibodies were used: For 
CD35 (Mouse Anti-Human CD35 Clone E11 (BD) primary 1:2000; Alexa Fluor® 647 Rabbit Anti-Mouse 
IgG secondary 1:2000); For CD47 (Mouse Anti-Human CD47 Clone B6H12 primary 1:2000; Alexa Fluor® 
647 Rabbit Anti-Mouse IgG secondary 1:500); For CD55 (Mouse Anti-Human CD55-PE conjugate 
Antibody NaM16-4D3 (Santa Cruz Biotechnologies) 1:10); For CD147 (Mouse Anti-Human CD147 Clone 
HIM6 (BD) primary 1:500; Alexa Fluor® 647 Rabbit Anti-Mouse IgG secondary 1:500); For Glycophorin A 
(GPA) (primary Rabbit Anti-Human CD235a/Glycophorin A (ThermoFisher Scientific/Pierce) 1:500 and 
secondary Alexa Fluor® 647 Goat Anti-Rabbit 1:2000); For sialic acid residues (Wheat Germ Agglutinin 
Alexa Fluor® 488 Conjugate (ThermoFisher Scientific/Molecular Probes) 1:2000); and for C3b deposition 
(primary Mouse Anti-Human Complement C3b Antibody 10C7 (ThermoFisher Scientific) 1:200; Alexa 
Fluor® 647 Rabbit Anti-Mouse IgG secondary 1:500). The Relative Fluorescence Intensity (RFI) of each 
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surface marker for each study sample was calculated using the MFI values (corrected for background), 
relative to MFI in the non-anemic donor as described in (29) . The exception was C3b which was reported 
as a percent of positively stained RBCs instead of MFI.  
Attachment assay. Assays and analysis of merozoite attachment to IDA vs. IR RBCs was 
performed based on (29, 30). In detail, tightly synchronized parasite cultures (15 ml of 4% hematocrit 
cultures containing 5% infected RBCs) were treated with 50U/ml of heparin as trophozoites. 
Approximately 12 hours later, upon visualization of schizonts by Geimsa stain, schizonts were purified by 
MACS. Resulting schizont concentration was quantified by Sybr Green I stain and flow cytometry, and 
schizonts were incubated in ACM containing 50U/ml heparin under standard culture conditions to allow 
for 3-4hrs of recovery. RBC concentrations of the donor samples were also quantified by flow cytometry. 
To set up the assay, schizonts were washed twice with 5ml heparin-free ACM and distributed equally 
amongst triplicate wells (of a 96-well plate) for each assay condition. RBCs from IR or IDA donors were 
then added to appropriate wells to bring the final concentration of schizonts to 10%. ACM with either no 
drug (to assay merozoite invasion), 1µM cytochalesin D (to assay merozoite attachment), or 200U/mL 
heparin (to block both invasion and attachment), was added to appropriate wells and plates were 
incubated under standard culture conditions. At each time point (0 h, 3 h, and 7 h), 50µl of each drug 
treatment condition from each blood sample were aliquoted in triplicate into 200µl of fixative (PBS 
containing 0.116M sucrose and 2% glutaraldehyde), with overnight fixation at 4⁰C before staining with 
DNA dye Sybr Green I and analysis by flow cytometry. Giemsa stains were also made from each time 
point and condition to confirm attachment and invasion events were prevented by the various treatments 
and to verify that new events in the ring region of the flow cytometry plot for DNA quantification could 
correctly be counted as either invasion or attachment events depending on the treatment condition (as 
attachment and invasion are indistinguishable by flow otherwise). Flow cytometry analysis allows the use 
of DNA levels in infected parasite cultures to distinguish seeded schizonts present apart from new 
invasion or attachment events which occur at 3 and 7 hours. To calculate attachment or invasion rates for 
each blood sample, the percent of new events was compared to the starting concentration of schizonts 
under each condition, then expressed relative to new events occurring in RBCs from healthy iron replete 
controls.  
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Flow cytometry analysis. Flow cytometry was performed onsite at MRCG in Keneba using a BD 
Accuri C6 flow cytometer. Channels and probes used included: SYBR Green I, FITC, and Alexa Fluor 488 
(488nm excitation with a 530/30nm bandpass emission filter, detector FL1); PE (488nm excitation with a 
585/40nm bandpass emission filter, detector FL2); and CellTrace Far Red DDAO and Alexa Fluor 647 
(640nm excitation with a 675/25nm bandpass emission filter, detector FL4). Detector gain setting 
changes and compensation were not necessary with this configuration. Accuri C6 data was collected and 
analyzed with Accuri software (BD Accuri CSampler Analysis Software). Linear amplification of forward 
scatter was used to set event threshold in order to exclude cell debris, microparticles and doublets. For all 
experiments, samples were diluted to 0.001-0.002% hematocrit and ≥ 100,000 total events were 
collected. 
Statistics. All experiments were done in triplicate. Growth rates, invasion assays, and 
hematological data were compared by two-tailed Student’s t-test, one-way ANOVA, and/or 95% CI values 
using GraphPad Prism 5.  
Multivariate modelling. We employed linear regression to estimate the effect of hematological 
characteristics on in vitro parasite growth rates. First, bivariate associations and their respective 95% CI 
were calculated between growth rates and hematological and patient characteristics at Day 0. We then 
used multivariate linear regression – specifically, we estimated the effect of hemoglobin and hemoglobin 
genotype on growth rate along with their respective 95% CI. We used directed acyclic graphs to identify 
potential confounders and controlled for them in our modelling approach (31). An a priori alpha of 0.05 
was used to determine statistical significance. All statistical analyses were performed using R software 
(RStudio Version 0.99.902).  
Ethics approval. The trial from which children were recruited was approved by the MRCG 
Scientific Coordinating and MRCG/Gambian Government Joint Ethics Committee (SCC 1357) and the 
UNC IRB (#13-3068). Participants were given a full description of the study in their native language and 
provided written signed consent. 
Role of the funding source. None of the funding sources had a role in study design, data 
collection or interpretation, writing of the manuscript, or the decision to submit for publication. The 
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corresponding author had full access to all the data included in the study and assumed final responsibility 
for the decision to publish; all authors reviewed the report and agreed to submit for publication. 
5.4 RESULTS 
5.4.1 P.falciparum in vitro growth rates are reduced based on level of anemia in pregnant Gambian 
women. 
We assessed parasite growth levels in RBCs taken from pregnant Gambian women at the time of 
study commencement prior to iron supplementation (Day 0). We consistently find reduced parasite growth 
compared to growth in RBCs from non-anemic, non-pregnant donors. Though not all of our study subjects 
are anemic (defined as Hgb <11g/dl), mean blood and iron parameter data amongst our population (see 
Table 5.1) do demonstrate a high level of anemia, and in particular iron deficiency anemia (IDA). This is 
not surprising considering past reports the WHO estimates anemia prevalence to be greater than 50% in 
pregnant women in the developing world and is reported as especially high in The Gambia (75% as 
reported by others) (32). It is difficult to assess anemia, and again, particularly IDA, in the pregnant 
woman (32). However our enrollment data indicate that our study population of pregnant Gambian 
women have much lower than average values for many common iron indices (MCH, MCHC, Hgb, Hct, 
ferritin, sTfR, for example; see Table 5.1). Growth rates in RBCs from anemic women are significantly 
lower than those in non-anemic women (Supplemental Figure S5.1A), noting 37.1% are anemic 
(Hgb<11g/dl) at baseline. In attempt to better understand the effect of anemia on parasite growth rates, 
we stratified RBCs by donor hemoglobin status at Day 0, and found growth rates were progressively 
lower in the lower hemoglobin groups (mean growth rate (GR) compared to control GR of 100%: 
Hgb<10.0g/dl 54.22%, Hgb 10.0-10.9 g/dl 68.84%, Hgb 11.0-11.9 77.62%, Hgb >12.0g/dl 87.67%) 
(Figure 5.1A). Means are significantly different by one-way ANOVA (p<0.001). To further examine the 
impact of iron deficiency on parasite growth given several common methods for defining iron deficiency 
and the difficulties of doing so with high levels of background inflammation, we additionally stratified 
anemic individuals using several different definitions of IDA (Figure 5.1B). We did not find any significant 
differences in mean parasite growth between classifications of IDA.  
To further understand influences of parasite growth in RBCs from our study population, we 
performed bivariate and multivariate linear regression analyses to examine the impact of hematological, 
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iron, and inflammatory variables. We assessed the influence of several key factors known or assumed to 
influence anemia and/or parasite growth (Table 5.2). Hemoglobin, hemoglobin genotype, MCV, transferrin 
saturation, and hepcidin (log values) all significantly influenced parasite growth in RBCs from pregnant 
women drawn prior to iron supplementation, whereas CRP, ferritin, the sTfR:log ferritin ratio, and 
gestational age did not. It should be noted that the only hemoglobin genotype we were able to measure 
differences between was normal (AA) and sickle-trait (AS) due to absence of any other genetic 
hemoglobin variations in our population. The growth rate changes were 8.9% increase for every g/dl 
increase in Hgb, 24.8% decrease from AA to AS, and 0.9% increase for every 1fl increase in MCV. We 
confirmed the effect of hemoglobin on parasite growth was independent of hemoglobin genotype (Table 
5.2), as well as other significant variables such as MCV, hepcidin, transferrin saturation, RDW, sTfR:log 
ferritin ratio, CRP, and gestational age (data not shown). We further standardized the impact of the 
significantly-associated variables to reflect percent GR change for every one standard deviation in the 
variable of interest, in order to better compare effect sizes between variables. Using this method, Hgb has 
the largest effect on parasite growth, changing 11.4% with every SD from the mean. Considering the 
distribution for Hgb ranges from 8g/dl to 12.5g/dl with mean of 11.3g/dl and SD of 1.28, this indicates a 
possible spread of nearly 35-40% GR within our population based on hemoglobin. Sickle-cell trait notably 
also has a large impact on parasite growth (no adjustment for SD so the same 24.8% reduction) (see 
Supplemental Figure S5.1B for visualization of the difference in growth rate comparing AA and AS 
individuals). Overall, this linear regression data is highly consistent with the dataset we reported in 
Chapter 4, and furthermore encompasses pregnant women who are non-anemic, thus allowing us to fully 
see the effects of hemoglobin on parasite growth in a broader population.  
5.4.2 RBCs from anemic pregnant women are resistant to invasion by P.falciparum, but invasion 
deficits in anemic RBCs are not attributable to PfRh invasion ligands nor parasite attachment.  
We proceeded to assess parasite invasion in RBCs from pregnant women at baseline, knowing 
growth rates in these RBCs were reduced compared to RBCs from non-anemic, non-pregnant controls. 
We have extensively proved parasite invasion is reduced into iron-deficient and anemic RBCs elsewhere, 
finding invasion deficits to be a large factor contributing to overall reduced growth in anemic RBCs (26, 
33) (and Chapter 4). Experiments here examined new invasion events in target RBCs of interest (from 
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anemic individuals or non-anemic controls) after incubation with purified late-stage schizonts. Results are 
normalized to invasion into the non-anemic control RBCs (set at 1.0); mean invasion rates for FCR3-FMG 
and 3D7 are 0.60 and 0.74, respectively (Figure 5.3A). 
Having confirmed invasion deficiency in RBCs from anemic pregnant women at baseline, we next 
began to examine possible mechanisms for reduced invasion into RBCs form anemic donors. First, we 
examined whether specific P.falciparum PfRh invasion ligands contributed mechanistically to the 
differential invasion into healthy non-anemic versus anemic RBCs. The hypothesis was that PfRh parasite 
ligands, from the reticulocyte binding like homolog family (one of 2 families of proteins encompassing 
parasite invasion ligands), may help the parasite “detect” the healthiest RBCs through putative ATP 
binding domains. Homolog domains in P.yoelii PfRh proteins were speculated to do just that, after 
merozoites initiate irreversible contact with RBCs which causes local release of ATP (34, 35). (The ATP 
release phenomenon is known to occur more in young vs. aged RBCs(36) and we hypothesized it would 
occur more in non-anemic versus anemic RBCs as well.) P.falciparum’s multiple invasion ligands 
represent redundant invasion pathways the parasite can utilize to enter the RBC (reviewed in (37)). We 
thus utilized transgenic parasite strains (ΔPfRh1, ΔPfRh2a, and ΔPfRh2b) to test in our RBC barcoding 
assay, to determine if invasion susceptibility index differences between anemic and control RBCs shifted 
significantly in the absence of any given invasion ligand. Our RBC barcoding invasion assay involves 
differentially labeling two populations of RBCs (here control non-anemic and test anemic RBCs) to easily 
detect and compare invasion rates into each cell type in the same well, providing results in the form of a 
“Susceptibility Index” (SI), an SI of 1.0 indicating no invasion difference and an SI<1.0 indicating reduced 
invasion compared to the control RBC population. Invasion experiments for the transgenic strains were 
performed in parallel with the genetic parent strain 3D7, in the same 15 anemic donors for each parasite 
strain and SI values for the transgenic strains were compared to SI values for parent strain 3D7. Mean SI 
values were all below 1.0 confirming reduced invasion into the anemic RBCs, however there were no 
significant differences in invasion rates into anemic RBCs between the parent and transgenic parasite 
strains (Figure 5.3B), suggesting individual PfRh invasion ligands do not contribute to the significant 
difference in invasion of control vs. anemic RBCs.  
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To further assess mechanisms which may contribute to differential parasite invasion of RBCs 
from anemic versus non-anemic donors, we next examined whether merozoite attachment was affected 
during invasion of anemic RBCs. To do so, we used control and randomly selected anemic pregnant 
women RBC samples at baseline and seeded infection wells in parallel with late-stage schizonts in the 
presence and absence of cytochalesin D, which prevents invasion steps beyond attachment. Thus we 
could differentiate invasion and attachment events by flow cytometry analysis of the different conditions 
(assay developed by (30)). Despite observing expected invasion differences between non-anemic and 
anemic donors (SI mean of 0.62, 95% CI 0.49-0.76), we found P.falciparum merozoites attach to RBCs 
from anemic Gambian children equally as well as they attach to RBCs from non-anemic donors (mean 
attachment rate of 0.97 with 95% CI 0.86-1.08 for anemic RBCs) (Figure 5.3C). This finding indicates 
mechanical properties of anemic RBC membranes may be a large factor influencing reduced invasion 
into anemic RBCs, which is consistent with recent literature reporting detailed live cell imaging of invasion 
events indicating that localized RBC deformation is a very important step in parasite invasion (38). It is 
known that anemia, especially IDA, can affect RBC membrane properties and deformability (39, 40). 
5.4.3 P.falciparum growth rates increase in RBCs from pregnant women undergoing iron 
supplementation. 
In order to assess malaria susceptibility in individuals taking iron supplements, we performed in 
vitro growth assays in RBCs drawn from pregnant women before (Day 0), during (Day 14 and Day 49), 
and after (Day 84) 12 weeks of iron supplementation. In vitro growth rates served as a proxy 
measurement for malaria susceptibility because it is not ethical to provide iron supplementation without 
extensive anti-malarial countermeasures, hence using in vitro growth assays allows us to still capture a 
pure representation of malaria susceptibility in a large number of people for whom we also have 
extensively characterized in terms of RBC, iron, and inflammatory parameters. Note that the women in 
our trial were visited biweekly for health check-ups and received weekly rapid diagnostic test screening 
for malaria, and only two incidences of positive RDTs occurred within our study population over the 12 
week iron supplementation period as the prevalence of malaria is low in The Gambia. Growth rates were 
always normalized to growth in RBCs from non-anemic, non-pregnant donors (set at 100%). Much like we 
have previously observed (see Chapter 4), we found that parasite growth rates were lower than non-
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anemic controls at Day 0 (75.59%, 95% CI 70.63-80.55%), but increased markedly at Day 14 (148.5%, 
95% CI 119.7-177.3%) and also remained higher than control levels at Day 49 (113.6%, 95% CI 99.16-
128.1%), finally falling back to baseline-like values by Day 84 (65.33%, 95% CI 58.61-68.46%) (Figure 
5.4A). One-way ANOVA reveals significant differences between the means (p<0.0001). We also 
examined growth rate changes in RBCs from those individuals for whom we were able to obtain RBCs 
from at each time point (n=44) and confirmed the same patterns of increased susceptibility over and 
above control levels of 100% at Day 14 and Day 49 (Supplemental Figure S5.2A). While the majority of 
individual’s growth rate increases peak at Day 14, some do peak at Day 49, which is understandable, as 
slight differences in gestational age and other physiological factors may influence peak changes in RBC 
properties and population dynamics in the pregnant women studied here. 
5.4.4 Pregnant women undergoing iron supplementation exhibit increased levels of young RBCs 
in circulation. 
To evaluate the RBC population age structure of pregnant women undergoing daily iron 
supplementation, we measured levels of CD71-positive reticulocytes in RBCs drawn at baseline (Day 0), 
during (Day 14 and Day 49) and after (Day 84) iron supplementation. Paralleling changes in parasite 
growth rates, CD71 levels (measured relative to non-anemic, non-pregnant control blood donors 
normalized to 1.0) increased significantly from Day 0 (mean 2.67, 95% CI 2.40-2.91) to Day 14 (mean 
4.06, 95% CI 3.65-4.46), remaining higher at Day 49 (mean 3.22, 95% CI 2.77-3.68), before normalizing 
to baseline-like levels at Day 84 (mean 1.95, 95% CI 1.75-2.15). One-way ANOVA indicates differences 
between the means are significant (p<0.0001). It is not surprising CD71 levels in pregnant women are on 
the whole higher than non-anemic, non-pregnant control donors, as pregnant women have an expanding 
blood volume with increased levels of erythropoietin. When we limit our examination to those pregnant 
women for whom we have CD71 values from all four time points (n=60), we see the same pattern of 
increases in young reticulocytes at Day 14 in particular, remaining somewhat higher at Day 49 as well 
(Supplemental Figure S5.2B).  
We further examined markers on RBCs the same pregnant women undergoing iron 
supplementation over time (n=5), in order to attempt to better understand changes in RBCs which may 
contribute to increased parasite growth rates following iron supplementation. All surface markers 
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examined either have been implicated as parasite invasion ligands (Glycophorin A, CD35, CD55, CD147, 
and sialic acid) and/or have been reported to be reflective of RBC age and membrane integrity (the 
aforementioned molecules, and additionally CD47 and C3b). Compared to relative surface expression 
levels in a non-anemic, non-pregnant control donor, we again found significant increases in markers from 
Day 0 to Day 14 (p<0.001) as reflected by GPA (a sialoglycoprotein which is a known invasion receptor of 
P.falciparum as well as known to be increased in young RBCs(41)), CD47 (an anti-phagocytic marker 
known to be increased on young RBCs (42)), CD35 (complement receptor 1 also known as an invasion 
receptor for P.falciparum and possibly higher on younger/healthier RBC populations (43)), CD147 
(basigin, a known essential RBC receptor for P.falciparum invasion (44)), CD55 (decay accelerating 
factor, another RBC receptor involved in P. falciparum invasion and regulation of complement levels on 
the RBC surface (43)), and C3b levels (part of the complement system, we hypothesized deposition on 
the cell surface to be reflective of increased RBC time in circulation or a less healthy RBC (43)). We also 
observed a significant increase (p<0.01) from Day 0 to Day 14 in sialic acid residues (known to be 
involved in P.falciparum RBC invasion as well as thought to be increased on younger and healthier RBC 
populations (42)) (Supplemental Figure S5.3). Some proteins measured also remain elevated at Day 49 
and beyond, though the biggest changes are consistently measured between Day 0 and Day 14. This 
data parallels the increases in circulating reticulocytes, as well as changes observed in RBC populations 
from anemic children undergoing iron supplementation (see Chapter 4). Shifts in relative expression of 
these RBC markers that we observed are highly indicative of an overall increase in young, healthy RBCs 
in circulation, a shift that can be observed quite quickly in pregnant women already subject to 
physiological drive to increase RBC volume and then additionally supplemented with iron. 
5.5 DISCUSSION 
Pregnancy encompasses one of the most complicated periods of health maintenance for women, 
particularly women in the developing world. Most obviously, delivery itself can involve many risks, 
especially in the absence of good health facilities and qualified attendants. Another large area of concern 
is the increased nutritional needs of the pregnant woman, an issue that can compound delivery related 
risks, as well as overall pregnancy-related health. Anemia, and iron deficiency anemia in particular, has 
long been known to impact large percentages of pregnant women globally, and can in turn affect fetal 
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growth and development (7, 16). Furthermore, pregnancy is a period of time where women in malaria 
endemic areas become highly susceptible to malaria infection due to the parasite’s ability to specifically 
home to the placenta – complications of which can also carry severe outcomes for maternal and fetal 
health (1).  
Because iron supplementation has been shown to positively impact hemoglobin and other 
markers of anemia and iron deficiency in pregnant women, and to potentially increase fetal growth (16, 
24), this strategy is an oft-cited WHO recommendation for prenatal care (15). However, because of the 
problematic relationship between iron and malaria susceptibility, these recommendations are not 
necessarily straight-forward to adopt. Several studies have found iron deficiency reduces malaria 
infection and malaria susceptibility can increase with iron supplementation (11–13, 21, 45–52), though in 
the case of pregnant women, this is particularly hard to study because of changing hematological 
parameters which complicate standard measurements for anemia and iron deficiency. Regardless of 
unknown hematological standards, this is a critical topic to study, as many women are very likely to 
receive iron during pregnancy, and the effects on increased malaria susceptibility may be very real. This 
is difficult to study, however, as clinical trials giving iron supplements will be ethically obligated to provide 
extensive anti-malarial assistance.  
We thus attempted to systematically measure malaria susceptibility in pregnant women 
undergoing iron supplementation via in vitro parasite growth rates measured in RBCs from women at 
Days 0, 14, 49, and 84 throughout a 12 week supplementation period. At baseline, we found significantly 
reduced parasite growth rates compared to growth in RBCs from non-pregnant, non-anemic control 
donors. Not all of our subjects were anemic (as defined by Hgb<11g/dl), but based on analyses with the 
entire population of subjects, growth rates directly correlated with hemoglobin levels, as well as further 
indicators of iron status such as MCV. Sickle-cell trait also significantly correlated with a reduction in 
parasite growth in RBCs drawn from pregnant women at baseline.  
Iron supplementation significantly increased parasite growth rates in RBCs drawn from study 
subjects at Day 14, over and above growth levels seen in non-anemic, non-pregnant control RBCs. 
Parasite growth rates remained slightly elevated above control growth levels at Day 49, before eventually 
reducing to approximately baseline status. These patterns in growth rate changes were exactly paralleled 
134 
 
by patterns in measurements of young RBCs in circulation, namely CD71-positive reticulocytes, but also 
other markers of RBC age such as glycophorin A and CD47, among others. While it is true that pregnant 
women naturally have elevated levels of erythropoietin driving a blood volume and RBC mass expansion, 
there is reason to believe the iron supplements given to our population of pregnant women increased 
hemoglobin and young RBC output over and above background normal levels, considering that 
hemoglobin rates did not decrease in our population (though they are known to decrease in normal 
pregnancy without iron supplementation (discussed in (8)).  
While classifications of anemia are difficult, as well as quantifying the increase in young RBCs 
and changing blood and iron parameters in our subjects due to iron supplementation versus normal 
physiology of pregnancy, the malaria data is real and speaks for itself: parasite growth rates are reduced 
in pregnant women amongst populations where anemia and iron deficiency are common, and growth 
rates increase significantly almost immediately following iron supplementation. Other significant limitations 
to our research certainly exist, namely that we are using in vitro parasite growth data in attempt to paint a 
broader picture of clinical malaria susceptibility in the real world. However, this parasite growth data using 
RBCs from a maternal population undergoing iron supplementation is highly consistent with all of our 
previous in vitro work (26). The data presented here are also exactly consistent with the vast amount of 
data we produced in a similar study examining in vitro parasite growth rates in RBCs from anemic 
Gambian children undergoing iron supplementation (see Chapter 4). Furthermore, all of our data 
combined fits clinically reported observations and provides one logical explanation for the relationship 
between iron deficiency, iron supplementation, and malaria susceptibility.  
While all of the data presented in this chapter remains very much a work in progress in terms of 
analyses and presentation, initial findings would certainly suggest we have yet more evidence to give 
reason to advocate for temporary malaria prophylaxis whenever iron supplements are distributed in 
malaria endemic areas. Pregnant women in many malaria endemic areas do receive IPTp (Intermittent 
Preventative Treatment for malaria in pregnancy) (53); our evidence may thus strengthen the need for 
stringent IPTp guidelines for routine antenatal care that includes iron supplementation.    
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5.5.1 Work in Progress  
We would like to emphasize to the reader that all the research presented in this chapter remains 
a work in progress in terms of data analysis and presentation. Currently, we are utilizing an unofficial 
dataset from the associated “Hepcidin and Iron in Pregnancy” iron supplementation trial, as the trial 
database is yet to be locked by the PI and data manager. We fully recognize we will need to revise some 
analyses, as well as investigate alternative methods and data presentation styles. However, we remain 
confident that the preliminary data presented here provides an accurate general overview of the results 
we will be able to convey from this study.  
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5.6 TABLES AND FIGURES 
Table 5.1: Blood, inflammatory, and iron parameters of donors whose RBCs were used for 
parasite growth assays before (Day 0), during (Days 14 and 49), and after (Day 84) iron treatment. 
Donors were enrolled (Day 0) between 14-22 weeks of gestation. Tests were performed in MRC Keneba 
laboratories using a Medonic M20M GP and Cobas Integra 400 plus, or in the field using a HemoCue 
301. Values in the Normal Range column are the normal or healthy range for each parameter for 2nd and 
3rd trimesters of pregnancy, as defined by standard guidelines (54), if known. Numerical values reflect the 
mean value of all individuals and values in parentheses indicate standard deviation (SD). Note control 
non-anemic, non-pregnant donors had an average hemoglobin of 14.13 g/dl (SD 0.85). The WHO defines 
anemia in pregnant women as <11g/dL (severe <7g/dL, mild 7-9.9g/dL, moderate 10-10.9g/dL) (55). 
 
Variable Normal 2nd 
Trimester 
Normal 3rd 
Trimester 
Day 0 
n=327 
Day 14 
n=82 
Day 49 
n=112 
Day 84 
n=115 
Red Blood Cell (x10^6 per µl) 2.81–4.49 2.71–4.43 3.76 
(0.52) 
3.75 
(0.72) 
3.74 
(0.53) 
3.72 
(0.40) 
White Blood Cell (x10^9 per l) 5.6–14.8 5.9–16.9 7.59 
(2.18) 
8.16 
(2.24) 
7.63 
92.33) 
8.00 
(1.85) 
Hemoglobin (g per dl) 9.7–14.8 9.5–15.0 10.86 
(1.45) 
10.93 
(1.54) 
10.90 
(0.94) 
11.07 
(1.00) 
Hematocrit (%) 30.0–39.0 28.0–40.0 29.68 
(4.12) 
30.48 
(4.88) 
30.57 
(3.95) 
30.44 
(2.92) 
Mean Corpuscular Volume (fl) 82–97 81–99 79.30 
(6.62) 
80.68 
(10.65) 
82.12 
(6.85) 
82.18 
(6.09) 
Mean Corpuscular Hemoglobin 
(pg per cell) 
30–33 29–32 29.10 
(2.89) 
29.50 
(3.02) 
29.64 
(2.83) 
29.95 
(2.35) 
Mean Corpuscular Hemoglobin 
Concentration (g per dl) 
 
 
36.65 
(1.45) 
39.97 
(1.17) 
36.06 
(1.03) 
36.43 
(1.06) 
Red Cell Distribution Width (%) 13.4–13.6 12.7-15.3 13.88 
(1.64) 
14.72 
(2.43) 
14.70 
(3.00) 
13.78 
(2.61) 
Platelet Count (x10^9 per l) 155–409 146–429 253.18 
(73.99) 
238.02 
(57.72) 
232.04 
(66.01) 
231.23 
(62.64) 
Iron Total (µ mol per l) 7.9-31.9 5.4-34.6 14.58 
(7.90) 
23.74 
(12.90) 
22.79 
(10.82) 
32.41 
(13.67) 
Transferrin (g per l) 2.20–4.41 2.88–5.30 3.35 
(0.67) 
3.11 
(0.69) 
3.14 
(0.62) 
3.10 
(0.66) 
Transferrin Saturation (%)  10–44 5–37 18.6 
(12.6) 
38.0 
(18.3) 
35.1 
(16.9) 
49.1 
(20.7) 
Ferritin (ng per ml) 2–230 0–116 33.90 
(35.24) 
40.60 
(23.86) 
44.04 
(32.16) 
41.38 
(23.58) 
Alpha 1 Anti-glycoprotein (g per l)  
 
0.65 
(0.26) 
0.55 
(0.17) 
0.42 
(0.19) 
0.44 
(0.16) 
C Reactive Protein (mg per dl) 0.04–2.03 0.04–0.81 5.93 
(13.28) 
4.80 
(4.48) 
4.69 
(5.28) 
4.33 
(3.48) 
Soluble Transferrin Receptor 
(nmol per l) 
 
 
4.32 
(2.48) 
4.20 
(4.43) 
3.78 
(1.30) 
3.42 
(1.05) 
Soluble Transferrin Receptor: log 
Ferritin Index  
 
 
3.85 
(14.80) 
2.85 
(2.13) 
2.55 
(1.09) 
2.40 
(1.48) 
Hepcidin (ng per ml)  
 
4.57 
(6.45) 
8.46 
(8.21) 
10.22 
(8.05) 
9.93 
(8.08) 
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Table 5.2. Effect of host hemoglobin, iron status, and other hematological characteristics on in 
vitro P. falciparum growth in RBCs from pregnant women (14-22 weeks gestation) at baseline. 
Growth rates (GR) were calculated relative to growth in healthy, non-anemic donors. Growth assays were 
performed in triplicate for each donor and the average value was used for linear regression modelling; 
multivariate analyses represent the estimated association for a given variable while controlling for 
potential confounders. Hgb genotype was evaluated solely based on AA vs. AS classification. For 
continuous variables, the β1 value represents the %GR change (x100) for every 1 unit increase in the 
primary variable. For categorical variables, the β1 value represents the %GR change (x100) based on 
yes-no genotype. For example, for Hgb AS, the %GR change is -24.8% relative to Hgb AA. Significant p 
values (<0.05) are bolded. The standardized %GR change for all continuous variables is calculated based 
on the SD for the exposure variable of interest (see Table 5.1) multiplied by β1 (x100%), to give the %GR 
change for every 1 SD change in the exposure variable; for Hgb genotype the adjusted %GR change is 
simply β1 (x100%).  
 
Condition B1 
value 
Lower 
CI 
Upper 
CI 
p value Standardize
d % change 
Bivariate analysis of measures affecting parasite growth 
Hgb (g/dL) 0.089 0.052 0.127 <0.0001 11.41 
Hgb genotype (AA vs AS) -0.248 -0.383 -0.114 <0.0001 -24.82 
MCV (fL) 0.009 0.002 0.017 0.017 6.02 
Ferritin (ng/ml) <0.001 -0.001 0.002 0.895 0.35 
Hepcidin (ng/ml) 0.006 -0.001 0.014 0.099 4.17 
CRP (mg/dL) 0.001 -0.003 0.005 0.503 1.73 
sTfR:log ferritin ratio -0.001 -0.009 0.006 0.789 -1.51 
Transferrin saturation (%) 0.687 0.297 1.078 0.001 8.66 
Gestational age (weeks) 0.005 -0.004 0.014 0.262 3.04 
RDW (%) 0.050 0.015 0.020 0.001 8.23 
log hepcidin 0.086 0.022 0.150 0.009 6.77 
Multivariate analysis of significant measures affecting parasite growth controlling for possible 
confounders 
Hgb affects parasite growth controlling for 
Hgb genotype 
0.085 0.047 0.123 <0.0001 10.89 
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Figure 5.1: Description of subjects and flow chart of sample collection and assays performed. 
Blood samples for hematological, biochemical, and parasite growth analyses were drawn at Day 0, as 
well as Days 14, 49, and 84 for those taking iron. A full hematology panel was measured in EDTA-
stabilized blood (Medonic M20M GP). We also assayed plasma ferritin, soluble transferrin receptor 
(sTfR), serum iron, transferrin saturation (TSAT), C-reactive protein (CRP), alpha 1-acid glycoprotein 
(AGP) (Cobas Integra 400 plus); and hepcidin (Hepcidin-25 (human) EIA Kit (Bachem)). Genotyping for 
hemoglobinopathies was performed using hemoglobin electrophoresis. For malaria assays, 2.5mL of 
venous blood was drawn directly into microvette tubes containing CPDA-1 (Sarstedt, Germany). 
Unavailable donors include safety exclusion (Hgb<7g/dl or positive malaria test (RDT positive)), those 
who delivered prematurely or aborted, or general loss to follow up (withdrawal and travel). Failure to 
collect blood from subjects (e.g. from phlebotomy failure, subject moved or withdrew, delivered, or 
became significantly ill) was 99.8% at Day 0, 95.2% at Day 14, 91.6% at Day 49, and 83.2% at Day 84. 
RBCs from study subjects were evaluated with in vitro P. falciparum growth assays (using strain FCR3-
FMG) as a proxy measure for malaria susceptibility. In order to standardize the growth assays, control for 
inter-assay variability and variability between parasite preparations, assays on clinical samples were run 
in parallel with and reported relative to growth assays done using RBCs from non-anemic donors. Each 
available blood sample at every time point was subjected to growth assays but not all produced growth 
data, as some blood was unusable (e.g. clotted, hemolysed, contaminated). Further growth data 
exclusions (e.g. parasites died or control blood did not provide a readable output for comparison) do not 
represent population sampling bias, as subject characteristics are the same between those with and 
without corresponding growth data (Supplemental Table S5.2). 
 
 
139 
 
Figure 5.2: Parasite growth and invasion in RBCs from pregnant women (14-22 weeks gestation) 
at baseline. A) P.falciparum (strain FCR3-FMG) growth rates are proportional to hemoglobin 
concentration. Growth assays were performed in RBCs drawn from pregnant women at baseline (Day 0) 
and values are presented relative to growth in RBCs from non-anemic, non-pregnant donors. Each dot 
represents the mean result of triplicate growth assays from each donor and the error bars represent 95% 
CI. One-way ANOVA indicates the means are significantly different between Days (p<0.05); specifically, 
post-hoc analysis with Tukey’s test indicates significant differences between Hgb levels <10 and 11.0-
11.9 (p<0.05) or >12 (p<0.001), and between Hgb 10-10.9 and >12.0 (p<0.05). B) Parasite growth rates 
in RBCs from pregnant women categorized by different definitions of anemia at baseline. In analysis of 
parasite growth rates in RBCs from pregnant women at Day 0, we stratified anemic participants 
(Hgb<11g/dl) with growth rate data at Day 0 (n=124) using four different definitions to categorize the 
severity and type of iron deficiency in the presence or absence of inflammation: those with 1) 
hepcidin<2.5ng/ml (n=85); 2) ferritin<12ng/ml (n=39); 3) ferritin12-30ng/ml with CRP>5mg/ml (n=6); 4) 
hemoglobin increase of >0.5g/dl from baseline after 49d or 84d of daily iron supplementation (n=77); 
definitions 1-4 are not necessarily mutually exclusive nor do they ultimately encompass everyone with 
anemia. Growth rate values are presented relative to growth in RBCs from non-anemic, non-pregnant 
donors. Each dot represents the mean result of triplicate growth assays from each donor and the error 
bars represent 95% CI. Mean growth rate results (with 95%CI) are: hepcidin<2.5ng/ml=58.71% (49.08-
68.34%); ferritin<12ng/ml=74.27% (58.90-89.64%); ferritin 12-30ng/ml with CRP>5mg/ml=51.73% (7.76-
95.69%), ΔHgb>0.5g/dl=68.51% (58.46-78.55%). There are no significant differences between the 
means. 
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Figure 5.3: P.falciparum PfRh invasion ligands and attachment rates are not involved in 
mechanisms of differential invasion into RBCs from anemic versus non-anemic donors. A) 
Comparison of invasion into RBCs from anemic pregnant women and non-anemic, non-pregnant donors 
using P.falciparum laboratory strains. Invasion experiments for RBCs from all anemic donors (drawn at 
Day 0) were performed independently and each experiment was performed in duplicate. Data show the 
mean relative invasion using RBCs from 4 donors for strain 3D7 and 3 for FCR3-FMG. The relative 
invasion was determined calculating the percent of ring-stage infected RBCs after incubating purified 
schizonts from culture with target RBCs from donors, taking into account percent infected RBCs at the 
experiment start time in each target RBC experimental set-up. All values are normalized to 1.0 being the 
invasion rate for the control non-anemic, non-pregnant donor in each experiment. The bars represents 
the 95% CI. Both strains 3D7 and FCR3-FMG give relative invasion values significantly decreased from 
the control value of 1.0: 3D7 mean 0.74 (95% CI 0.60-0.87); FCR3 mean 0.60 (95% CI 0.44-0.76). B) 
Competitive invasion of subject and control RBCs using P. falciparum parent strain 3D7 and transgenic 
strains missing individual PfRh invasion ligands. Invasion experiments for RBCs from all test subject 
donors were performed independently and each experiment was performed in triplicate. Data show the 
mean SI using RBCs from 15 pregnant test donors for each strain. The SI defines the relative 
susceptibility to invasion of two different types of RBCs, control and test subject. The marker represents 
the SI point estimate and the bar represents the 95% CI. An SI of 1.0 indicates no difference in parasite 
invasion of two RBC populations. 95% CI are shown; there are no statistically significant differences in SI 
values from the transgenic strains versus the parent strain 3D7. C) P. falciparum merozoite invasion into 
and attachment to RBCs from anemic pregnant women (Hgb<11g/dl) compared to RBCs from non-
anemic, non-pregnant donors. Purified schizonts were incubated with control or subject RBCs in parallel 
for 3-7hrs to allow for schizont rupture. Subsequent fixation and staining with DNA dye allows for 
detection of either new invasion events or attachment events, which are distinguishable from seeded 
schizont-infected RBCs by flow detection of DNA content. Attachment was specifically assayed with 
inclusion of cytochalesin D during schizont incubation to prevent further invasion. New parasite events 
relative to starting seeding parasitemia were compared between subject and control RBCs (with rates in 
subject RBCs normalized to those in control RBCs within each experiment, in order to allow for inter-
experiment comparisons). Results are shown from 2 experiments with RBCs from 3 control and 5 subject 
donors each, assayed in triplicate. Error bars represent 95% CIs. There is a significant difference in 
merozoite invasion in subject RBCs compared to control RBCs (mean RBC invasion value of 0.63 for 
subject relative to controls, *p<0.001 by student’s t-test), but no difference in merozoite attachment (mean 
RBC attachment value of 0.85 for subjects relative to controls).  
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Figure 5.4: Malaria susceptibility increases transiently during iron supplementation and pregnant 
women receiving iron supplements have increased numbers of young RBCs. A) P.falciparum in 
vitro growth rates in RBCs from pregnant women increase over time with iron supplementation (60mg iron 
daily for 84 d). Parasite growth assays were conducted in RBCs from pregnant women at Day 0, Day 14, 
Day 49, and Day 84 using strain FCR3-FMG. Growth rates are reported relative to growth in RBCs from 
non-anemic, non-pregnant donors. Each dot represents the mean of triplicate assays and error bars 
represent the 95% CI. Differences between growth rates at the different time points were significant 
(p<0.0001 by one-way ANOVA); specifically, post-hoc analysis with Tukey’s test indicates significant 
differences between Day 0 and Day 14 (***p<0.001), between Day 0 and Day 49 (***p<0.001), between 
Day 14 and Day 49 (**p<0.01), between Day 14 and Day 84 (***p<0.001), and between Day 49 and Day 
84 (***p<0.001). The only non-significant differences were between Day 0 and Day 84. n=327 pregnant 
women at Day 0, n=82 pregnant women at Day 14, n=112 pregnant women at Day 49, and n=115 
pregnant women at Day 84. B) Levels of CD71 positive RBCs increase over time in pregnant women 
undergoing iron supplementation. Percent CD71-positive RBCs was measured by flow cytometry analysis 
of CD71 surface expression. Error bars represent the 95% CI; one-way repeated measures ANOVA 
indicates the means are significantly different between Days (p<0.0001); post-hoc analysis with Tukey’s 
test indicates significant differences between Day 0 and Day 14 (***p<0.001), between Day 0 and Day 49 
(*p<0.05), between Day 0 and Day 84 (**p<0.01), between Day 14 and Day 49 (*p<0.05), between Day 
14 and Day 84 (***p<0.001), and between Day 49 and Day 84 (***p<0.001). n=209 pregnant women at 
Day 0, n=83 pregnant women at Day 14, n=152 pregnant women at Day 49, and n=142 pregnant women 
at Day 84.  
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5.7 SUPPLMENTAL TABLES AND FIGURES 
Supplemental Table S5.1: Description of subjects at baseline. Hemoglobin genotyping was 
performed by electrophoresis. *A portion of subjects (% of total) were unable to be tested for hemoglobin 
genotype so are not included in the denominator for other genotypes (which denote % of those tested). 
 
 
Characteristic All 
participants 
(n=498) 
Those to receive 60 
mg iron daily 
(n=167) 
Age, years, mean (SD) 27.1 (5.8) 27.0 (5.9) 
Gestational age at enrollment, weeks, mean (SD) 19.9 (6.1) 19.4 (6.8) 
Hemoglobin genotype, n (%) 
  
 
AA 400 (82.3) 129 (79.6) 
 
AS 86 (17.7) 33 (20.4) 
 
SS 0 0 
 
AC 0 0 
 
SC 0 0 
 
Untested* 12 (2.4) 5 (3.0) 
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Supplemental Table S5.2: Blood, inflammatory, and iron parameters of study participants with 
reportable parasite growth rate data versus those without. Numerical values reflect the mean value of 
all individuals of a particular category and time point, and values in parentheses are the SD. 
 
 
Variable Day 0 
w/ GR 
n=327 
Day 0 no 
GR 
n=172 
Day 14 
w/ GR 
n=82 
Day 14 
no GR 
n=83 
Day 49 
w/ GR 
n=112 
Day 49 
no GR 
n=45 
Day 
84 w/ 
GR 
n=115 
Day 84 
no GR 
n=29 
Red Blood Cell (x10^6 per 
µl) 
3.76 
(0.52) 
3.73 
(0.48) 
3.75 
(0.72) 
3.55 
(0.36) 
3.74 
(0.53) 
3.56 
(0.36) 
3.72 
(0.40) 
3.55 
(0.43) 
White Blood Cell (x10^9 
per l) 
7.59 
(2.18) 
7.14 
(1.89) 
8.16 
(2.24) 
7.39 
(1.85) 
7.63 
92.33) 
7.22 
(1.89) 
8.00 
(1.85) 
8.63 
(2.47) 
Hemoglobin (g per dl) 10.86 
(1.45) 
10.61 
(1.32) 
10.93 
(1.54) 
10.44 
(0.96) 
10.90 
(0.94) 
10.72 
(1.06) 
11.07 
(1.00) 
10.74 
(1.22) 
Hematocrit (%) 29.68 
(4.12) 
29.65 
(3.62) 
30.48 
(4.88) 
28.49 
(2.61) 
30.57 
(3.95) 
29.23 
(3.05) 
30.44 
(2.92) 
29.74 
(3.52) 
Mean Corpuscular Volume 
(fl) 
79.30 
(6.62) 
78.89 
(7.44) 
80.68 
(10.65) 
80.56 
(6.51) 
82.12 
(6.85) 
82.26 
(5.12) 
82.18 
(6.09) 
84.19 
(7.93) 
Mean Corpuscular 
Hemoglobin (pg per cell) 
29.10 
(2.89) 
28.71 
(3.13) 
29.50 
(3.02) 
29.62 
(2.83) 
29.64 
(2.83) 
30.25 
(2.12) 
29.95 
(2.35) 
30.48 
(3.03) 
Mean Corpuscular Hgb 
Concentration (g per dl) 
36.65 
(1.45) 
36.33 
(0.96) 
39.97 
(1.17) 
36.72 
(1.11) 
36.06 
(1.03) 
36.77 
(1.06) 
36.43 
(1.06) 
36.2 
(0.80) 
Red Cell Distribution Width 
(%) 
13.88 
(1.64) 
13.51 
(1.68) 
14.72 
(2.43) 
14.00 
(1.89) 
14.70 
(3.00) 
13.70 
(1.83) 
13.78 
(2.61) 
13.45 
(1.04) 
Platelet Count (x10^9 per l) 253.18 
(73.99) 
262.72 
(67.88) 
238.02 
(57.72) 
268.86 
(72.54) 
232.04 
(66.01) 
232.76 
(71.75) 
231.23 
(62.64) 
231.46 
(65.21) 
Iron Total (µ mol per l) 14.58 
(7.90) 
15.73 
(6.97) 
23.74 
(12.90) 
22.14 
(12.68) 
22.79 
(10.82) 
16.92 
(7.78) 
32.41 
(13.67) 
34.01 
(12.06) 
Transferrin (g per l) 3.35 
(0.67) 
3.23 
(0.60) 
3.11 
(0.69) 
2.92 
(0.70) 
3.14 
(0.62) 
2.47 
(0.43) 
3.10 
(0.66) 
3.32 
(0.50) 
Transferrin Saturation (%) 018.6 
(12.6) 
23.8 
(12.7) 
38.0 
(18.3) 
34.7 
(18.1) 
35.1 
(16.9) 
27.7 
(12.6) 
49.1 
(20.7) 
48.6 
(18.1) 
Ferritin (ng per ml) 33.90 
(35.24) 
36.35 
(50.01) 
40.60 
(23.86) 
50.02 
(42.18) 
44.04 
(32.16) 
41.24 
(38.33) 
41.38 
(23.58) 
38.88 
(20.17) 
Alpha 1 Anti-glycoprotein 
(g per l) 
0.65 
(0.26) 
0.68 
(0.27) 
0.55 
(0.17) 
0.57 
(0.18) 
0.42 
(0.19) 
0.39 
(0.17) 
0.44 
(0.16) 
0.50 
(0.37) 
C Reactive Protein (mg per 
dl) 
5.93 
(13.28) 
5.95 
(11.89) 
4.80 
(4.48) 
5.96 
(7.78) 
4.69 
(5.28) 
4.62 
(4.99) 
4.33 
(3.48) 
5.12 
(5.41) 
Soluble Transferrin 
Receptor (nmol per l) 
4.32 
(2.48) 
4.58 
(2.06) 
4.20 
(4.43) 
3.99 
(1.63) 
3.78 
(1.30) 
3.18 
(1.06) 
3.42 
(1.05) 
3.38 
(0.96) 
Soluble Transferrin 
Receptor: log Ferritin Index  
3.85 
(14.80) 
3.56 
(8.91) 
2.85 
(2.13) 
2.62 
(1.37) 
2.55 
(1.09) 
2.28 
(1.08) 
2.40 
(1.48) 
2.26 
(0.92) 
Hepcidin (ng per ml) 4.57 
(6.45) 
7.75 
(8.87) 
8.46 
(8.21) 
8.65 
(8.33) 
10.22 
(8.05) 
8.71 
(7.98) 
9.93 
(8.08) 
9.43 
(6.70) 
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Supplemental Figure S5.1: Parasite growth in RBCs from different donor groups at baseline. A) 
Parasite growth rates in RBCs from pregnant women categorized by anemia status, non-anemic 
(Hgb≥11g/dl) and anemic (Hgb<11g/dl). Growth rate values are presented relative to growth in RBCs 
from non-anemic, non-pregnant donors. Each dot represents the mean result of triplicate growth assays 
from each donor and the error bars represent 95% CI. Mean growth rate results (with 95%CI) are: non-
anemic 82.67% (76.38-88.96%) and anemic 64.01% (56.28-71.74%). Student’s t-test indicates significant 
difference between the means (p<0.001). n=203 non-anemic and n=124 anemic donors. B) Parasite 
growth rates in RBCs from pregnant women categorized by hemoglobin genotype, normal (AA) and with 
the sickle-cell trait mutation (AS). Growth rate values are presented relative to growth in RBCs from non-
anemic, non-pregnant donors. Each dot represents the mean result of triplicate growth assays from each 
donor and the error bars represent 95% CI. Mean growth rate results (with 95%CI) are: AA 79.84% 
(74.19-85.48%) and AS 55.02% (44.47-65.58%). Student’s t-test indicates significant difference between 
the means (p<0.001). n=263 with AA genotype; n=52 with AS genotype.  
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Supplemental Figure S5.2: Changes in parasite growth and reticulocytosis in RBCs from pregnant 
women before, during, and after daily iron supplementation. A) Levels of parasite growth rates 
increase over time in pregnant women undergoing iron supplementation, as depicted by line graph in 
order to highlight changes for each individual that had data available at all time points (n=44 pregnant 
women with complete repeat growth measures at Day 0, 14, 49, and 84), with 88.6% having increased 
growth rate at Day 14 and 54.5% having increased growth rate at Day 49. One-way repeated measures 
ANOVA of growth rate values indicates the means are significantly different between Days (p<0.0001); 
post-hoc analysis with Tukey’s test indicates significant differences between Day 0 and Day 14 means 
(p<0.001), between Day 14 and Day 49 (p<0.001), and between Day 14 and Day 84 (p<0.001), but no 
significance between Day 0 and Day 49 or Day 84, nor between Day 49 and Day 84 for those pregnant 
women with repeat measures. B) Levels of parasite growth rates increase over time in pregnant women 
undergoing iron supplementation, as depicted by line graph in order to highlight changes for each 
individual that had data available at all timepoints (n=60 pregnant women with complete repeat CD71 
measures at Day 0, 14, 49, and 84), with 78.3% having increased growth rate at Day 14. One-way 
repeated measures ANOVA of growth rate values indicates the means are significantly different between 
Days (p<0.0001); post-hoc analysis with Tukey’s test indicates significant differences between Day 0 and 
Day 14 means (p<0.001), between Day 14 and Day 49 (p<0.001), and between Day 14 and Day 84 
(p<0.001), but no significance between Day 0 and Day 49 or Day 84, nor between Day 49 and Day 84 for 
those pregnant women with repeat measures. 
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Supplemental Figure S5.3: Surface markers of RBC age and integrity change in a pattern 
consistent with an increase in erythropoiesis in pregnant women undergoing iron 
supplementation (60mg daily). We measured GPA (an abundant sialoglycoprotein which contributes to 
RBC surface charge and is found at higher levels on younger RBCs (41)), CD47 (an anti-phagocytic 
marker which influences RBC senescence and is found in lower levels in RBCs that have been in 
circulation longer or are less healthy (42)), surface deposition of complement factor C3b (higher levels of 
which would correlate with increased RBC time in circulation, or less healthy RBC membranes (43)), and 
levels of P.falciparum merozoite receptors (CD35, CD147, CD55, and sialic acid residues). Note that GPA 
is also a merozoite receptor, and CD35 and CD55 involved in the complement system have also been 
described as reflecting RBC age (more abundant on younger/healthier RBCs (43)), as has sialic acid 
abundance (reduced on older RBCs) (42). CD147, known as basigin, is the only known essential 
P.falciparum invasion receptor (44). Data represent relative expression based on subject donor RBC MFI 
values (GPA, CD47, CD35, CD147, CD55, and sialic acid residues) or percent positive population values 
(C3b), compared to RBCs from a non-anemic, non-pregnant control donor not receiving iron 
supplementation (relative expression=1.0). RBCs from the same 6 donors were examined over time. 
Error bars represent the 95% CIs. If indicated, one-way repeated measures ANOVA with post-hoc 
Tukey’s test analysis indicates significant difference between expression levels (*p<0.05, **p<0.01, 
***p<0.001). 
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CHAPTER SIX: DISCUSSION AND FUTURE DIRECTIONS 
 
6.1 BRIEF SUMMARY OF WORK PRSENSED IN THIS DISSERTATION 
The research undertaken in this dissertation was designed to expand upon epidemiological 
findings of reduced malaria infection in people with iron deficiency and potentially increased malaria 
susceptibility following iron supplementation, attempting to understand this relationship on a cellular level.  
This was initiated with a study enrolling people from UNC hospitals who were iron deficient or iron 
replete and using their RBCs to conduct in vitro assays comparing various aspects of parasite growth 
(Chapter 2). We determined that parasite growth was significantly reduced in RBCs from iron deficient 
individuals, and we went on to characterize this reduced growth as involving both reduced invasion into 
as well as replication within iron deficient RBCs, but not altered parasite maturation. In RBCs from iron 
deficient and iron replete donors who received iron supplementation, there were no differences. We 
further characterized increased parasite growth and invasion in young RBCs and put forth a model 
hypothesizing that RBC population dynamics influenced malaria susceptibility, not just simple iron 
withholding as is the case with many other pathogens such as bacteria. In our model, presence of iron 
deficient RBCs limits infection potential due to their reduced susceptibility to parasite infection, and when 
someone receives iron they begin to erythropoiese at elevated rates, such that they have a much higher 
level of young RBCs in circulation which are highly susceptible to malaria infection. Above-average 
numbers of young RBCs and replacement of protective iron deficient RBCs would thus constitute a period 
of increased malaria risk before finally, RBC populations would normalize as would infection 
susceptibility. 
In anticipation of testing this model using RBCs from relevant populations in malaria endemic 
areas, we next sought to develop a method for preserving valuable RBCs to allow for prolonged usage in 
in vitro malaria experiments (Chapter 3), as established malaria culture protocols require freshly drawn 
RBCs (utilized within 2-4 weeks from blood draw). We first characterized growth, invasion, and replication 
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within RBCs stored over time, confirming significant reductions in parasite growth and invasion in RBCs 
stored longer than 2 weeks. We tested several different RBC storage medias, but did not find any 
improved RBC viability. However, we did find that biopreservation of RBCs in liquid nitrogen provided a 
means for preserving RBCs for prolonged periods without any detriment to in vitro parasite growth 
indices. 
We next conducted a field study partnering with clinical trial research of iron supplementation in 
anemic Gambian children aged 6-24 months (Chapter 4). We attempted to better characterize the degree 
of protection from iron deficiency as well as changes in RBC population dynamics following iron 
supplementation that influence parasite growth. This work was all conducted using in vitro malaria culture 
as a proxy measure of malaria susceptibility, both because clinical malaria incidence is very low in The 
Gambia currently, and because this method provided a better means of systematically measuring malaria 
infection potential without biases from anti-malarial preventative measures (provided to trial participants in 
accordance with ethical safety precautions). We determined that RBCs from anemic children significantly 
reduced parasite growth and invasion, and that parasite growth rates specifically correlated with 
hemoglobin concentration within our study population. In fact, within our population of anemic children, 
the parasite growth reduction was on par with or greater than growth reduction observed in RBCs from 
those children with sickle-trait. Following iron supplementation, we observed significant increases in 
parasite growth and invasion in subject RBCs, over and above growth in non-anemic controls. These 
growth changes paralleled increases in circulating reticulocytes and other measures of young RBC 
populations following iron supplementation, fitting with our proposed model of how RBC population 
structures might influence overall infection susceptibility. 
Briefly, regarding the data from this study, it should be mentioned why we have ultimately focused 
on anemia (as defined by hemoglobin values <11g/dl) and thus hemoglobin as the primary variable 
influencing parasite growth, as opposed to the degree of iron deficiency – especially when we have spent 
so much time throughout this dissertation discussing the importance of iron deficiency specifically. It is 
true anemia can have multiple causes beyond iron deficiency and the term anemia is less specific than 
iron deficiency anemia. There are a number of reasons for our shift towards using the term anemia. First, 
in our linear regression modeling examining which variables correlated with parasite growth rates, we did 
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not find any measurements relating to iron status were significant (i.e. ferritin, serum iron, soluble 
transferrin receptor (sTfR), hepcidin, transferrin saturation). We believe this is due to the second point – 
that it is notoriously difficult to measure iron deficiency in populations with high levels of inflammation, 
such as seen with children exposed to many infectious organisms and less sterile environments (as is 
common in developing countries). This influences accurate measurement of iron status because several 
markers of iron status are also acute phase proteins that rise with inflammation, thus falsely portraying 
the true iron status of an iron deficient individual simultaneously experiencing inflammation. 
Understanding this point, it is not surprising that we found no significant correlation of parasite growth 
rates with iron markers, because so many of the children in our study do have high levels of inflammation 
(specifically, 24.9% had CRP >5mg/dl at baseline and 61.5% had AGP levels >1 at baseline). Multiple 
definitions of iron deficiency anemia have been proposed to more accurately measure iron status in the 
presence of inflammation. We thoroughly examined the data our study population to enumerate the 
number of children fitting into several well-known or practical definitions of iron deficiency anemia (based 
on ferritin, CRP, hepcidin, and Hgb response to iron supplementation) and consistently found that 
approximately 60% of our population had iron deficiency based on these measurements (discussed in 
Chapter 4). However, taking into account other very relevant variables, nearly every child could be 
categorized as having iron deficiency anemia specifically. In particular, we found MCV to be below normal 
levels (<70fL) in 83.8% of the population at baseline and sTfR:log ferritin ratios to be >2 in every single 
participant (ratios above 2 being highly indicative of iron deficiency anemia as soluble transferrin receptor 
levels rise in the presence of iron deficiency and ferritin levels drop). Thus, we remain confident in saying 
that our study population of anemic children was in fact suffering from iron deficiency anemia. This 
discussion of measurements of iron deficiency anemia closely relates to the final point of why we focused 
on using the terms hemoglobin and anemia as impacting parasite growth rates in presentation of our 
results – because hemoglobin is a simple measurement which allows for very practical and easy 
translation to the field setting in malaria endemic areas where it would be desirable to predict malaria 
susceptibility and the impact of iron supplementation. Hemoglobin measurements can be made on-the-
spot with relatively simple and inexpensive diagnostic tools, rather than the complex and expensive 
diagnostic machines required for measuring complete iron panels which are nearly entirely absent from 
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the developing world with the exception of research laboratories. Our results show that hemoglobin 
measurement alone is sufficient to predict malaria susceptibility, as measured by our in vitro growth data, 
thus providing a more practical option for researchers and clinicians who have continuously struggled to 
measure iron deficiency and understand the relationship between iron status markers and malaria 
susceptibility. 
Finally, we also partnered with a clinical trial of iron supplementation in pregnant women, in order 
to investigate the same malaria-related safety questions in this population (Chapter 5). Not all participants 
were anemic, but we still found significantly reduced parasite growth in RBCs from study subjects at 
baseline, compared to growth in RBCs from non-anemic, non-pregnant donors. Again, parasite growth 
rates correlated significantly with hemoglobin concentration, and again, the growth reductions seen with 
anemia status were on par with growth reductions observed in RBCs from donors harboring the sickle-
trait genotype. We attempted to further characterize mechanisms of reduced invasion into RBCs from 
anemic donors, but did not find the invasion deficit was due to either specific PfRh proteins being able to 
“identify” differences in iron replete versus iron deficient RBCs, nor to merozoite attachment differences. 
Yet again, we observed significantly elevated parasite growth rates in subject RBCs following iron 
supplementation with growth rate changes paralleling increases in young RBC populations in circulation. 
Analyses for the pregnant women iron supplementation study are ongoing, but preliminarily they clearly 
match our findings from the study involving anemic children undergoing iron supplementation and also fit 
our larger model describing the relationship between iron deficiency, iron supplementation, and malaria 
susceptibility. 
6.2 WAYS FORWARD 
Our research has contributed significantly to knowledge of factors driving parasite growth 
reductions in RBCs from people with anemia, as well as solidified the reality of clinical epidemiological 
work suggesting iron supplementation may put people at increased risk for malaria infection. Of course, 
there is still much to be learned and many possible pathways forward for the overarching research topic 
of iron and malaria. 
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6.2.1 Further investigating mechanisms of reduced invasion into iron deficient RBCs.  
The reduced growth of P.falciparum in RBCs from iron deficient donors raises important 
questions: What molecular properties of IDA RBCs confer protection from malaria, and can these 
properties be exploited by medical interventions? Invasion is critically important to blood stage vaccine 
development and IDA provides a rare opportunity to characterize a strong natural difference in invasion 
phenotype. The merozoite is one of the rare parasite stages directly exposed to the host immune system, 
and if unable to invade a RBC, merozoite viability quickly diminishes (1). Therefore, the speed and ease 
with which the merozoite is able to identify and invade its target cell is critical to parasite survival, and 
determining the mechanisms responsible for reduced invasion of IDA RBCs could benefit understanding 
of parasite biology and counter-infection research.   
We have begun probing both host and parasite factors which could impact reduced parasite 
invasion into iron deficient RBCs. RBC invasion by merozoites occurs via a series of well-orchestrated 
steps (2). When a merozoite encounters an uninfected RBC, it will form a low affinity, reversible specific 
interaction, which triggers a deformation of the RBC that tumbles the merozoite over the surface and 
allows it to reorient such that its apical end is irreversibly attached to the RBC. Subsequently, a moving 
tight junction is formed between the parasite and host RBC which involves parasite proteins AMA1 and 
the RON complex. The junction moves from the merozoite apical to posterior end using a junction-
associated actin-myosin motor to propel itself inside (3). Merozoite invasion ligands important for target 
cell recognition and junction formation signaling so far belong to two major families, the erythrocyte 
binding-like antigens (EBA) and the reticulocyte binding-like homologs (RBL or PfRh). P.falciparum has 
an extensive array of invasion ligands and can utilize a variety of host receptors to bind RBCs. The 
parasite is very adaptable: if a host receptor is absent from a RBC, the parasite may utilize an alternate 
receptor through differential EBA and PfRh binding pathways. Multiple physiological differences between 
IDA and IR RBCs could impact invasion. We initially focused on interrogating host receptors and parasite 
invasion ligands for determining mechanisms governing reduced anemic RBC invasion. We did this by 
characterizing levels of host receptors on RBC surfaces over time following iron supplementation, as well 
as examining whether invasion preference for IR RBCs relied on any of the PfRh proteins based on 
competitive invasion experiments with transgenic parasites missing the PfRh proteins. While we did find 
157 
 
levels of several host receptors increased on RBCs following iron supplementation, many of these 
receptors are also markers of RBC age. This makes it difficult to interpret whether their increased levels 
simply reflect increases in young RBCs which are known to be more amenable to parasite invasion, as 
opposed to increased levels of parasite receptors aiding invasion. It is also true young and iron replete 
RBCs are larger in size, which could contribute to differential receptor levels, although that is difficult to 
determine definitively with the methods we used just looking at overall relative expression levels. More 
precise measurements of receptor levels per cell as well as the impact of cell size could be further 
pursued. We did not find that absence of any PfRh ligand disrupted the parasite’s ability to preferentially 
differentiate between iron deficient and iron replete RBCs, though this could be explored further through 
knockout strains missing the other invasion EBA ligands. We could also focus on interrogating invasion 
ligands and host receptors more through antibody inhibition invasion experiments.  
However, we believe our results finding reduced invasion but not reduced attachment to RBCs 
from IDA donors points to mechanical membrane differences as playing a more important role in 
differential invasion of RBCs from IDA donors. It is well known that IDA RBCs have greater osmotic 
fragility and membrane rigidity and accelerated in vivo ageing (4–6). There is also growing evidence in 
the malaria literature that localized membrane deformability is a critical factor in merozoite invasion, with 
novel live cell imaging studies breaking down invasion into more discreet steps (7). These researchers 
found slight RBC deformation occurred following an initial weak interaction of merozoites with the RBC 
surface, followed by strong interactions of merozoite PfRh and EBA proteins with the RBC surface which 
in turn strongly deform the RBC. The authors interestingly hypothesized about “host cell selection through 
deformation which possibly helps embed the merozoite in the erythrocyte surface, leading to subsequent 
downstream events”. Their interpretation of the data was that RBC deformation might be a large factor 
contributing to rapid selection of a host RBC to invade, as they observed that when a merozoite was 
unable to efficiently trigger echinocytosis of the target RBC, it often detached and attempted to invade a 
different RBC (7).  
In relation to our system, it would be very interesting to compare extensive live cell imaging of 
invasion into RBCs from anemic donors versus non-anemic donors, in order to try to visualize which steps 
of invasion are impaired, the RBC deformation dynamics during invasion of anemic RBCs, and whether 
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merozoites do detach from anemic RBCs more often. We could additionally use confocal imaging to 
examine merozoite-RBC tight junction integrity in anemic RBCs through staining of parasite proteins 
involved in tight junction formation (such as RON4 and AMA-1), to see if junction proteins colocalize with 
RBC membranes, as opposed to attached merozoites which are not properly reoriented and forming 
junctions and thus still reversibly bound to RBCs. Furthermore, we could determine the impact on 
invasion of different levels of RBC deformability, quantifying deformability of RBCs from anemic and non-
anemic donors through methods such as ektacytometry or microfluidic flow chambers, as well as altering 
deformability of non-anemic RBCs with cell-stiffening agents such as diamide (8). We could also try to 
alter intracellular ATP content to see if this impacted invasion, as intracellular ATP is also known to 
influence both parasite invasion and membrane deformability (8–11). To better understand other host 
membrane properties which might be altered in IDA RBCs beyond the known parasite invasion receptors 
we examined, mass spectrometry analysis of RBC membranes from anemic individuals before and after 
iron supplementation could also provide useful information. Finally, we could attempt to adapt the parasite 
to grow in IDA RBCs and see whether over time it can invade IDA RBCs as efficiently and examining 
adapted parasite protein expression for clues as to invasion pathways. This method has been 
successfully employed previously in studying sialic acid independent invasion, identifying parasite use of 
specific invasion proteins by causing upregulation of certain invasion pathways over time with adaptation 
to growth in RBCs treated to remove sialic acid residues (12). Overall, there are many methods which 
could be utilized to try to further characterize the mechanisms causing reduced invasion of RBCs into iron 
deficient donors. Further research into this arena may help elucidate natural mechanisms for inhibiting 
parasite pathogenesis which could be exploited by drug or vaccine development, or would help contribute 
to overall knowledge of parasite pathogenesis and biology.  
6.2.2 Further investigating iron acquisition and utilization pathways in the falciparum malaria 
parasite. 
Although we have focused on the effects of iron status on RBC physiology and RBC population 
structure affecting parasite invasion, growth, and overall malaria susceptibility, another direction forward 
would be to delve into understanding iron acquisition and utilization pathways in P.falciparum, as has 
been a more traditional aspect of nutritional immunity in the case of other pathogens like siderophoric 
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bacteria. 
There is no question that iron is an essential nutrient for P. falciparum. Iron is required for 
parasite DNA synthesis, glycolysis, pyrimidine synthesis, heme synthesis, and electron transport. The 
parasite rapidly proliferates inside RBCs, multiplying 8-32 times in its 48hr life cycle. The host RBC does 
contain iron, but a majority is sequestered in heme which is incorporated into hemoglobin. While the 
parasite’s iron source is unclear, most evidence indicates it obtains iron from the host – not from 
hemoglobin, but from another intra-erythrocytic pool, possibly labile ferrous iron and/or ferritin (13–15). 
The parasite efficiently metabolizes hemoglobin protein in its acidic digestive vacuole and uses the 
resultant amino acids for its own protein needs. However, the parasite cannot extract the iron molecule 
from heme: it lacks heme oxygenase activity and to our knowledge, no plasmodial iron storage proteins, 
siderophores, or chelators have been identified. As iron is critical to the parasite, much work has been 
done investigating iron chelating agents as possible anti-malarials. In fact, many iron chelating agents 
suppress parasite growth in vitro and in animal models (16, 17). Given the parasite’s iron requirement, it 
was understandably initially believed that reduced iron availability was responsible for malaria protection 
associated with IDA. Although our data indicates iron withholding is not the mechanism by which IDA 
confers resistance to malaria, identifying parasite iron acquisition and utilization pathways could be of 
significant importance in understanding parasite pathogenesis and finding novel antimalarial drug targets.  
Despite the parasite living in an intracellular niche where iron is a central component (as part of 
hemoglobin), it is still debatable exactly from where and how the parasite acquires iron – either from 
serum sources (e.g. transferrin or non-transferrin bound iron) or intracellularly (e.g. hemoglobin, ferritin, or 
a labile iron pool), or perhaps a combination. There is evidence to suggest transferrin associates   
with infected parasites, that labeled transferrin-bound iron is incorporated into parasite infected RBCs, 
and it has even been published that parasite transferrin receptors exist (15, 18–21), however other 
evidence has not found transferrin-bound iron to specifically associate with or be incorporated into 
infected RBCs and called into question the findings about transferrin receptors (22–24) (all reviewed in 
(25)). It has been difficult to parse out whether levels of serum iron affect parasite growth because in vitro 
the parasite must always live within a cell in which iron sources are available, though evidence to date 
has not found differences in parasite growth following iron depletion or addition to culture media 
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(reviewed in (25)). In terms of intracellular iron, there is no significant evidence that the parasite utilizes 
iron in heme, at least not via any traditional heme-oxygenase activity-like pathway (13, 26), and though 
there is some evidence the parasite does liberate some type of intracellular iron (as the bioavailable iron 
pool increases in maturing infected RBCs (15)), it is unclear where from or how. However, it is important 
to keep in perspective that given the RBC is one of the most iron-rich environments in the entire human 
body, the parasite would only need to acquire a small amount of heme-bound or ferritin-incorporated iron 
intracellularly for its needs (reviewed in (25)).  
Given that several unknowns still exist when it comes to iron and the malaria-infected RBC, there 
are numerous opportunities to try to learn more. More work could be done to determine whether a 
transferrin receptor exists, or where exactly the parasite gets its iron sources from, through radiolabeling 
experiments, pull-down assays, and membrane analyses. More could be done to examine whether 
malaria development in iron deficient RBCs affects pathogenic properties of the parasite, such as parasite 
protein export to the RBC surface and endothelial cytoadherence, or phagocytosis susceptibility. To learn 
more about iron utilization pathways, we could employ RNA sequencing (RNA-Seq; also called whole 
transcriptome shotgun sequencing) to compare parasite development in iron deficient versus iron replete 
RBCs throughout the developmental cycle. Now that merozoite isolation is more feasible (bearing in mind 
the merozoite is extremely short-lived as the extra-cellular parasite stage), it could be possible to do 
further experiments examining invasion in an iron-depleted or saturated extracellular environment. It is 
also possible now to more easily develop knockout strains of P.falciparum, which could be utilized to test 
whether an identified heme-oxygenase homolog (not known to be active) is essential in the erythrocytic 
stage of infection, or to follow up on the role of any interesting proteins identified through RNA-Seq 
exploration of parasite development in iron deficient and iron replete RBCs. Clearly there are many 
avenues which can be pursued, and elucidating exactly from where and how the parasite utilizes host iron 
could lead to interesting developments understanding parasite pathogenesis, development, and growth, 
and possibly help with novel antimalarial development – this basic role of iron in intraerythrocytic malaria 
growth should not be confused with the role we have put forth for iron affecting RBC physiology and 
population dynamics in a way that significantly affects overall infection potential in a host.  
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6.2.3 Clinical needs: further understanding impact of anemia on malaria pathogenesis and 
implications for global health strategies. 
Given the epidemiological evidence and now our strong confirmatory in vitro research showing 
reduced malaria infection in the face of iron deficiency anemia, as well as the increased susceptibility 
following iron supplementation, there are many public health issues which should be addressed in the 
near future. For one thing, our research adds to the evidence that antimalarial prophylaxis is necessary 
when giving iron supplements. This is in line with the most recent Cochrane reviews and World Health 
Organization guidelines stating that universal iron supplementation in malaria endemic areas is important 
and favorable as long as antimalarial public health measures exist (27–29) (such as health surveillance, 
health clinics available nearby, or other factors such as insecticide-treated bed net distribution). There is 
no question iron deficiency anemia is in and of itself a significant health burden for pregnant women and 
children, and iron supplementation is a simple and logical way to counter this in areas where nutritional 
deficiencies are common. However, our work would suggest that not only should standard public health 
measures be available to people undergoing iron supplementation, but that it would be best to include 
temporary provision of antimalarial chemotherapy in conjunction with iron supplementation campaigns, 
much like Intermittent Preventative Treatment (IPT) measures for antimalarial drug delivery in pregnancy 
and other high risk populations living in malaria endemic areas. IPT/temporary prophylaxis would be 
particularly advantageous given our in vitro findings that in RBCs from both pregnant women and children 
undergoing iron supplementation, there is a defined period of increased malaria susceptibility which 
eventually wanes to normal or pre-supplementation levels (Chapters 4 and 5). Of course there are further 
unknowns, such as the exact length of increased susceptibility (as we only had access to RBCs from one 
or two time points during a 12 week supplementation period), but our research at least strongly advocates 
for the need for a clinical trial studying iron supplementation in conjunction with antimalarial drug 
provision. We hope that our findings will provide useful justification for doing this research. 
Aside from relating to safety of iron supplementation in malaria endemic areas, there are other 
significant ways in which understanding the impact of anemia on malaria pathogenesis might become an 
important public health issue, such as malaria drug sensitivity and transmission potential.  
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To begin with drug susceptibility, it is a well-known reality that the P.falciparum parasite has 
successfully developed drug resistance to every kind of antimalarial drug class used in the human 
population to date. With drug resistance now arising to even the most important first line artemisinin-
based antimalarials (30), careful understanding of artemisinin activity and proper drug usage is essential, 
to avoid inadvertently worsening any growing drug resistance spread or independent emergence outside 
of Asia. As iron deficiency is common in populations amongst which malaria treatment is sought, and the 
mechanism of action of artemisinin deals with reactive oxygen species (ROS) which are known to exist at 
altered levels in iron deficient RBCs, examining artemisinin efficacy in iron deficient versus iron replete 
RBCs is important. Although the parasite possesses mechanisms that have been identified to work to 
maintain red-ox balance in the RBC where its digestion of hemoglobin increases ROS potential due to 
heme liberation (31), ROS do still rise in infected RBCs and many antimalarials further exploit ROS 
activity against the parasite (32). Early studies of the artemisinin mechanism of action showed that the 
compound interacted with heme and iron, and was hypothesized to involve cleavage of an endoperoxide 
ring which gave artemisinin oxidizing properties through formation of free radicals( 33, 34). More recent 
work shows artemisinin activity to be promiscuous, and confirms that artemisinin activation relies on heme 
interactions (much more so than iron) that subsequently form reactive oxygen species (largely via 
oxidation of the iron associated with free heme), which in turn causes lots of downstream cascading 
damage to many RBC proteins and functions important to the parasite as well (35). Parasite-infected 
RBCs are thought to be more sensitive to artemisinin because of increased levels of free heme (both 
parasite-synthesized in early ring stages and digested from host hemoglobin in later trophozoite stages) 
which interact with artemisinin to initiate downstream ROS damage (35, 36). It might be assumed that iron 
deficient infected RBCs would have increased susceptibility to artemisinin activity because of the added 
levels of ROS already present in iron deficient RBCs. However, this may not necessarily be the case – 
what if there is less room for the artemisinin to act “over and above” the ROS already present in iron 
deficient RBC, or what if some pathways for ROS creation in the iron deficient RBC have already been 
exhausted? While recent studies did not find artemisinin activation to rely on iron interactions as opposed 
to heme (35), it is also true past evidence indicates iron chelators antagonize artemisinin activity (33), 
again giving a mechanism by which artemisinin activity might differ in the iron deficient RBC. While 
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reduced artemisinin activity in iron deficient RBCs may not be a likely or intuitive phenomenon, it is worth 
exploring further in order to rule out the possibility. Evaluating this can be initiated through simple in vitro 
drug sensitivity assays infecting RBCs from iron deficient and iron replete donors, using the standardized 
ring stage sensitivity assay for examining artemisinin efficacy.  
  Finally, the potential effect of iron deficiency on malaria transmission dynamics is very real and 
deserves further study. Malaria transmission depends on mosquito feeding of infected individuals which 
ingest sexual stage-infected RBCs, which then go on to further develop and sexually reproduce in the 
mosquito, eventually allowing for transmission to a new host. Induction of the sexual stage gametocyte is 
relatively rare compared to normal asexual parasite forms, and the life cycle is quite different as it takes 
15 days of development within the RBC for gametocytes to reach maturity (reviewed in (37)). While exact 
mechanisms driving genetic switch to gametocyte fate is an ongoing area of research, clearly the number 
of mature gametocytes formed and how early they start to form within an infected individual, can play a 
big role in overall transmission potential. This is especially true as not all commonly used antimalarial 
drugs are active against the gametocyte stage infection. It is known that stressors can induce 
gametocytogenesis, which is not surprising from an evolutionary standpoint for the threatened parasite to 
try to ensure ongoing survival in another host. Such stressors can include drug treatment, lack of 
nutrients, or high infection numbers, which cause a portion of asexual stage parasites to undergo genetic 
programming to induce gametocyte gene expression upon division into merozoites, and these merozoites 
go on to infect new RBCs destined to develop into gametocytes (reviewed in (37)). Other stressors can 
include RBC mutations such as sickle-trait and thalassemias, with gametocyte formation reported to be 
elevated in these people (38–40). Similarly, it is highly plausible that gametocytogenesis will be more 
readily induced in an iron deficient person, in which parasites cannot invade RBCs or replicate as well. In 
fact, it would be a “perfect storm” if iron deficient individuals had fewer malaria symptoms and were able 
to control infection better (thus less frequently seeking drug treatment), but simultaneously had higher 
levels of gametocytes in their blood to increase overall malaria transmission potential. To study this, we 
could easily begin with in vitro gametocyte growth assays in iron deficient versus iron replete RBCs, 
assessing whether gametocytes start to form earlier, or at higher rates. Gametocyte cultures require 
human serum; we could also test whether serum from iron deficient versus iron replete individuals 
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differentially influences gametocytogenesis. Gametocytes are quantifiable by microscopy or more 
scalable methods such as flow cytometry using parasites with gametocyte stage proteins fluorescently 
tagged, or RT-PCR examination of gametocyte specific transcripts. It could be more difficult to enumerate 
gametocytes in blood smears from infected and uninfected individuals as gametocytes are rare in 
circulation until they reach maturity, but it is another possible method to use. Studies using gametocyte 
growth in vitro in RBCs from anemic and non-anemic individuals followed by membrane feeding 
techniques to infect mosquitos can help determine true transmission viability of gametocytes formed 
under different conditions. Following mosquito infection, midgut and salivary gland dissection can reveal if 
malaria oocysts and sporozoites properly developed, and there is also the ultimate test of controlled 
refeeding on humans to monitor infection potential. These are certainly more complicated techniques, but 
do admittedly more stringently measure the entire transmission cycle potential of the issue at question. 
Regardless of technique chosen, evaluating gametocytogenesis in the face of iron deficiency is a highly 
relevant question when it comes to malaria elimination campaigns and certainly deserves further study. 
6.2.4 New research into human evolution against blood stage malaria infection. 
Our research examining the relationship between anemia, iron, and malaria is now becoming 
highly relevant to the broader picture of understanding human RBC adaptation to thousands of years of 
malaria pressure. As discussed in Jallow et al., only 2% of variation in severe malaria disease is 
attributable to the most well-known genetic alteration of sickle-cell trait, as compared to an estimated 25% 
total impact of genetics on severe malaria formation. Thus there is presumably much room for discovery 
and improved understanding of other genetic factors contributing to malaria susceptibility (41). Anemia is 
widespread throughout the developing world, iron deficiency being the most prevalent cause (42). 
Certainly, much of this is due to nutritional availability of iron sources. However, it is also intriguing to think 
about tendency towards anemia having evolved as a protective survival advantage in the presence of 
longstanding malaria pressure.  
In fact, it is well-established that African American populations have lower hematocrit, 
hemoglobin, mean corpuscular volume (MCV), white blood cell (WBC) counts, and transferrin saturation 
(albeit higher serum ferritin) than their non-black American counterparts. This idea largely originated from 
the first American National Health and Nutrition Examination Survey (NHANES). This was originally 
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hypothesized to relate back to nutrition and/or economic status, but it was determined that the finding still 
holds true after controlling for these factors (discussed in (43)). The hematological discrepancies 
remained even after accounting for incidence of hemoglobinopathies and other RBC variations known to 
disproportionately affect African Americans (44) and correcting for outlying low transferrin saturation (45). 
Another study of population-matched black and non-black Americans found the difference in hemoglobin 
levels was not due to influence of different levels of iron, zinc, or copper, and also that MCV and mean 
corpuscular hemoglobin (MCH) was consistently lower in black populations (46). Perry and coworkers 
further confirmed with NHANES II that differences in hemoglobin were not due to differences in iron 
intake or other obvious iron-related factors, instead questioning whether there were innate differences in 
erythropoiesis or iron metabolism factors (47). It should be mentioned though, that others found in a study 
of military personnel that accounting for iron intake did reduce differences in hemoglobin somewhat(48). 
However, significant differences in hemoglobin levels and hematological parameters in black and non-
black Americans despite controlling for confounders are persistently found in more recent studies using 
data from NHANES III( 49). Regardless of cause, it is now indisputable that separate reference values 
are necessary for black and white populations in terms of hemoglobin levels and MCV, with blacks having 
consistently lower Hgb (on the order of 0.5-1.0 g/dL) and MCV (on the order of 3-6fL) across age-
matched, income-matched, sex-matched individuals and also accounting for prevalence of genetic RBC 
disorders (44–47, 50).  
Why did these difference arise? What if anemia is in fact one of the most widespread and 
influential contributors to malaria attenuation in the developing world? This idea was brought to our 
attention due to results in this dissertation (Chapter 4) and is a line of research that deserves further 
analysis and inquiry. If this were the case, it would be predicted that genetic variations leading to anemia 
or lower hemoglobin levels should exist, which will again have to be examined further. Known mutations 
do exist to cause, for example, iron refractory iron deficiency anemia (IRIDA). In IRIDA, mutations in the 
TMPRSS6 gene (coding for a serine protease) affect pathways of the iron regulatory peptide hormone 
hepcidin, ultimately amounting to persistently elevated hepcidin levels (51, 52). High levels of hepcidin 
(normally induced by inflammation or high iron stores) prevent uptake of intestinal iron through 
degradation of the ferroportin transporter on the basal surface of duodenal cells, preventing dietary 
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absorbed iron from reaching the blood stream; it also increases macrophage uptake of serum iron and 
reduces erythropoiesis (53). A meta-analysis of the association of risk alleles in TMPRSS6 across 
different ethnicities does find increased levels of certain risk alleles in Asians (significantly elevated) and 
African Americans (elevated but not significant) compared to Caucasians, but there was very limited data 
available for the African Americans so the topic could be examined further (54). Other recent research 
adds weight to the idea that hepcidin levels are in careful evolutionary equilibrium, indicating that higher 
levels of hepcidin at birth indeed correlate with increased risk for anemia but simultaneously reduce risk 
of malaria infection (55). Of course much of the anemia in malaria endemic areas can be explained by 
nutritional limitations, but more research into genetic causes for anemia and lower hemoglobin values in 
people of African descent could lead to further understanding of whether the anemia prevalence is at 
least in part historically related to malaria pressure. 
6.3 CONCLUSIONS 
Not only have humans evolved to increase survival against infection and severe malaria, but so 
too have malaria parasites evolved to counter human protective measures. The most obvious present-
day example of this is drug resistance. There is now also clear evidence of P.vivax infection of duffy-
negative individuals, which could possibly reflect new invasion ligand adaptation. P.knowlesi, traditionally 
infecting apes, now crosses over to cause human zoonotic infections at increasing rates (56). Plausibly, 
the parasite has even evolved ways to take advantage of human genetic adaptations, with evidence that 
gametocyte formation and thus transmission potential is higher in people with hemoglobinopathies (38–
40). Another intriguing development is the finding that parasites are potentially responding to selective 
pressure from extensive rapid diagnostic testing (and subsequent drug treatment) to have lost the hrp2 
gene whose protein product is detected by most rapid diagnostic tests (57, 58).  
Clearly, the evolutionary relationship between the malaria parasite and the human host is far from at 
an end point, and we have much more to be learned. Studying natural human evolutionary adaptation to 
malaria infection can provide much insight into parasite pathogenesis and help identify strategies to 
develop new antimalarial targets and vaccines. Research into human erythrocyte-related genetic 
adaptations to malaria in populations originating from malaria endemic areas can also help us identify and 
better understand human conditions and biological differences. This is certainly the case with 
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hemoglobinopathies in African American populations, and as proposed, now may also shed light on 
widespread prevalence of anemia in African populations and people of African descent. 
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